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The distal compartments of the motor neuron represent early and significant targets 
across situations of both neurodegenerative disease and traumatic injury. In this 
thesis, we address two distinct scenarios of axonal and synaptic degeneration. First, 
we explore neuromuscular junction pathology in a mouse model of the heritable 
motor neuron disease spinal muscular atrophy (SMA) and address the capacity for 
neuronal regeneration following restoration of the pathologically depleted Survival 
Motor Neuron (SMN) protein. We demonstrate that motor neurons exhibit a robust 
and phenotypically translatable recovery from considerable levels of cellular and 
molecular dysfunction. In the second chapter, we explore the phenomenon of 
delayed Wallerian degeneration in neonatal mice. We employ a quantitative mass 
spectrometry approach to profile proteins exhibiting a temporal expression pattern in 
line with previously observed postnatal changes in axonal and synaptic vulnerability 
to injury. We then utilise a variety of proteomics tools to identify pathways which may 
mechanistically contribute to age-dependent resistance to degeneration. Together, 
these results provide a preliminary insight into the cellular and molecular 
mechanisms underlying motor neuron vulnerability in two independent models of 
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Chapter ONE: General Introduction 
1.1 Motor neuron vulnerability in neurodegeneration 
While it is evident that neurons in both the central and peripheral nervous systems 
(CNS and PNS) are vulnerable to degenerate in response to a number of injury, 
disease, and toxic-related insults, the mechanisms underlying these degenerative 
processes remain elusive. Amongst the diverse body of neurodegenerative conditions 
representing a significant emotional and economic burden across the globe, diseases 
and traumatic injury to the lower motor neuron remain largely untreatable, and 
therefore have garnered a great deal of interest from both basic researchers and 
clinicians. This chapter seeks to provide a very brief review of the literature comprising 
the current understanding of the architecture of the lower motor neuron, with a 
particular emphasis on the peripheral synapse between the lower motor neuron and 
the muscle, otherwise known as the neuromuscular junction.  
1.2 The Neuromuscular Junction (NMJ) 
1.2.1 Overview 
Lower motor neurons are long neuronal processes that connect the spinal cord to the 
skeletal muscle in order to facilitate electrochemical signalling for voluntary movement. 
The cell bodies of motor neurons are located within the ventral horn of the spinal cord 
(for control of muscles of the trunk and limbs), or within the facial nuclei of the 
brainstem (for control of the muscles of the head and neck), from which they project 
as bundles of axons into the periphery (Bear et al., 2001). Lower motor neurons may 
be further classified as either gamma motor neurons, responsible for regulating the 
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muscle spindle stretch reflex, or as alpha motor neurons, which dictate the force of 
voluntary muscle contraction (Bear et al., 2001). This thesis will primarily concern 
alpha motor neurons and their peripheral synapses, the specialised nerve-muscle 
interfaces known as neuromuscular junctions (NMJs) (Bear et al., 2001).  
Synapses within both the CNS and the PNS, including NMJs, are early and significant 
pathological targets in degeneration promoted by disease, injury, or toxic insult 
(Baxter, Gillingwater, & Parson, 2008; T H Gillingwater & Ribchester, 2001; Murray et 
al., 2008). As it is of utmost interest to elucidate what cellular and molecular factors 
contribute to, or conversely, attenuate the degenerative process, it is prudent to 
understand that the integrity of highly vulnerable NMJ often reflects the status of the 
remaining motor neuron under the influence of these factors. Prior to an examination 
of the cellular and molecular basis of motor neuron degeneration in the subsequent 
chapters of this thesis, I will provide a simplistic summary of healthy motor neuron 
structure and function, with a particular emphasis on the NMJ, before summarising 
two distinct mechanisms by which motor neurons may degenerate.  
1.2.3 Cytoarchitecture 
The term “neuromuscular junction,” referring to the interface of the motor neuron nerve 
terminal with the skeletal muscle, may be attributed to the celebrated German 
electrophysiologist Wilhelm Kühne in his 1862 description of nerve cells terminating 
on the leg muscles of a frog (Kühne, 1862).  
Broadly speaking, the neuromuscular junction is an interface of three distinct cell 
types: the nerve terminal of the motor neuron, the skeletal muscle, and the terminal 
myelinating Schwann cell (Bear et al., 2001). A number of structural proteins are 
required to maintain the architectural integrity of this interface, including the 
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neurofilament family (Bear et al.,2001). The pre-synaptic nerve terminal of the motor 
neuron represents the physical locale of neurotransmitter release, and subsequently 
harbours a complex network of assembled microtubules responsible for the transport 
and reuptake of vesicle-enclosed neurotransmitters (Bear et al., 2001; Grinnel et al., 
1995). An increasing body of evidence suggests that this pre-synaptic compartment 
harbours its own unique molecular and metabolic composition, including uniquely 
synapse-specific mitochondria and ubiquitin proteasome system components 
(Bertoni-Freddari et al., 1993; Wishart et al., 2014).  
Unlike other synapses within the CNS or PNS, the NMJ facilitates electrochemical 
signalling utilising exclusively acetylcholine (ACh) as a neurotransmitter (Bear et al., 
2001). The post-synaptic acetylcholine receptor (AChR), or endplate, receives all 
synaptic transmission and is comprised of a series of folds in the membrane of the 
post-synaptic muscle fibre (Bear et al., 2001).  
1.2.3 Development 
Both the mammalian pre-synaptic nerve terminal and the post-synaptic motor endplate 
undergo a series of developmental alterations, commencing in utero and ending during 
late gestation in humans, and in early postnatal life in mice (Sanes and Lichtman, 
1999). In simplistic terms, the most important developmental events in the pre-synaptic 
nerve terminal may be summarised by axon pathfinding from the embryonic spinal 
cord to the muscle, culminating in the polyinnervation of the post-synaptic endplate by 
multiple nerve terminal inputs. This polyinnervation is selectively eliminated over 
postnatal maturation to yield the “adult” innervation pattern of a single nerve terminal 
input per endplate. The post-synaptic AChR also undergoes a marked degree of 
ultrastructural transformation during this developmental period, evolving from an 
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immature simple “plaque”-like structure to a complex, highly invaginated “pretzel”-like 
mature endplate (Kariya et al., 2008). 
 
1.3 Mechanisms of neurodegeneration: Dying-back neuropathy  
While a number of heritable or spontaneous diseases, as well as injuries, of the PNS 
have been demonstrated to significantly disrupt the integrity of the motor neuron, it is 
clear that there are distinct pathways, harbouring unique morphological 
characteristics, by which the motor neuron may degenerate (Murray et al., 2008). 
capable of disrupting the integrity of peripheral nerves. Motor neuron diseases, such 
as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are 
classified as “dying-back” neuropathies, due to their characteristic withdrawal of the 
pre-synaptic nerve terminal from the NMJ.  
1.3.1 Dieback neuropathology: a loss of NMJ integrity 
Die-back neuropathies, exemplified by conditions such as SMA and in the wasted 
mouse model of motor neuron degeneration, are characterised by the retrograde 
withdrawal of the pre-synaptic terminal from the distal synapse (Murray et al., 2008; 
Newbery et al., 2005). The retracting distal nerve terminal and axon appear to shrink 
back into themselves, in a structure referred to as a “retraction bulb,” leaving the 








1.4 Mechanisms of neurodegeneration: Wallerian degeneration  
The earliest characterisation of the neuronal response to traumatic injury was provided 
by Augustus Volney Waller in 1850, in his description of severed frog hypoglossal and 
glossopharyngeal nerves (Waller, 1850). He observed that a marked degree of 
neuronal fragmentation occurred distal to the point of injury and was subsequently 
cleared away by an unknown mechanism, while the portion of nerve proximal to the 
cut was retained for a comparably longer period of time (Waller, 1850). This process, 
now termed “Wallerian degeneration,” is a highly regulated means of degeneration 
conserved between multiple species and is the typical neuronal response to traumatic 
injury, although it is also observed in multiple sclerosis (Gillingwater & Ribchester, 
2001; Ge et al., 2006). For an in-depth review of the structural events comprising 
Wallerian degeneration, see Gillingwater & Ribchester, 2001; however, Wallerian 
degeneration may be simplistically summarised as the following: (1) A “latent” phase, 
occuring within 24-48 hours in mice (Beirowski et al., 2005), in which axons 
disintegrate distally from the point of injury and draw back from the nodes of Ranvier 
to form distinct small  fragments. (2) Subsequent to fragmentation, phagocytosing cells 
such as Schwann cells and macrophages clear up fragments, while (3) 
Simultaneously, Schwann cells that are still intact secrete various growth factors to 
promote the regeneration of the disintegrated nerve terminal (Gillingwater & 
Ribchester, 2001). 
1.4.2  Wallerian Degeneration Slow (WldS) 
The spontaneous WldS mutation, resulting from the chimeric fusion of a portion of the 
ubiquitination factor Ube4b with the nicotinamide mononucleotide adenylyltransferase 
(Nmnat) gene, was identified in 1989, and has provided a significant degree of  insight 
into the cellular and molecular factors constituting neuroprotection from degeneration 
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(Lunn et al., 1989; Mack et al., 2001). As described previously, Wallerian 
fragmentation following axotomy generally occurs within 24-28 hours after insult; an 
identical procedure performed in Wlds mice results in the striking preservation of 
axonal and synaptic structural and functional integrity for up to two weeks following 
injury (Ribchester et al., 1995). Application of the WldS mutation to attenuate 
degeneration in a number of mouse models of disease, injury, or toxic-induced nerve 
trauma has suggested that the degenerative response to highly distinct insults may 
involve common mechanisms (Ferri, Sanes, Coleman, Cunningham, & Kato, 2003; 
Gillingwater et al., 2006; Wang, Davis, Culver, & Glass, 2002). Nevertheless, the 
processes comprising this commonality, as well as an understanding of why other 
conditions, such as SMA, are not influenced by the introduction of Wld, remain poorly 
understood (Kariya et al., 2009).  
1.5 Aims of this thesis 
1.5.1 Summary 
From both the existing literature to be outlined subsequently in this thesis and from 
studies conducted within our own laboratories, it is clear that the cellular and molecular 
basis of vulnerability to either disease or injury-induced degeneration at the 
neuromuscular junction (NMJ) remain unknown. In this thesis, I will perform two 
parallel studies investigating the factors influencing NMJ integrity under degenerative 
conditions: firstly, in a murine model of the childhood neurodegenerative disease 
spinal muscular atrophy (SMA) and secondly, in wildtype mice exhibiting an 
endogenous and developmentally-regulated resistance to injury-induced 
degeneration. These findings contribute to our understanding of the complex cellular 
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and molecular cascades influencing the ultimate outcome of the motor neuron in 
situations of injury and disease.  
Hypothesis 1: Neuromuscular junction and molecular correlates of motor neuron 
degeneration are present in the SmnRes  mouse model of SMA at a time of symptomatic 
onset. 
AIM 1: Investigate the extent of cellular and molecular pathology present within 
the SmnRes mouse model at P4, a symptomatic time point within the therapeutic 
window.  
1a. Characterise the typical disease time course of the SmnRes mouse model of 
SMA in our hands, in order to identify the point of symptomatic onset. 
1b. Investigate the presence of both pre- and post-synaptic neuromuscular 
junction pathology in a selection of muscle groups within the SmnRes model at 
an early-symptomatic time point identified in 1a.  
1c. Determine if molecular alterations suggesting an up-regulation of the p53 
apoptotic cell death pathway in other mouse models of SMA are present in the 
SmnRes model at early-symptomatic time point outlined in 1a.  
1d. Assess whether select transcriptional alterations identified from large-scale 
screens of two different early-symptomatic SMA mouse models are also 





Hypothesis 2: Postnatal restoration of the pathologically depleted SMN protein at the 
symptomatic time point outlined in AIM 1, promotes phenotypic improvement that may 
be attributed to improvements in the cytoarchitecture of the damaged NMJ.  
AIM 2:  Investigate structural modifications at the neuromuscular junction that 
accompany rescue of neuromuscular phenotype after conditional re-expression 
of SMN at an early symptomatic time point in the SmnRes model. 
2a. Induce re-expression of SMN at the early symptomatic time point identified 
in 1a in order to evaluate phenotypic improvement and survival in our hands.  
2b. Assess and compare the pathological status of neuromuscular junctions 
within a variety of muscle groups in rescued versus non-rescued SmnRes mice. 
2c. Determine whether the differences in pathology between rescued and non-
rescued mice reported in 1b are the result of restored SMN slowing, halting, or 
reversing pre-synaptic degeneration at the neuromuscular junction.  
 
Hypothesis 3: Molecular alterations in both the nerve and muscle may contribute to 
the marked increase in neuromuscular junction vulnerability to injury-induced 
degeneration in wildtype C57BL/J mice over the P12-P24 postnatal period.  
AIM 3: Profile molecular alterations occurring in both the pre-synaptic nerve and 
post-synaptic muscle over a period of increasing NMJ vulnerability in the 
wildtype C57BL/6 mouse. 
3a. Evaluate the efficacy of the TMT10plex™ mass tagging technique, which 
to date has not been definitively evaluated in whole-tissue studies, as a 
quantitative proteomics method.  
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3b. Perform functional annotation analysis on applicably filtered proteomic 
results to understand what biological processes may be evolving over this 
critical postnatal period. 
3c. Utilise pathway analysis software to generate cellular and molecular 
predictive networks from the data set to further understand what mechanisms 


















Chapter TWO:   Introduction 
2.1 Overview 
Spinal muscular atrophy (SMA) is a devastating childhood autosomal recessive 
disorder resulting from the heritable insufficiency of the ubiquitously expressed SMN 
(Survival Motor Neuron) protein. With 1 in 40 individuals estimated to be heterozygous 
carriers of the causative mutation, and an incidence of an estimated 1 in 6-12,000 live 
births, SMA may be considered the leading genetic cause of childhood and infant 
mortality worldwide (Farrar, Johnston, Grattan-Smith, Turner, & Kiernan, 2009; Pearn, 
1978; Sugarman et al., 2012). Despite the ubiquitous expression of SMN, the 
archetypal clinical manifestation of this deficit is largely neuromuscular; denervation 
and death of the lower alpha motor neurons with accompanying atrophy of the 
proximal skeletal muscles promotes paralysis, respiratory failure, and ultimately, in the 
majority of cases, death within the first decade of life (Russman, 2007). Within the 
motor neuron, the neuromuscular junction (NMJ), the point at which the neuron 
synapses with the skeletal muscle, represents an early and significant pathological 
target (Dachs et al., 2011; Kariya et al., 2008; Kong et al., 2009; Murray et al., 2008). 
An increasingly therapeutics-driven body of research shows promising results in the 
capacity for systems-wide postnatal restoration of SMN to ameliorate the 
neuromuscular phenotype and improve lifespan, but only if this is performed at an 
early symptomatic time point (Foust et al., 2010; Hua et al., 2011; Kariya et al., 2014; 
Lutz et al., 2011; Robbins, Glascock, Osman, Miller, & Lorson, 2014). The precise 
cellular and molecular mechanisms underlying this phenotypic rescue, as well as the 
basis behind the apparent temporal limitations of this approach, also remain poorly 
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understood. Consequentially, determining the cellular and molecular consequences of 
SMN restoration upon the motor unit will not only enhance our understanding of the 
degenerative process, but also highlight which aspects may fail to recover, or 
conversely, improve, upon re-expression of SMN. These findings may ultimately 
influence the efficacy of future SMN-based treatments by determining which 
pathological aspects remain the most vulnerable, and which harbour the capacity for 
therapeutically-driven repair.  
2.1.1 Clinical Background 
From its earliest clinical descriptions in the late 19th century by physicians Guido 
Werdnig and Johann Hoffman, spinal muscular atrophy has been considered a 
primarily neuromuscular disorder, characterized by its distinctive symptoms of 
proximal muscle weakness and eventual paralysis; these symptoms paired with SMA’s 
typical manifestation in the first year of life lend it the colloquial term of “floppy infant 
syndrome” (Farrar et al., 2009). Biomedical advances in the centuries following 
Werdnig and Hoffman’s clinical observations confirmed that this neuromuscular 
phenotype is the result of the degeneration and death of alpha motor neurons in the 
ventral horn of spinal cord and lower brainstem, responsible for innervating the 
muscles of the proximal extremities and abdomen (Markowitz, Tinkle, & Fischbeck, 
2004). Electromyographic (EMG) readings in severely affected patients that comprise 
the majority of diagnoses confirm this profound loss of whole motor units, with 
remaining motor neurons failing to respond or compensate for neighbouring 
denervation (Crawford & Pardo, 1996). Conversely, the EMGs of symptomatically 
milder, juvenile or adult onset SMA cases suggest the presence of overdeveloped 
motor units that may have responded to neighbouring denervation by compensatory 
sprouting (Crawford & Pardo, 1996).   
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Both clinical reports of human patients and the characterisation of animal models of 
the disease present the phenomenon of differential degrees of pathology between 
muscles and their respective associated motor units. A stark clinical example exists in 
the contrast between the marked denervation of the intercostal and axial muscles of 
the abdomen, and the relative sparing of the neighbouring diaphragm (Farrar et al., 
2009). Due to the majority of respiration relying upon the diaphragm during the gradual 
atrophy of the remaining abdominal musculature, respiration becomes predominantly 
diaphragmatic; this overdevelopment of the compensatory diaphragm and atrophy of 
trunk muscles results in many patients developing a characteristic bell-shaped torso 
(Farrar et al., 2009). This curious selective vulnerability to neurodegeneration between 
muscle types is mirrored in multiple mouse models of SMA, with select muscles 
consistently exhibiting significant pathological denervation while others are relatively 
spared (Mélissa Bowerman, Murray, Beauvais, Pinheiro, & Kothary, 2012; Murray et 
al., 2008; Thomson et al., 2012). Consequentially, determining why selective proximal 
muscles and indeed, the motor neuron in general, are especially vulnerable to the 
depletion of a ubiquitous protein, remains crucial in elucidating the mechanisms 









2.2 Molecular Genetics 
2.2.1 The Survival Motor Neuron Gene 
The majority of SMA cases are monogenetic disorders exhibiting a classical autosomal 
recessive inheritance pattern, with patients harbouring the homozygous inheritance of 
a mutation or deletion in the Survival Motor Neuron 1 (SMN1) gene, and resultant null 
or non-functional production of its ubiquitously expressed translational product, 
Survival Motor Neuron (SMN) protein. Patients are therefore entirely reliant upon the 
insufficient compensatory production of SMN by the paralogous Survival Motor Neuron 
2 (SMN2), which is nearly identical to SMN1 save for a single CT base-pair transition 
within exon 7 (C L Lorson, Hahnen, Androphy, & Wirth, 1999a; U. R. Monani et al., 
1999).  Nevertheless, this single nucleotide difference generates an exonic splicing 
silencer or suppresses an exonic splicing enhancer within exon 7; the majority of 
SMN2 transcripts produced therefore lack exon 7 and are translated into unstable and 
rapidly degraded SMN isoforms (Lorson et al. 1999; Lorson & Androphy 2000). SMN2 
exists in varying copy numbers between individuals, with a higher copy number—and  
therefore higher levels of compensatory bioavailable SMN—correlating to a milder 
disease severity. Indeed, the inverse correlation between SMN2 copy number and 
disease severity is so closely linked that the clinical spectrum of SMA, based on 
parameters such as age of onset, extent of paralysis and lifespan, is almost inevitably 
linked to SMN2 copy number (Lefebvre et al., 1997). However, it should be noted that 
SMN2 copy number itself is not the sole disease modifier, as genomic sequencing of 
several SMA patient cases in which SMN2 copy number did not directly correlate to 
clinical phenotype, indicated that splice variations themselves within exon 7 of SMN2 
also hold significant influence upon clinical severity (Prior et al., 2009). Tragically, in 
the majority of cases, affected individuals possess two or fewer copies of SMN2 and 
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accompanying very low production of compensatory SMN, and therefore experience 
















Figure 2.1.  Homozygous deletion of SMN1 results in insufficient 
compensatory production of Smn by SMN2.   
A. Normal inheritance of one or two fully-functional copies of SMN1 results in the 
physiologically sufficient production of full-length Smn transcripts. B. SMA individuals 
inherit a homozygous mutation or deletion of the SMN1 gene, resulting in null 
production of mSmn. Smn transcript levels are therefore reliant upon production by 
the paralogous SMN2, in which a single nucleotide transition within exon 7 promotes 
aberrant splicing. The majority of transcripts lack exon 7 and are truncated and 
extremely short-lived, and are translated into equally unstable isoforms. SMN2 copy 




2.2.2 The Survival Motor Neuron Protein 
The translational product of SMN1 and SMN2, Survival Motor Neuron (SMN), is a 
ubiquitously expressed 38kDa protein, with higher levels of expression present in the 
heart, kidney, and brain (Coovert et al., 1997). Mechanistically, SMN has been 
implicated in a variety of sub-cellular roles, the most definitive being the biogenesis of 
the molecular agents responsible for the intronic splicing of pre-mRNA (Chari, Paknia, 
& Fischer, 2009). Consequentially, one of the more prevalent theories behind the 
motor neuron-specific degeneration in SMA suggests that dysregulated spliceosomal 
assembly may impact upon transcripts particularly critical to motor neuron stability. 
Additionally, SMN has been shown to be involved in axonal mRNA transport, with 
another hypothesis suggesting that disrupted transport of key transcripts to and from 
the distal compartments of the lower motor unit promotes the degenerative process 
(Rossoll et al., 2003). There is also a theorized third mechanism combining the two 
hypotheses, in which abnormal splice isoforms resulting from aberrant snRNP 
assembly may perturb molecular pathways involved in the axonal transport of mRNAs. 
This thesis seeks to provide a subsequent brief summary of SMN’s hypothesised 
endogenous functions and how they may correlate to the neurodegenerative 








2.2.3 Function of the Survival Motor Neuron Protein 
The best-characterised cellular role of the SMN protein is that of the assembly of the 
SMN complex, a large, ubiquitous molecular structure facilitating the biogenesis and 
transport of small nuclear ribonucleo proteins (snRNPs) to the nucleus (Chari et al., 
2009). These snRNP core complexes form the basis of the pre-mRNA spliceosome, 
nuclear molecular complexes responsible for intronic splicing of pre-mRNA as well as 
other post-transcriptional modifications (Chari et al., 2009).  
Although the precise stoichiometry of the SMN complex has not been conclusively 
described, its function appears to rely upon self-association of SMN, with both in vitro 
and in vivo complementation assays supporting its oligomeric existence (Christian L. 
Lorson et al., 1998; Umrao R Monani et al., 2003). In the majority of tissues, the SMN 
multimer is sequestered in both the cytoplasm and nuclear bodies known as “gems”, 
which may be identified by immunohistochemical labelling of SMN itself to distinguish 
complex-enriched spots from other nuclear bodies (Q Liu & Dreyfuss, 1996). An 
examination of normal cardiac and smooth muscle revealed an absence of these 
gems, suggesting that these nuclear bodies may serve to collate reserve SMN and 
other snRNP-associated proteins rather than play a more integral role in Smn’s 
function (Young et al. 2000).   
The currently established structure of the oligomeric SMN complex consists of SMN 
bound to the gemin proteins (of which Gemins 2-8 are currently best characterized) 
and the unr-interacting protein (unrip), although interactions with several additional, 
non-gemin substrates, usually components of various RNP complexes, have also 
been identified (Battle et al., 2006; Qing Liu, Fischer, Wang, & Dreyfuss, 1997). The 
SMN-gemin complex, via Gemin 5, binds to small nuclear RNAs (snRNA), termed U1, 
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U2, U4, U5, U12 and U4atac , which are synthesised in the nucleus as pre-snRNA by 
RNA polymerase II (RNA polII) and modified prior to export into the cytosol (Yong, 
Kasim, Bachorik, Wan, & Dreyfuss, 2010). The SMN-gemin associated snRNAs then 
bind to complementary cytosolic Sm proteins recruited by Gemin 2, to form an 
intermediate snRNP RNA-protein complex with an Sm core. The SMN 
assemblyosome then chaperones these snRNPS  through the remainder of their 
biogenesis through their import into the nucleus, where the snRNP core complexes 
undergo final modifications before oligomerizing as components of either the major 
(snRNPs U1, U2, U4, U5) or minor (snRNPs U11, U12 and U4atac) spliceosome. 
Broadly speaking, both the major and minor spliceosome are responsible for the 
recognition, splicing and removal of intronic sequences of pre-mRNAs, with the minor 
spliceosome processing a specific subset of low-abundance pre-mRNAs. Additionally, 
the snRNP U1 appears to hold specialised functions outwith its spliceosomal role in 
regulating transcript levels by selectively protecting transcripts from premature 
cleavage or polyadenylation(Berg et al., 2012).  
 Although a characterisation of the broad range of molecular cascades influenced by 
snRNPs, whether as part of the SMN assemblyosome or through non-splicing roles, 
remains largely non-comprehensive, snRNP activity is clearly crucial in the translation 
from the relatively limited genome to a multifarious proteome spanning diverse tissues 
and systems. It is therefore natural to consider that elucidating SMN-dependent 
disruptions in snRNP assembly and their potential influence upon the functional 
proteome within the lower motor neuron may reveal candidate mechanisms of 







Figure 2.2. The SMN complex 
A. Schematic representation of the known structure of the SMN-gemin complex. 
Complex is representatively shown to be dimeric. Binding sites of Gemin 2 (G2), 
Gemin 5 (G5) and Gemin 3 (G3) feature direct binding with Smn. Gemin 4 (G4) is 
indirectly associated with Smn through binding to Gemin 3. To date, the binding sites 
of Gemins 6-8 (G6-8) have not yet been determined. B. Schematic representation of 
SMN-gemin complex mediated snRNP assembly. Formation of the SMN complex-
bound snRNPs occurs in the cytosol through the interactions of snRNAs and a 
corresponding Sm protein core. The complex is imported back into the nucleus, where 
the snRNP cores form the basis of either the major or minor spliceosome. Dissociated 




2.2.4 The SMN complex and snRNP Assembly in Spinal Muscular Atrophy 
While a precise mechanism demonstrating the direct impact of defective snRNP 
assembly upon the motor neuron-specific degenerative cascade in SMA has not been 
definitively proven, an increasing body of evidence reveals a marked deficiency in 
snRNP biogenesis in human patients as well as across multiple animal models of 
SMA. Prior to a report of these observed defects, it should be noted that the structural 
characterisation of the SMN protein in its native conformation, as well as the 
development of several functional assays to evaluate complex-substrate binding, has 
established a set of parameters evidently integral to the functionality of the SMN 
assemblyosome (Battle et al., 2006; Berg et al., 2012; Christian L. Lorson et al., 1998; 
Lutz et al., 2011; Yong et al., 2010). Intrinsic defects in SMN expression impacting 
upon these parameters may disrupt SMN complex assembly and snRNP biogenesis, 
spliceosomal formation, and ultimately, mediate potentially degenerative 
transcriptional and translational perturbations. The parameters for normal SMN-
complex associated SMN function may be broadly summarised by the following 
criteria: 
1. The capacity for self-association (oligomerization). 
2. In the instance of a mutated SMN isoform, the capacity for association with co-
existing full-length SMN (FL-SMN).  
3. The capacity to bind gemin proteins. 
4. The capacity to bind Sm proteins. 
An examination of the structural biology of the SMN protein highlights several motifs 
and domains that are functionally critical for the execution of the above parameters. 
Figure 2.3 outlines the location of several of these key domains within exons 2, 3 and 
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6 of SMN, and their functional significance upon either substrate binding or self-




Figure 2.3. Schematic representation of exons 1-7 of Smn and translational 
domains understood to be key binding sites of the assembled SMN complex. The 
lysine-rich region within exon 2 contains sequences critical to Gemin 2 binding, 
responsible for recruitment of Sm proteins to the SMN-gemin complex. The 50 amino 
acid “Tudor” domain within exon 3 is integral to Sm protein binding and thus the 
formation of the snRNA-Sm core complex. The “YG-box” within exon 6, so called for 
its conserved (Y-xxx-G)3 motif, contains sequences integral to SMN oligomerization. 
Mutations within SMN1 that affect these critical domains therefore influence potentially 
influence snRNP assembly. Figure adapted from Burghes & Beattie, 2009. Diagram 
not to scale. 
  
Although 95% of SMA patients exhibit an inherited absence of SMN1, the remaining 
5% of cases harbour various missense mutations within the gene (Alías et al., 2009). 
Investigations into the functional outcome of these mutations reveal that a striking 
majority exist within the aforementioned critical motifs, thereby impairing the native 
confirmation of SMN and its functional role in snRNP biogenesis (Burghes & Beattie, 
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2009). Indeed, approximately 50% of SMN1 missense mutations are mapped to the 
YG-box motif of exon 6, which is integral for SMN oligomerization ( Young et al. 2000). 
A large remainder of currently identified mutations in SMN1 are mapped to other 
domains integral to either oligomerization or SMN complex formation, including 
binding sites for both gemins and Sm proteins (Burghes & Beattie, 2009).  
A large proportion of these mutations have been explored to determine their influence 
upon snRNP binding, usually in conjunction with a comparably small amount of FL-
SMN in order to molecularly recapitulate the in vivo situation of an SMA patient 
expressing very low levels of bioavailable FL-SMN. These mutant isoforms have been 
subjected to a number of binding assays developed to assess their ability to associate 
with FL-SMN, oligomerize, or bind Sm proteins. From assaying select variants from 
the currently identified library of human mutations, it is apparent that different 
missense sequences within SMN1 confer differential effects upon substrate and/or 
SMN binding, suggesting that there is indeed a spectrum of functional outcome to 
mutations within SMN1 and that not all mutations are equal in their attenuation of 
snRNP biogenesis. For a comprehensive list of SMN1 mutations identified in patients, 
and their influence upon snRNP assembly when applied in vitro, see review by 
Burghes & Beattie, 2009 (Burghes & Beattie, 2009) 
Prior to the development of a viable animal model of the disease, the scarcity of 
immunohistochemically- labelled SMN-complex enriched nuclear “gems” in primary 
cultured fibroblasts from severe patients immediately suggests that the a lack of 
functional machinery required for snRNP assembly may indicate aberrant snRNP 
biogenesis in SMA (Coovert et al., 1997). Functional defects in patients were finally 
highlighted when lymphoblasts isolated from a severe SMA case exhibited a 
decreased capacity for snRNP assembly in culture compared to those obtained from 
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age-matched controls (Wan et al., 2005). These findings, combined with the 
aforementioned functional defects in SMN assemblyosome formation from missense 
mutations in SMN1, strongly implicate the “snRNP biogenesis theory” in SMA 
pathophysiology.  Indeed, SMN2’s insufficiency as a phenotypic modifier in SMA 
individuals has been proposed to result from the inability of SMN2 truncated isoforms 
to oligomerize or effectively bind SMN-complex substrates, thus disrupting snRNP 
biogenesis and intronic splicing (Workman et al., 2009). 
 
2.2.5 Disrupted snRNP assembly and subsequent splicing alterations in murine 
models of Spinal Muscular Atrophy. 
A greater exploration of the mechanistic relevance of snRNP biogenesis to SMA 
pathophysiology has arisen from the application of previously outlined human 
missense mutations into animal, particularly murine, models of the disease  
snRNP biogenesis and motor neuron defects in mouse models of SMA 
The case for a close relationship between snRNP biogenesis and neuromuscular 
integrity is perhaps most strongly represented by the application of the SMN1 
missense allele A111G, a mutation demonstrably capable of high snRNP assembly in 
vitro, into in vivo models of SMA (Carrel et al., 2006; Shpargel & Matera, 2005; Sun et 
al., 2005; Workman et al., 2009). The SMN(A111G) mutation, located in the Sm-
protein binding Tudor domain of exon 3, exhibits a significantly greater ability in vitro 
than other missense alleles to bind FL-SMN and Sm proteins as well as to assemble 
snRNPs upon co-transfection with FL-SMN. Upon introduction into the Smn-/-; SMN2 
severe mouse model of SMA, SMN(A111G) mediated a robust extension of lifespan 
corresponding to an up-regulation in spinal cord snRNP assembly and snRNA 
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expression, notably those pertaining to the minor spliceosome (Workman et al., 2009). 
Additionally, introduction of SMN(A111G) RNA constructs at high concentrations to 
Smn-knockdown SMA zebrafish rescued archetypal axonal defects as well as 
extended lifespan (Workman et al., 2009). However, this phenotypic attenuation was 
not possible in Smn null mice without co-expression of transgenic SMN2, nor in 
zebrafish administered lower concentrations of RNAs (Workman et al., 2009). This 
suggests that in order to mediate neuromuscular improvement, snRNP assembly 
operates upon a physiological baseline of oligomerized SMN, from either the 
association of mutated isoforms to the low levels of FL-SMN endogenously present in 
mice with an SMN2 background, or the self-assembly of these isoforms occurring 
under sufficiently high concentrations. Nevertheless, these results provide convincing 
implications for SMN’s function in snRNP assembly as a potent modulator of the SMA 
neuromuscular phenotype.  
Through an assessment of snRNP assembly activity across various mouse models of 
SMA varying in phenotypic severity, the link between snRNP assembly and SMA 
symptomology appears to overlie the established correlation between SMN levels and 
phenotypic severity. Severe mouse models of SMA exhibit very low levels of snRNP 
assembly, with assembly levels significantly increasing in milder models of SMA, yet 
still less than asymptomatic heterozygous or wildtype mice (Gabanella et al., 2007; 
Zhang et al., 2008). Conversely, the post-symptomatic restoration of SMN into a 
moderate to severe mouse model spinal muscular atrophy, induced a significant 
increase in snRNP assembly to complement an improvement motor defects and 
extension of lifespan (Lutz et al., 2011). Additionally, aberrant snRNP assembly in 
SMA does not appear to be relegated to the lower motor neuron; Gabanella et al 
(2007) report widespread defects in snRNP assembly across a variety of neuronal and 
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non-neuronal tissues in a severe mouse model of the disease. However, although 
transcriptional dysregulation appeared to be universally present, the most severe 
defects occurred within the spinal cord, pertaining to transcripts regulated by the minor 
spliceosome(Gabanella et al., 2007).  
Several experiments have attempted to elucidate the mechanism by which defective 
snRNP assembly may contribute to the degenerative cascade. Administration of pre-
assembled snRNPs to a zebrafish model of SMA, exhibiting motor axon defects, 
rescued axonal morphology and neuromuscular phenotype, strengthening the 
correlation between reduced snRNP assembly and motor neuron defects (Winkler et 
al., 2005). The same study also reported that knockdown of Gemin 2, responsible for 
the recruitment of Sm proteins to the SMN-gemin complex, is also sufficient to promote 
morphological defects in zebrafish motor axons. However, a novel study suggests that 
to the interaction between SMN and Gemin-2 may be more broadly involved in RNA 
metabolism, with potential interactions in a wide variety of RNPs in addition to snRNP 
assembly (So et al., 2016).  
 
Splicing alterations in mouse models of SMA 
Exploration into the downstream consequences of disrupted snRNP activity, 
particularly that of the minor spliceosome, highlights widespread transcriptional 
dysregulation hypothesised to contribute to disease pathogenesis. Among the large 
number of aberrantly spliced transcripts identified in, several have been proposed to 
harbour a mechanistic influence upon neuronal stability.  
Large-scale transcriptional screens of spinal cords or laser-captured motor neurons 
from a number of murine models report significantly detectable transcriptional changes 
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at early or even pre-symptomatic stages(Murray, Beauvais, Gibeault, Courtney, & 
Kothary, 2015; Zhang et al., 2008, 2013). However, transcriptional profiling of the Δ7 
mouse model of SMA by Baumer et al (2009) argues that the majority of splicing 
alterations occurred at P7, a relatively mid- to late-time point in the Δ7 disease time 
course, and therefore were independent of early pathogenic events (Bäumer et al., 
2009).  
Consequentially, the timing of transcriptional alterations and their contribution to the 
ultimate pathophysiology of SMA remains controversial. However, it is clear that, 
regardless of their timing within the disease time course, a broad degree of 
transcriptional dysregulation comprises a significant proportion of the molecular 
pathology characteristic of SMA. Convincingly, postnatal restoration of SMN in a 
tamoxifen-inducible mouse model of the disease improves snRNP assembly, 
supporting the implication of snRNP biogenesis and accompanying splicing regulation 
in the structure and maintenance of the motor unit(Lutz et al., 2011).   
 
2.2.6 The SMN protein, RNA transport and additional substrates 
In their evaluation of snRNP assembly across multiple mouse models of SMA, 
Gabanella et al (2007) report that snRNP assembly, while severely attenuated in the 
severe Taiwanese model compared to littermate controls, is not significantly less than 
the longer-lifespan Δ7 model expressing higher levels of SMN (Gabanella et al., 2007). 
These findings suggest that SMN may have additional, snRNP-related roles impacting 
upon the structure and function of the lower motor neuron. Of these proposed alternate 
mechanisms, SMN has perhaps been most convincingly implicated in a number of 
non-splicing RNA metabolism roles within the motor neuron axon. For example, 
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Rossoll et al. (2003) reported that SMN was crucial for axonal transport of β-actin 
mRNA, thereby implicating both β-actin and additional transcripts that may be required 
for axonal development and integrity (Rossoll et al., 2003). These findings further invite 
debate as to whether transcriptional dysregulation resulting from low levels of SMN 
impact upon critical neuronal pathways in particular, or whether SMN harbours an 
additional, non-spliceosomal role particular to the motor neuron.  
Evidence also exists for other, non-snRNP roles in different tissues. For example, 
SMN has been suggested to bind to various other CNS proteins, including  the 
quintessential FMRP (fragile X-mental retardation protein) protein implicated in Fragile 
X syndrome, but these associations have not been demonstrated definitively(Meister 
et al., 2000; Piazzon et al., 2008). Nevertheless, while SMN may be involved in a 
number of other molecular pathways, these remain to be explored and validated in 
vivo before they may be definitively implicated in motor neuron-specific pathogenesis.  
 
2.2.7  Non-SMN molecular pathways in spinal muscular atrophy 
While there appears to be a clear implication for disrupted snRNP assembly in SMA, 
it remains difficult to determine whether it is the critical molecular pathway promoting 
disease pathogenesis. A number of studies have outlined alternative molecular 
candidates capable of modifying disease severity. These include the actin-binding 
protein plastin-3 and ubiquitination-activating enzyme Uba1, which have both been 
demonstrated to influence phenotype outcome to varying success upon therapeutic 
targeting in mouse models of SMA (Ackermann et al., 2013; McGovern et al., 2015; 




2.3 Mouse Models of Spinal Muscular Atrophy 
The near-duplication of SMN1 on chromosome 5q13 to yield centromeric copies of the 
paralogous SMN2 is a phenomenon conserved to the human species (Rochette, 
Gilbert, & Simard, 2001). A prominent challenge in the modern SMA research field has 
therefore been to design an animal model of SMA that effectively recapitulates not 
only the phenotype, but also the molecular genetics of the disease. Although 
knockdown or deletion of SMN has been explored in diverse organisms from 
invertebrate organisms Schizosaccharomyces pombe(Qing Liu et al., 1997; Owen, 
Doe, Mellor, & Davies, 2000; Talbot et al., 1997), Drosophila melanogaster (Chan et 
al., 2003; H. C.-H. Chang et al., 2008), Caenorhabtidis elegans, and the zebrafish 
Dario renia (Boon et al., 2009; McWhorter, Monani, Burghes, & Beattie, 2003), the 
generation of a mammalian model in the mouse has perhaps yielded the most 
informative insights into SMA pathophysiology. 
The first mouse model of SMA, generated by disrupting exon 2 of the murine SMN 
allele (Smn) with a reporter cassette to produce Smn null progeny, proved to be 
embryonically lethal before implantation(Schrank et al., 1997). Analysis of embryonic 
tissue revealed a large degree of apoptotic cell death at the eight-cell stage post-
fertilization, emphasising the critical role of SMN during prenatal 
development(Schrank et al., 1997). Indeed, complete absence of both SMN1 and 
SMN2 in humans has never been reported, suggesting that a base level of SMN must 
be required for complete gestation and embryonic viability.  
The first breakthrough in the development of a postnatally viable mouse model of SMA 
was conceived via transgenic expression of SMN2 on an SMN null murine background 
(Hsieh-Li et al., 2000; U R Monani et al., 2000). The resultant mice, Smn-/-; SMN2, 
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possessing one or two copies of the human transgene, are extremely short-lived and 
phenotypically representative of the most severe infantile forms of SMA. Mice with two 
copies of SMN2 on an Smn-/- background die at approximately 4 to 6 days old and 
exhibit severe motor defects reflective of aggressive motor neuron loss and muscle 
wasting (U R Monani et al., 2000). However, introducing 8 or more copies of SMN2 
virtually eliminates the SMA phenotype and extends lifespan to a normal duration (U 
R Monani et al., 2000). A second transgenic SMN2 model features introduction of 
SMN2 on a novel SMN null background generated by homozygous replacement of 
exon 7 with a reporter cassette (Hsieh-Li et al., 2000). These “Taiwanese” mice with 
2 copies of SMN2 also exhibit a severe phenotype and a lifespan of 8 to 10 days 
(Hsieh-Li et al., 2000; Lin et al., 2016). Introducing 4 or more copies of SMN2 extends 
lifespan to normal duration, again demonstrating that SMN2 is a potent modulator, 
albeit not a sole one, of phenotypic severity.  
Introduction of a second transgene, consisting of human transgenic SMN cDNA 
lacking exon 7 (SMNΔ7) cDNA onto the severe Smn-/-; SMN2 background modestly 
ameliorates the severe SMN2; Smn-/- phenotype (Le et al., 2005). These mice 
(SMNΔ7; SMN2; Smn-/-), referred to hereon as the SMNΔ7 model, survive to a lifespan 
ranging from 12 to reported 17 days, and exhibit sufficient structural and functional 
neuromuscular defects to be considered a phenotypically moderate to severe model. 
Phenotypic attenuation and extension of lifespan has also been reported from the 
introduction of human transgenic SMN1 mutations, such as the SMN(A111G) mutation 
mentioned previously, onto the severe Smn-/-; SMN2 model(Workman et al., 2009). 
Although the precise mechanisms by which the addition of SMNΔ7 and other SMN 
mutations to the severe model promote phenotypic improvement, it is hypothesised 
that the SMNΔ7 isoform, as well as SMN1 missense mutations, contribute an increased 
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capacity to associate with the low levels of FL-SMN produced by SMN2.  Transgenic 
addition of the SMN(A2G) mutation to the Smn-/-; SMN2 model, which reduces severity 
and extends lifespan to a greater degree than the SMNΔ7 transgene, also exhibits a 
greater binding affinity for FL-SMN in vitro than SMNΔ7, thereby supporting this 
theory(Umrao R Monani et al., 2003).  
Finally, a recent longer-lifespan, intermediate mouse model of SMA was generated by 
the knock-in disruption of an exonic splicing enhancer sequence of the murine Smn 
exon 7 allele(Mélissa Bowerman et al., 2012). The resultant Smn2B/- mouse, so named 
for its expression of both the novel knock-in 2B allele and null allele originally designed 
by Schrank et al.,  harbours an intermediate phenotype, with symptomatic onset 
occurring around 10 days and lifespan extending to a median of 28 days (Mélissa 
Bowerman et al., 2012). 
From the development of diverse mouse models of SMA, ranging in 
symptomatic severity and lifespan, it has been possible to determine that the lower 
motor neuron remains an uncontested primary victim of SMN depletion regardless of 
phenotypic severity, with the distal compartments of these neurons appearing 
particularly vulnerable.  The conservation of structural and functional characteristics 
between the murine and human motor unit has been vital to enhance our 
understanding of the mechanisms underlying the degenerative processes in spinal 
muscular atrophy. 
2.3.1  Cellular and Molecular Pathology in the SMA Mouse Motor Neuron 
Since Werdnig and Hoffman’s original descriptions of the infantile form of the disease, 
it remains highly evident that the motor neuron is subject to a broad range of 
morphological and molecular alterations in both patients and in mouse models of 
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spinal muscular atrophy (Werdnig 1891; Hoffman 1892). On a modern perspective, 
the contemporary theory of a highly compartmentalized motor neuron, with the cell 
soma, axon and synapse retaining molecular and metabolic individuality, has lent 
considerable reconsideration to the SMA field regarding the specificities of motor 
neuron degeneration. For example, although post-mortem reports of human patients 
commonly identify a profound loss of motor neuron cell bodies in the ventral horn and 
brainstem, post-mortem data from mouse models of the disease suggests that this 
somatic death is actually a pathologically late event in the disease time course (Monani 
et al., 2000). Indeed, post-mortem analyses of the facial nuclei and ventral horn of 
Smn-/-; SMN2 mice, which exhibit neuromuscular weakness from postnatal day 1, 
reveals indistinguishable motor neuron counts from age-matched controls until 
postnatal day 3 or 4, in which approximately 40% and 35% of cell bodies were lost (U 
R Monani et al., 2000).  
By contrast, a broad range of morphological and molecular changes in the distal 
compartments of the lower motor neuron appear early in the disease time course, 
often at early symptomatic stages. Neuromuscular junctions (NMJs) from post-mortem 
analyses of skeletal muscle from end-stage patients indicated a significant degree of 
structural and functional disruption (Mishra et al., n.d.; Soubrouillard et al., 1995; 
Swoboda et al., 2005). The generation of mouse models of SMA enabled the ability to 
profile NMJ pathology throughout the disease time course; subsequent studies 
therefore conclude that the NMJs are not only definitively altered in mouse models of 
SMA, but are also amongst the earliest pathological targets (Umrao R Monani et al., 
2003; Murray et al., 2008). Significant morphological changes in the integrity of the 
NMJ, accompanied by multiple abnormalities in presynaptic vesicular distribution, 
synaptic transmission and intracellular calcium homeostasis, appear to precede the 
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loss of cell bodies in the ventral horn of the spinal cord (Jablonka, Beck, Lechner, 
Mayer, & Sendtner, 2007; Kariya et al., 2008; Kong et al., 2009; Lin et al., 2016; Ling, 
Gibbs, Feng, & Ko, 2012). This thesis seeks to provide a brief summary of the cellular 
and molecular rather than functional perturbations present in individual compartments 
compartments of the motor neuron, with a particular emphasis on the synapse or 
neuromuscular junction.  
Cellular aspects of motor neuron pathology. 
 Consistent with other heritable motor neuron diseases such as ALS, the archetypal 
classification of motor neuron degeneration in SMA is a “die-back” pathology of pre-
synaptic nerve terminals from post-synaptic acetylcholine (AChR) endplates, a 
conserved process distinct form other mechanisms of neuronal degeneration such as 
those induced by traumatic injury (Cifuentes-Diaz et al., 2002). Disrupted connectivity 
at the NMJ remains a consistent feature across multiple mouse models of SMA, albeit 
to varying extents depending on the phenotypic severity of model.  
In addition to disruption of synaptic connectivity, additional morphological defects have 
been reported across multiple mouse models of SMA and have been subsequently 
integrated into the canon of pathological hallmarks. Perhaps the most consistently 
reported is the abnormal accumulation of neurofilament at the presynaptic nerve 
terminal (Cifuentes-Diaz et al., 2002; Kariya et al., 2008; Murray et al., 2008). These 
have also been reported in ALS patients and in mouse models in both the somatic 
body and at the distal nerve terminals of motor axons (Gurney et al., 1994; Mizusawa 
et al., 1989).  
Postsynaptic aspects of the motor neuron also appear to be altered in mouse models 
of SMA, with a developmental delay in the maturation of the acetylcholine receptor 
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endplates reported in both the Δ7 and Smn2B/- models of SMA compared to age-
matched controls (Mélissa Bowerman et al., 2012; Kariya et al., 2008; Kong et al., 
2009).  
 The aforementioned morphological correlates of NMJ pathology convincingly 
implicate the distal synapse as a significant cellular target of SMN depletion in mouse 
models of spinal muscular atrophy. However, an increasing body of evidence suggests 
that subtle morphological and molecular perturbations are also detectable within the 
cell soma of pre-symptomatic period of the Smn2B/- mouse model of SMA, prior to any 
manifestation of neuromuscular junction alterations (Murray et al., 2015). It therefore 
remains to be determined where and when motor neuron pathology, from a molecular 
to a morphological level, begins. Regardless, cytoarchitectural defects in the NMJ are 
undoubtedly robust and well-established pathological correlates of SMA, and will serve 
as the benchmark of the majority of morphological analyses presented in this thesis.  
Molecular aspects of motor neuron pathology.  
Studies aiming to elucidate the molecular basis of these cellular events have revealed 
that perturbations may be present at pre-symptomatic time points prior to any evidence 
of structural or functional changes. An RNAseq analysis of laser-captured motor 
neurons from the longer-lifespan Smn2B/- model suggests that a wide range of  
molecular perturbations, including an upregulation of transcripts involved in apoptotic 
signalling,  are upregulated in motor neuron cell bodies at pre-symptomatic time points 
(Murray et al., 2015). 
The majority of molecular analyses of the motor units of SMA mice has been 
performed in post-symptomatic tissue. Several large-scale transcriptional screens of 
pre- or early-symptomatic SMA tissue, including the spinal cord, reported ubiquitous 
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and extensive transcriptional dysregulation across multiple tissues, despite the 
absence of significant neuromuscular symptoms (Murray et al., 2015; Zhang et al., 
2008, 2013). Among the transcripts dysregulated in both screens, chondrolectin 
(Chodl), has been demonstrated to mediate growth cone defects in the motor axons 
of zebrafish upon knockdown.  Conversely, a similar large-scale exon-level time 
course screen by Baumer et al  (2009) claims that majority of splicing alterations, 
including aberrant splicing of Chodl, occur post-symptomatically in the Δ7 model of 
SMA (Bäumer et al., 2009). In a similar paradox to morphological characterisation of 
the motor neuron in SMA, a greater understanding of the molecular pathways key to 
initiating and executing the degenerative process in the motor unit is required to 
conclusively determine which factors represent definitive therapeutic targets. 
Nevertheless, overlaps in transcriptional changes between mouse models of SMA 
enables consistently altered transcripts, such as chondrolectin, to represent 
transcriptional dysregulation occurring on a larger-scale within the motor unit and 
beyond.   
 
2.3.2 Systemic Pathology in Mouse Models of SMA and Patients 
Although the loss of structural and functional integrity of the lower motor neuron 
appears to be a central defect in the pathogenesis of SMA, histopathological analysis 
of peripheral organs, as well as various tissue-specific knockout models has revealed 
a degree of systemic involvement occurring in SMA, suggesting that SMA is a 
spectrum of pathologies across multiple neuronal and non-neuronal systems. Indeed, 
the involvement of non-neuronal organs and systems, such as the heart and peripheral 
vasculature, has never been more greatly implicated than in recent times when our 
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understanding of the motor neuron degenerative processes has improved, and 
represent an important consideration for the development of future therapeutics.   
In the central nervous system, thalamic degeneration has been reported in severe 
Type I patients(Shishikura, Hara, Sasaki, & Misugi, 1983). Similarly, a morphological 
analysis of the brain of SMN2;Smn-/- mice reported altered morphology in the 
hippocampus, a region with higher relative endogenous expression of SMN, attributed 
to defective neurogenesis, while regions such as the motor cortex, featuring relatively 
lower expression of SMN, remained structurally unaffected(Wishart et al., 2010). 
Functional clustering of the widespread transcriptional alterations identified throughout 
the disease time course of the Δ7 mouse also revealed potential defects in molecular 
pathways responsible for cell proliferation within the spinal cord (Bäumer et al., 2009). 
In the peripheral nervous system, evidence for a disruption in afferent sensory neuron 
signalling has been cited in both clinical findings and from the study of mouse models 
(Jablonka et al., 2006; Mentis et al., 2011).  
Low levels of SMN also appear to affect non-neuronal tissues. Vascular abnormalities, 
manifesting as necrosis of the tail and ears, were originally identified within the first 
transgenic murine models of SMA (Hsieh-Li et al., 2000; U R Monani et al., 2000). 
Necrotic tails and ears have also been reported in models exhibiting a therapeutically-
extended lifespan (Foust et al., 2010; Narver et al., 2008). Similarly, necrosis of the 
distal digits has also been reported in several severely affected SMA Type 1 patients 
(Araujo, Araujo, & Swoboda, 2009).  Mechanistically, an investigation into the 
development process of the peripheral vasculature in the severe Taiwanese mouse 
model reveals widespread developmental defects and accompanying functional 
hypoxia in the spinal cord (Somers et al., 2016). 
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Metabolic tissues, such as the pancreas and liver, also appear to suffer structural and 
functional abnormalities conserved between human patients and mouse models of the 
disease (Bowerman et al. 2012; Hua et al. 2011).  
Cardiac defects appear to be the most notable systemic pathology reported in both a 
number of mouse models and post-mortem analyses of severely affected patients. 
These defects range from morphological abnormalities, such as ventricular thinning 
and atrial-septal malformation, translating to functional deficiencies such as chronic 
brachycardia (Bevan et al., 2010; Gogliotti, Hammond, Lutz, & DiDonato, 2010; 
Rudnik-Schöneborn et al., 2010; Shababi et al., 2010). Perhaps most importantly, 
cardiac defects remain present in several therapeutically-augmented mouse models 
after amelioration of neuromuscular symptoms. In a notable example, a significant 
proportion of the phenotypically mild “Burgheron” mice, developed as a mouse model 
of less severe, SMA Type II and III patients, died suddenly in adulthood without 
exhibiting any overt neuromuscular deterioration. Post-mortem analysis concluded 
that cause of death was attributed to gross cardiac deficits (Bogdanik et al., 2015). 
Likewise, the identification and pharmacological reduction of beta catenin, a 
downstream target of the SMN-associated ubiquitin factor Uba1, successfully 
improved neuromuscular junction pathology and motor deficits in severe Taiwanese 
mice. However, this strategy ultimately failed to modify the lifespan of treated mice; 
histopathological necropsy implicated gross deficits in both the heart and liver of 
treated mice as the cause of death. After an analysis of beta catenin levels in both the 
heart and liver of SMA mice revealed that they were unaffected by ubiquitous depletion 
of Uba1 levels, it became evident that the Uba1-beta catenin pathway was restricted 
to the neuromuscular system and therefore therapeutically irrelevant on a systemic 
level (Wishart et al., 2014). 
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While the ultimate contribution of each of these tissue-specific deficiencies to the 
ultimate pathogenesis of SMA remains under considerable debate, it is clear that 
systemic involvement may significantly influence the severity of the disease time 
course. Together, this information suggests that future therapies must address 
systemic factors in addition to motor neuron defects in order to maximise long-term 
phenotypic outcome. On a relevant sequel to the original Uba1 study, recent findings 
reported that systemic administration of AAV9-Uba1 promoted a robust rescue of 
neuromuscular phenotype, extension of lifespan, and amelioration of molecular 
defects in the ubiquitination pathway in Taiwanese mice. These findings reinforce the 
concept that a systemic approach to targeting molecular candidates affecting 
potentially distinct downstream pathways between tissue types harbours the greatest 
promise in therapeutic efficacy (Powis et al., 2016). 
 
2.4 Therapeutics: Current Studies and Future Implications 
As there is currently no commercially available treatment or cure, the only resources 
available to SMA patients are focussed upon disease management, and in the 
instances of Type I children, palliative care. However, since the characterisation of the 
SMN1 gene in 1995, the overwhelming majority of translational research in SMA has 
aimed to restore pathologically depleted SMN protein levels. To date, a number of 
strategies attempting to increase SMN levels have generated excellent promise in 
basic preclinical studies, enabling several to continue through to early clinical trials. 
Broadly speaking, these proposed SMN-restoration therapies operate on the basis of 
either (1) targeting SMN2 at the gene or protein level in order to enhance endogenous 
production of full-length, stable SMN protein, or (2) restoring SMN1 via viral gene 
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therapy. SMN2-targetting compounds may be further subdivided into antisense 
oligonucleotides designed to inhibit the exonic splicing silencer within exon 7 of SMN2, 
or small molecules either enhancing SMN2 transcription or stabilising fragile SMN 
isoforms translated from SMN2.  
Although the majority of therapeutic developments aim to ameliorate symptoms via 
direct restoration of SMN levels, a number of non-SMN-based compounds have also 
been evaluated for their potential to attenuate neuromuscular symptoms in SMA 
patients, with a number currently in early clinical trials. This thesis seeks to provide a 
brief summary of both SMN-based and non-SMN based therapeutic strategies, 
including outlining the factors identified from translational research to be crucial 
determinants of therapeutic efficacy.  
2.4.1 Non-SMN based therapeutics 
While the majority of translational research in SMA has, unsurprisingly, focussed upon 
the restoration of SMN levels, a number of compounds targeting pathways 
independent of SMN have been championed for their disease-modifying potential. 
These non-SMN-based therapeutics may be broadly categorised as either (1) 
neuroprotective agents or (2) muscular agents. Of particular note is the neurotrophic 
agent olesoxime (TRO19622, Roche, formerly Trophos), which successfully improved 
motor performance in Phase II clinical trials with Type II and Type III patients, and is 
currently entering Phase III trials as of June 2016 (CureSMA, 2016). A comprehensive 
list of non SMN-based compounds registered for clinical trials as of June 2016 has 
been summarised in a review by Shorrock and Gillingwater, 2016 (Shorrock & 
Gillingwater, 2016). 
2.4.2 SMN-based therapeutics 
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Promising translational research using animal models of SMA has produced a number 
of attractive treatment strategies centred around SMN induction, many of which have 
earned a promising position on the drug pipeline. The earliest attempts to increase 
SMN levels utilised histone deacetylase (HDAC) inhibitors, with the aim of inhibiting 
any histone-mediated suppression of the SMN2 gene (Chang et al., 2001).  Application 
of a host of HDAC inhibitors, including sodium butyrate, valproic acid (VPA), 
hydroxamic acids, and trichostatin A (TCA), were successful in increasing production 
of SMN2 transcripts in both patient-derived iPSCs and in phenotypically mild murine 
models harbouring SMN2 (Avila et al., 2007; Brichta et al., 2003; J. G. Chang et al., 
2001; Narver et al., 2008; Riessland, Brichta, Hahnen, & Wirth, 2006; Somers et al., 
2013; Sumner et al., 2003). However, application of these HDACs in both SMA mice 
and in early cohorts of patient trials produced highly variable phenotypic improvement 
despite the consistent increase in SMN2 levels (Avila et al., 2007; Kissel et al., 2011; 
Swoboda et al., 2010). Nevertheless, a comparison of muscular functionality between 
very young (2-3 years of age) and older (6-8 years of age) treated cohorts suggests 
that HDAC inhibitors may prove more beneficial in the earlier stages of disease 
progression, particularly before ambulatory capacity is lost (Kissel et al., 2011; 
Swoboda et al., 2010). Additionally, application of the HDAC Trichostatin A (TSA) also 
promoted notable improvement in both lifespan and motor function of the Smn2B/- 
model, which does not harbour transgenic SMN2 and therefore did not experience an 
accompanying increase in SMN levels, suggesting that TSA may beneficially impact 
molecular pathways out with those directly dependent on SMN (H. Liu, Yazdani, 
Murray, Beauvais, & Kothary, 2014). Other attempts to increase transcription of SMN2 
included identification of a class of compounds, termed quinazolines that inhibit activity 
of the scavenger enzyme DcpS to increase SMN2 promoter activity. However, 
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application of the quinazoline RG3039 to multiple mouse models of SMA ranging in 
phenotypic severity increased lifespan and motor performance despite only a minimal 
increase in SMN levels, also suggesting that RG3039 may mediate the majority of its 
translational activity in non-SMN dependent pathways (Van Meerbeke et al., 2013).  
A second class of therapeutic agents have sought to modulate the aberrant splicing 
pattern of SMN2, rather than merely increase its transcriptional output, via antisense 
oligonucleotide (ASO) technology. ASOs are capable of binding to mRNA sequences 
to silence their translation or promote degradation, as well as binding to pre-mRNA 
sequences to promote their splicing into transcriptional and translational variants.  
Antissense technology has been applied to SMN2 to either favour splice isoforms 
inclusive of exon 7, or else to subjugate intronic splicing repressor regions around 
exon 7.  Of particular note is the antisense oligomer targeting the ISS-N1 intronic 
splicing silencer in SMN2 intron 7 identified by Singh et al., in 2006; operating under 
the commercial name Nusinersin (formerly known as ISIS-SMNRx), ASOs targeting 
ISS-N1 have demonstrated remarkable success through increasing SMN levels in 
both patient-derived cells and systemic induction in mouse models of SMA (Hua, 
Vickers, Baker, Bennett, & Krainer, 2007; Hua, Vickers, Okunola, Bennett, & Krainer, 
2008; Mitrpant et al., 2013; Porensky et al., 2012; Singh, Singh, Androphy, & Singh, 
2006). Phenotypically, this robust induction of SMN upon the ISS-N1 ASO has 
translated into a profound extension of lifespan and amelioration of neuromuscular 
phenotype across a number of mouse models ranging in symptomatic 
severity(Williams et al. 2009; Hua  et al. 2011; Porensky et al. 2012)                                           
.       
Subsequent clinical trials of Nusinersen in both Type I and later-onset patients have 
produced similar success in motor improvement, muscular strength, and extension of 
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lifespan (Ionis Pharmaceuticals, Clinical Trials: NCT02386553, NCT02462759, 
NCT02594124, NCT02292537, NCT02193074, NCT02052791, NCT01839656, 
NCT01780246, NCT01703988, NCT01494701). On 1 August 2016, plans were 
announced to conclude Phase III clinical trials in Type I infants, thereby signifying 
preparation for the approval process by the Food and Drug Administration (CureSMA, 
2016).  
Finally, a third class of agents have utilised gene therapy to replace SMN1. SMN cDNA 
was first delivered intravenously via the self-complementary adeno-associated virus 
serotype 9 AAV9 (scAAV9-SMN), in neonatal one- or two-day old Δ7 mice, to mediate 
a robust prevention of in neuromuscular damage and striking extension of lifespan to 
a near-normal average(Foust et al., 2010). Application of scAAV9-SMN has 
recapitulated this phenotypic rescue through systemic administration in both 
nonhuman primates and pigs, while exhibiting similar capacities for efficient blood 
brain-barrier and systems-wide penetration(Duque et al., 2015; Meyer et al., 2015). 
As of June 2016, intravenous injection of scAAV9-SMN gene therapy sponsored by 
AveXis is currently under Phase I clinical trials (AveXis, Clinical Trial: NCT02122952).  
Despite extraordinary advancements in the extension of lifespan and improvement of 
neuromuscular phenotype through SMN-based therapeutics, the precise molecular 
mechanisms by which postnatally-restored SMN either halts or improves the 
degenerative process remain poorly characterised. However, from the studies outlined 
above, it is evident that efficacious SMN-based therapeutic intervention requires must 
adhere to a set of limitations, which are summarised by the following three criteria:   
(1) systemic, rather than a CNS-based, delivery method 
(2) sufficient increase in the level and bioavailability of restored SMN  
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  (3) early postnatal administration, at a pre- or early-symptomatic time  point 
This thesis seeks to briefly discuss these criteria, with a particular emphasis on the 
crucial need for restoration to occur at an early and pre- or early-symptomatic time 
point.  Indeed, there appears to be a clearly defined therapeutic time window for the 
induction of SMN, in which attempted restoration out with these early postnatal days 
results in significantly reduced efficacy. By examining the cellular and molecular 
factors underlying this apparent temporal “window of opportunity,” it may be possible 
to enhance our understanding of SMN’s role in the maintenance and function of the 
motor unit. It will also be possible to identify what factors are critical for neuromuscular 
repair, and which aspects may be irreparable despite intervention and therefore 
represent a target for alternate therapeutic strategies.   
Systemic versus CNS-based delivery method 
As described previously in this thesis, it has become increasingly evident that the 
cellular and molecular dysfunction resulting from depleted SMN levels is not restricted 
to the motor unit.  Previous work therapeutically targeting a neural-specific molecular 
pathway in mice failed to improve overall survival; indeed, these results emphasised 
the involvement of multi-organ, particularly cardiovascular, pathology in disease 
prognosis (Wishart et al., 2014). Subsequently, it appears that systemic, rather than 
previously explored CNS- or neural-specific delivery methods harbour the greatest 
potential in improving not only motor neuron pathology, but also overall survival. These 
findings are effectively represented in comparison studies with an equivalent dose of 
ASO administered introcerebroventricularly (ICV) versus systemically in severe, 
Taiwanese pups at P10. While pups receiving systemic injection of the ASO survived 
43 
 
to a median of 108 days, pups receiving an identical ICV dose of the ASO limited to 
the CNS only survived to a mean of 16 days (Hua et al., 2011). 
Threshold requirement for SMN 
Due to the long-established correlation between SMN levels and disease severity, it 
is perhaps natural to conclude that therapies promoting only a minimal increase in 
SMN level prove largely inefficient in attenuating neuromuscular or systemic pathology 
alike upon application in mouse models and clinical trials. Indeed, the overall minimal 
impact of quinazoline compounds upon phenotypic outcome in mouse models has 
been attributed to its failure to increase in SMN levels sufficiently in vivo (Van 
Meerbeke et al., 2013). From an understanding of the molecular genetics behind the 
disease as well as aforementioned studies restoring SMN by exogenous agents, there 
is an evident physiological threshold dictating the onset, or conversely, amelioration, 
of an SMA phenotype. Bowerman et al. (2012) utilised the novel 2B allele, which 
produces approximately 15% of SMN compared to the wildtype Smn allele, to explore 
the point at which an SMA phenotype becomes evident. Their findings concluded that 
the “switch” from asymptomatic status to an SMA phenotype must occur upon 
depletion of SMN to below 30% of normal levels, thereby supporting the existence of 
a rigid threshold requirement for SMN (Bowerman et al. 2012). This physiological 
threshold must be considered in ensuring high bioavailability of postnatally-restored 
SMN, with only delivery methods capable of exceeding this threshold considered to 
be clinically relevant. With consideration to the increasing implications of multi-organ 
involvement in SMA, this threshold must also therefore be considered on a systems-
wide level. 
Timing of postnatal administration: “the earlier the better” 
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Finally, mounting evidence highlights the existence of a “therapeutic time window” for 
SMN-based treatments. From both gene therapy and ASO studies in multiple animal 
models of SMA, it is clear that early treatment, at either a pre-symptomatic time point 
or at initiation of phenotypic onset, profoundly attenuates pre-existing neuromuscular 
weakness and prevents the neuromuscular junction denervation and muscle wasting 
characteristic of the normal disease course. Most importantly, early intervention has 
been demonstrated to robustly prolong survival, often to a duration comparable with a 
normal murine lifespan (Foust et al., 2010; Hua et al., 2011; Passini et al., 2011; 
Porensky et al., 2012). However, efficacy of this phenotypic rescue drops accordingly 
with a temporal delay in administration; indeed, of survival capacity has been shown 
to be significantly reduced when administration is delayed by as little as 48 hours 
(Foust et al., 2010; Hua et al., 2011; Kariya et al., 2014; Lutz et al., 2011; Robbins et 
al., 2014). The mechanisms underpinning this limited window of opportunity remain 
poorly understood, but must be elucidated in order to ensure the accessibility of SMN-
based therapeutics to all patients. As prenatal screening of SMA is not currently 
available, the indisputable majority of SMA patients are diagnosed after 
neuromuscular symptoms—and therefore neuronal and systemic pathology—have 
already manifested. If indeed, as the animal data to be discussed below has 
suggested, the therapeutic benefit of SMN restoration is significantly hindered by the 
presence of existing pathology, there is therefore an utmost urgency to understand 
what cellular or molecular factors comprise this therapeutic window and how they may 
be pharmacologically manipulated in order to extend it.   
 
2.4.3 The therapeutic window: from the perspective of the NMJ 
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In addition to the robust evidence detailing the temporal limitations of SMN-based 
therapies via scAAV9-SMN and ASO targeting techniques, a study generating a 
conditional model of SMN restoration in a mouse model of SMA further reaffirmed the 
existence of an SMN-dependent therapeutic window (Lutz et al., 2011). By 
engineering a floxed murine allele, termed Res, in which murine Smn exon 7 was 
replaced by a sequence containing SMN2 exon 7 (inclusive of exonic splicing silencer) 
and inverted murine Smn exon 7, the so-called SmnRes mouse served as, in absence 
of Cre-mediated recombination at the loxP sites, an mouse model of SMA exhibiting 
a similar disease course to the Δ7 model of SMA. Phenotypic onset occurred at 
approximately 4 days old and reached end-stage at approximately 14 to 16 days (Lutz 
et al., 2011). Administration of tamoxifen activated the expression of the oestrogen 
receptor-fused Cre recombinase, which in turn promoted recombination of the Res 
allele and therefore re-expression of full-length SMN inclusive of exon 7 (Lutz et al., 
2011). By providing an elegant system for the conditional postnatal induction of SMN, 
Lutz et al. (2011) generated an efficient model in which it was possible to examine 
neuromuscular and systems-wide pathology after SMN was restored at different 
postnatal time points.  
Initial experiments administering tamoxifen at different postnatal time points within the 
SmnRes model recapitulated the therapeutic window outlined by previous studies 
utilising gene therapy or ASOs; maximal rescue was achieved with treatment at P2 
and P4, with efficacy dropping by treatment at P6 (Lutz et al., 2011). Strikingly, 
administration of tamoxifen at P8, by which neuromuscular symptoms had advanced 
significantly, was virtually ineffective in attenuating neuromuscular symptoms or 
prolonging lifespan beyond that of the untreated Δ7 model (Lutz et al., 2011). 
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From this study and others, there is therefore a clearly defined therapeutic window in 
which postnatal restoration of SMN is effective, but the mechanisms behind this 
temporal limitation are poorly understood. Importantly, the in-depth characterisation of 
this therapeutic window by Lutz et al. (2011) highlights that phenotypic outcome 
systematically decreases in direct correlation delays in treatment. This gradual 
decrease in therapeutic efficacy invites the suggestion of a number of dynamic 
processes occurring within the motor unit and beyond, that evolve over this period to 
produce differential outcomes following SMN treatment. It is perhaps natural to 
assume that these dynamic alterations are merely the progression of motor neuron 
pathology to a late-symptomatic “point of no return” after which treatment with SMN is 
futile. By this hypothesis, it would be possible to infer that postnatally-restored SMN 
produces no unique effect upon the motor unit beyond halting subsequent 
degeneration. In other words: Does induction of SMN merely maintain the status quo 
of the motor unit at time of rescue, and therefore must be performed at an early time 
point, before degeneration has progressed to a lethal extent?  
However, it is not unreasonable to hypothesise that intervention with SMN-dependant 
therapeutics may enable repair mechanisms to occur within the motor unit. 
Regeneration of the peripheral nervous system, including reinnervation of 
neuromuscular junctions following traumatic injury has been reported, albeit never 
investigated in a model of SMA (Barry & Ribchester, 1995). In examining the muscles 
of successfully rescued SmnRes mice (ie. those treated from P2-P6), Lutz et al. (2011) 
observed a marked absence of neuromuscular junction pathology, a finding concurrent 
with other reports of SMN-mediated phenotypic rescue. However, in both the Lutz 
study and in other studies to date, it is unclear whether the lack of NMJ pathology in 
phenotypically improved mice is attributed to a mere halting of any degeneration 
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present at time of rescue, or whether early intervention with SMN enables regenerative 
mechanisms to repair pre-existing damage, the capacity for which is lost at later time 
points? In other words: Is postnatal induction of SMN capable of mediating processes 
capable of repairing pre-existing damage? If so, what aspects of the motor neuron are 
successfully corrected, and which remain damaged beyond repair? 
By determining what cellular events may occur at the highly vulnerable neuromuscular 
junction in the event of early versus late-symptomatic SMN restoration—promoting 
successful versus failed phenotypic rescue, respectively—it will be possible to 
understand the mechanisms dictating the therapeutic window. After first profiling the 
extent of cellular and molecular disruption present within a mouse model of SMA at a 
point of early symptomatic onset, it will then be possible to utilise these findings to 
conclude whether restoration of SMN to the early-symptomatic motor unit merely halts 
or truly reverses degeneration.   
Defining the neuromuscular junction response to postnatally restored SMN at different 
symptomatic phases will not only enhance our understanding of SMN’s role in the 
maintenance and function of the motor unit, but will also be critical in providing the 
most efficacious treatment for SMA patients. At the moment, there is no postnatal 
screening for SMA available; consequentially, patients are usually diagnosed because 
they are exhibiting neuromuscular abnormalities or missing developmental motor 
milestones. Understanding what cellular and molecular events limit the therapeutic 
window may enable us to develop a means of manipulating and extending these 
limitations with other methods, thereby rendering SMN-based treatments an 




2.5 Aims of this chapter 
2.5.1 Summary 
To summarise, spinal muscular atrophy is a heritable neurodegenerative 
disease caused by insufficient production of SMN protein. The archetypal pathological 
hallmark of SMA remains definitively neuromuscular, with a series of pre- and post-
synaptic perturbations promoting a loss of cytoarchitectural integrity at the 
neuromuscular junction. These morphological deficits are accompanied by a broad 
range of dysregulated molecular cascades within the motor unit and beyond. Recent 
therapeutic advances in the SMA field demonstrate a remarkable amelioration of 
disease phenotype and extension of lifespan through postnatal restoration of SMN. 
However, the success of this SMN-based rescue phenomenon appears to be 
temporally limited; maximal rescue is achieved when SMN is restored at an early 
postnatal time point, but efficacy of rescue drops with later restoration of SMN. There 
is therefore an apparent “therapeutic window” of opportunity for effective SMN 
treatment, the mechanisms behind which are currently poorly understood. 
Additionally, it has become evident that the fate of pathological correlates within the 
motor unit, particularly at the neuromuscular junction, remain uncharacterised in 
situations of successful improvement versus failed amelioration of gross phenotype. 
We hypothesise that an understanding of the cellular and molecular factors comprising 
successful SMN-based recovery versus deterioration may provide a mechanistic 
explanation of the temporal limitations of SMN-based therapies.  
We have established a conditional mouse model of SMN restoration designed by Lutz 




“Which pathological features present in the motor unit, particularly the neuromuscular 
junction, at time of SMN restoration are irreparable, and which harbour the capacity 
for recovery?” 
 In this thesis, I perform an extensive cellular and molecular characterisation of the 
SmnRes  mouse model of SMA with a particular emphasis on synaptic pathology, pre- 
and post-restoration of SMN, to address the following aims: 
 
2.5.2 Aims  
AIM 1: Investigate the extent of cellular and molecular pathology present within 
the SmnRes mouse model at P4, a symptomatic time point within the therapeutic 
window.  
1a. Characterise the typical disease time course of the SmnRes mouse model of 
SMA in our hands, in order to identify the point of symptomatic onset. 
1b. Investigate the presence of both pre- and post-synaptic neuromuscular 
junction pathology in a selection of muscle groups within the SmnRes model at 
an early-symptomatic time point identified in 1a.  
1c. Determine if molecular alterations suggesting an up-regulation of the p53 
apoptotic cell death pathway in other mouse models of SMA are present in the 
SmnRes model at early-symptomatic time point outlined in 1a.  
1d. Assess whether select transcriptional alterations identified from large-scale 
screens of two different early-symptomatic SMA mouse models are also 




AIM 2:  Investigate structural modifications at the neuromuscular junction that 
accompany rescue of neuromuscular phenotype after conditional re-expression 
of SMN at an early symptomatic time point in the SmnRes model. 
2a. Induce re-expression of SMN at the early symptomatic time point identified 
in 1a in order to evaluate phenotypic improvement and survival in our hands.  
2b. Assess and compare the pathological status of neuromuscular junctions 
within a variety of muscle groups in rescued versus non-rescued SmnRes mice. 
2c. Determine whether the differences in pathology between rescued and non-
rescued mice reported in 1b are the result of restored SMN slowing, halting, or 














Chapter TWO: Methods 
2.6 The Cre-ER; SMN2; Δ7; SmnRes Mouse 
Design of the “Res” allele. The tamoxifen-inducible Cre-ER; SMN2; Δ7; SmnRes mouse 
model used in this thesis was generated by Lutz et al, (2011) and established in our 
own facilities. In addition to expressing both SMN2 and SMNΔ7 (see et al), the Cre-
ER; SMN2; Δ7; SmnRes mouse harbours a novel, rescuable Smn allele designed by 
Lutz et al (2011), hereforth referred to as the “rescue” or Res allele. BAC clones 
containing human SMN2 (BAC 939i7) and murine Smn (BAC 148d4) were used as 
the starting sequences to target endogenous murine Smn. A BAC-based targeting 
vector was designed (Valenzuela et al., 2003) via homologous recombination to 
replace endogenous Smn exons 7 and 8 with a donor cassette, containing the 
following in order: a short upstream region (homogology upstream [HU]), homologous 
to mouse BAC, a lox71 site, a 380bp sequence containing exon 7 and flanking intronic 
sequences of human SMN2, a 387bp fragment containing, in an inverted orientation, 
the sequences of murine Smn exon 7 and flanking introns, a lox66 site in inverted 
orientation to lox71, a hygromycin resistance gene under both prokaryotic and 
eurkaroytic promoters flanked by FRT sites, a 928bp fragment containing exon 8 of 
human SMN2, and a short downstream region (homology downstream [HD]) 
homologous to the mouse BAC (see Figure 2.4). This vector, comprising endogenous 
Smn exons 1-6 fused to the hybrid sequence outlined above, was linearized and 
electroporated into VGF1 ES cells. A LONA assay was used to isolate hygromycin-
resistant ES colonies (Osoegawa et al., 2000). After FLP-mediated removal of the 
hygromycin resistance gene, cells were microinjected into donor 8-cell embryos to 
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generate mice on an FVB background (Poueymirou et al., 2007). Mice heterozygous 
for this novel rescue allele (SmnRes/+); (stock no. 007249, Jackson Laboratory) formed 
the basis of breeding to generate the Cre-ER; SMN2; Δ7; SmnRes line. 
Figure 2.4 Construction of the Res allele with corresponding transcriptional 
products. A. Wildtype murine Smn (exons 6, 7 and 8) shown for reference, with 
transcriptional outcome being production of full-length murine Smn transcript. B. The 
Res allele designed by Lutz et al comprises a BAC-based targeting vector containing 
endogenous murine Smn exons 1-6 fused to the following hybrid sequence: intronic-
inclusive sequences of SMN2 Exon 7 and inverted intron-inclusive sequences of 
murine Smn Exon 8 is floxed by two loxP sites in opposing orientations, as well as a 
FRT-flanked hygromycin resistance gene and exon 8 of human SMN2. This vector 
was introduced into VGF1 ES cells, which were then selected for hygromycin 
resistance. After FLP-mediated removal of the hygromycin resistance gene, the 
inverted orientation of murine Smn Exon 7 within the SmnRes allele results in the 
majority of transcripts produced to be truncated and unstable due to their lack of exon 
7 (SmnΔ7).  C. Following administration of tamoxifen, Cre-mediated recombination at 
loxP sites results in restoration of normal orientation of murine exon 7, and therefore 




Generation of the EIIa-Cre; SMN2; Δ7; SmnRes/+ mouse. SmnRes/+ mice were then 
crossed to heterozygous Δ7 SMA carriers (Jax stock no. 007951; Jackson 
Laboratory). These progeny, termed SMN2; Δ7; SmnRes/+ were then crossed to TM-
inducible (Cre-ER) carriers (Jax stock no. 004682; Jackson Laboratory) to generate 
heterozygous SmnRes/+ progeny either carrying (EIIa-Cre; SMN2; Δ7; SmnRes/+) or 
lacking (SMN2; Δ7; SmnRes/+ ) the EIIa-Cre allele, ie. the capacity for tamoxifen-
induced recombination. The Cre-ER; SMN2; Δ7; SmnRes line was imported, bred and 
maintained in our own facilities at the University of Edinburgh.  
Generation of tamoxifen-inducible SMN2; Δ7; SmnRes/Res mice. The SMN2; Δ7; 
SmnRes/+ carriers, either carrying or lacking the EIIa-Cre allele outlined above were 
intercrossed to generate the experimental cohorts used in this project.  EIIa-Cre; 
SMN2; Δ7; SmnRes/+ mice were crossed to SMN2; Δ7; SmnRes/+ mice to yield litters with 
approximately 25% SMA pups. Of these SMN2; Δ7; SmnRes/Res offspring, 
approximately 50% harboured the EIIa-Cre allele and were therefore tamoxifen-
rescuable, with the other approximate 50% not expressing EIIa-Cre to serve as 







Figure 2.5.  Schematic of breeding to generate experimental cohort. 
Crossing EIIa-Cre; SMN2; Δ7; SmnRes/+ mice to SMN2; Δ7; SmnRes/+ produced litters 
of which approximately 25% were homozygous for the SmnRes allele, ie. SMN2; Δ7; 
SmnRes/Res; homozygosity of the Res allele ensured majority production of truncated 
Smn transcripts, and therefore molecularly to phenotypically recapitulated SMA. Of 
these SMA pups, approximately 50% (ie. 12.5% of the total litter) also carried the EIIa-
Cre allele, and therefore the capacity to undergo Cre-mediated recombination of the 













2.7 Animal Breeding and Maintenance 
All mice used in this project were treated in accordance with the guidelines outlined 
by the UK Animal Scientific Procedures Act (1986), following the three principles of 
Reduction, Refinement and Replacement. The Cre-ER; SMN2; Δ7; SmnRes colony was 
maintained under Specific and Opportunistic Pathogen-Free conditions in individually 
ventilated cages (IVC) in breeding facilities at the University of Edinburgh.  
All mice were sacrificed by an overdose of anaesthetic (IsoFlo, Abbott, Quebec, 
Canada). All procedures were performed in accordance with the guidelines outlined 
by the Home Office, United Kingdom. For molecular and morphological 
characterisation of the postnatal time point at which tamoxifen-inducible recombination 
and phenotypic rescue was reported to be maximally effective by Lutz et al (2011), 
pups were sacrificed at an early symptomatic timepoint (P4). For molecular and 
morphological characterisation of post-phenotypic rescue, pups were sacrificed at P10 












DNA was extracted from ear notches (weaned) or tail tips (sacrificed pups) by 
digesting the tissue in Tail Tip Lysis Buffer (TTLB); 0.5M EDTA, 1M Tris-HCl, 1M NaCl, 
10% SDS, ddH2O) and Proteinase K (1mg/ml) overnight at 55°C. DNA was 
precipitated in isopropanol and washed in 70% ethanol before suspension in 200µl of 
ddH2O to yield a concentration of approximately 200ng/µl.  
SmnRes genotyping. To determine the presence of the non-inverted Res allele, 
polymerase chain reaction (PCR) was performed using a Kapa2G Robust PCR kit with 
dNTPs (Kapa Biosystems Ltd). Oligos (Sigma-Aldrich) were designed for specific 
binding to the noninverted, native Res allele based on the forward (5’- 
GGCAGTTTTAGACTCATCATGTATCTG-3’) and reverse (5′-
ACTTATGGAGATCCCTCGAGATAAC-3′) primer sequences published by Lutz et al. 
Amplification was performed in a CFX Connect™ Real-Time PCR Detection System 











Table 2.1 SmnRes genotyping thermocycling conditions 
 
Amplified product was separated by gel electrophoresis; product was run in 1x TAE 
buffer on a 1.5% agarose gel containing 0.01% SYBRSafe© DNA stain (Invitrogen) at 
100V for 40 minutes. Gel was imaged on a UV transilluminator and identity of PCR 
product was distinguished based on band size. The product of the wildtype reaction 
produced a band of approximately 150bp and the transgenic reaction of 103bp.   
Cre-ER genotyping. To determine the presence of the CreER allele, PCR was 
performed using an Invitrogen Taq polymerase kit (Promega) and primers were 
designed based on publication by Lutz et al. Primers were designed according to the 
forward: (5’ – GCGCTCTCCCAGTAAAAACTATC – 3’) and reverse (5’ – 
GTGAAACAGCATTGCTGTCACTT – 3’) primer sequences published by The Jackson 
Lab’s Cre-transgenic genotyping protocol. Amplification was performed in a T1 
Thermoblock thermal cycler (Biometra) to the following temperature cycling protocol: 
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Table  2.2 EIIa-Cre genotyping thermocycling conditions. 
 
    
 
Amplified product was separated by gel electrophoresis; product was run in 1x TAE 
buffer on a 1.5% agarose gel containing 0.01% SYBRSafe© DNA stain (Invitrogen) at 
100V for 40 minutes. Gel was imaged on a UV transilluminator and identity of PCR 
product was distinguished based on band size. The product of the wildtype reaction 










2.9 Phenotypic Assessment of Mice 
Weight/righting reflex. Litters from SmnRes/+; SmnRes/+ breed pairs were monitored daily 
for SMA-like phenotypes. At P4, pups were weighed and righting reflex was tested to 
evaluate muscle strength.  Pups were turned over on their back on a flat bench top 
with all four paws in the air, and the time for them to right and stably place all four 
paws on the bench top was recorded.  Cut-off time for righting was set at 30 seconds. 
All pups were righted twice, with a minimum of two minutes rest in nests between tests 
to minimise the possibility of hypothermia-induced fatigue. For experiments 
characterising pups at an early symptomatic time point, pups and littermate controls 
were sacrificed by overdose of inhalational isoflurane and decapitation at P4. For 
experiments characterising restoration of SMN at an early symptomatic time point, 
pups were dosed at P4 with a 75mg/kg solution of tamoxifen in corn oil and monitored 
closely in the following days for signs of musculoskeletal weakness. Pups were 
weighed and subjected to time to right test at P6, P8 and P10, at which they were 











2.10 Tamoxifen Dosing 
A tamoxifen solution of 40mg/ml TM (Sigma-Aldrich) was prepared in corn oil (Sigma-
Alrdich) by 3x15 minutes dissolution in a sonicating water bath at 37.5°C.  P4 pups 
from SmnRes/+; Cre-ER+/- and SmnRes/+; Cre-ER-/- crosses phenotypically identified to 
be SMA were administered a 75 mg/kg dose of this solution by oral gavage. Following 
dosing, pups were closely monitored, and weight and motor performance were noted 
at P6, P8 and P10, before sacrifice by overdose of inhalational isoflurane and 
decapitation at P10.  n=3 mice exhibiting phenotypic rescue were continually 
monitored, weighed and motor performance tested through weaning into adulthood. 
1-2cm tail tips were taken from sacrificed pups for DNA extraction and retrospective 














2.11 Quantitative Fluorescent Western Blotting 
Extraction and sample preparation. Spinal cords were freshly dissected and halved at 
the dorsiventral midline, and immediately snap-frozen on dry ice and stored at -80°C. 
Tissue was homogenized using a handheld motorized pestle (VWR International) in 
100µl RIPA buffer (Fisher Scientific) with 1% Halt protease inhibitor cocktail (Sigma 
Aldrich). Homogenate was cooled on ice for 10 minutes, then centrifuged at 4°C at 
14000rpm for 10 minutes. Centrifuged samples were immediately re-transferred to ice 
and supernatant was removed by pipetting, while pellet was discarded. Concentration 
of extracted protein was determined by micro-BCA kit (Pierce Biosystems). 
Quantitative fluorescent western blotting. Samples were prepared to load between 10 
and 25µg of protein in 10 µl deionised water and 5µl of NuPage® LDS Sample buffer 
4X (Invitrogen, UK). Samples were denatured at 98°C for 2 minutes and were loaded 
in a NuPAGE™ Novex™ 4-12% Bis-Tris protein gel (Invitrogen, UK) alongside 5µl of 
Novex® Sharp Pre-stained Protein Standard (Thermo Fisher). Gels were run at 80mV 
for 5 minutes to ensure equal stacking, then 150mV for 50 minutes. Gels were excised, 
removed to a pre-prepared i-Blot2® transfer stack (Invitrogen, UK) and transferred 
using an 8.5 minute transfer cycle in the i-Blot2® transfer system (Invitrogen, UK).  
After transfer, membranes were excised and transferred to 20ml Falcon tubes 
containing 5ml of Ponceau S solution; 0.1% Ponceau S (Sigma-Aldrich), 0.5% acetic 
acid (Sigma-Aldrich) in ddH2O. Membranes were stained for 20 minutes, rolling, at 
room temperature then washed in ddH2O until bands were visible. Membranes were 
scanned in greyscale using a CanoScan LiDE220 digital scanner (Canon) and saved 
as a TIFF image for total protein analysis. Membranes were washed in ddH2O and 
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blocked in 5ml Odyssey® Blocking Buffer (Li-COR Biosciences) at room temperature 
for 30 minutes.  
Membranes were incubated in primary antibody solution containing primary antibodies 
at the following concentration (Fas 1:1000, Abcam) in a solution of 1% tween-20 
(Sigma) in 5ml Odyssey® Blocking Buffer (Li-COR Biosystems) at 4°C overnight. 
The following day, membranes were washed 6x 5 minutes in PBS, rolling, at room 
temperature. Membranes were incubated in secondary antibody solution containing 
IRDye® 680RD  donkey anti-rabbit IgG (H+L) (Li-COR Biosciences) at a concentration 
of 1:5000 (0.02%) in a solution of 1% tween-20 (Sigma) in 5ml Odyssey® Blocking 
Buffer (Li-COR Biosciences). Membranes were incubated for 90 minutes at room 
temperature and covered to prevent photobleaching.  
After secondary antibody incubation, membranes were washed 2x 5 minutes, then 3x 
10 minutes in PBS, rolling, at room temperature. Membranes were dried and stored at 
4°C prior to imaging and analysis. 
Measurement and analysis. TIFF images of Ponceau-stained blots were imported into 
Odyssey® ImageStudio Lite software (Version 5.2). ImageStudio Lite (Version 5.2) 
was used to analyse the intensity of identical sections of total protein banding against 
background. Readouts of the intensity of total protein banding relative to background 
were imported into Microsoft Excel (Windows 2013) to calculate loading consistency 
and normalisation factors. Western blots were imaged on the 700nm channel using 
the Odyssey® Infrared Imaging System at a resolution of 169µm. All quantification 
was performed on the 700nm channel, with the intensity of bands normalised using 
the factors generated from total protein analysis. All statistical analysis and generation 
of graphs was performed in GraphPad Prism7 (Windows). All data are presented as a 
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scatter plot of individual n  with mean ± SE unless otherwise noted. Individual statistical 
tests used are noted in figure legends. Statistical significance was considered to be p 





















Dorsiventrally halved spinal cords of freshly dissected mice were snap-frozen on dry 
ice and stored at -80°C. RNA was extracted from thawed tissue using a microRNeasy 
kit (Qiagen) according to manufacturer’s instructions and concentration was 
determined using NanoDrop (Thermo Scientific). Reverse transcription was performed 
using an RT2 First Strand Kit (Qiagen) using 1µg of RNA per reaction to generate 
cDNA.  
SYBR Green Assays. For SYBR-Green compatible primer-designed assays to 
determine relative expression of Fas, Phorbol-12-Myristate-13-Acetate-Induced 
Protein 1 (PMAIP) and (Cyclin-Dependent Kinase Inhibitor 1A) CDKN1a, RT-qPCR 
was performed using KAPA2G Robust PCR Master Mix  with dNTPs (KAPA 
Biosystems) in a CFX Connect™ Real-Time PCR Detection System according to the 
following temperature cycling protocol compatible with KAPA2G Robust PCR Master 
Mix with dNTPs:  




Three housekeeping genes (GAPDH, YWHAZ, β-actin) were used in each assay. All 
samples were run in technical triplicate.  
TaqMan Assays. To determine relative expression of chondrolectin (Chodl), ETS 
Variant 1 (Etv1) and Ubiquitin specific peptidase-like 1 (Uspl1), pre-optimised 
Taqman®  gene expression assays were used in combination with TaqMan® Gene 
Expression Master Mix according to manufacturer’s instructions. RT-qPCR was 
performed in a CFX Connect™ Real-Time PCR Detection System according to 
temperature cycling protocol compatible with TaqMan® Gene Expression Master Mix: 
Table 2.4  TaqMan® Gene Expression Master Mix Thermocycling Conditions 
 
 Four housekeeping genes (β-actin, Gusb, Hprt and GAPDH) were used in each 
assay. All samples were run in technical triplicate.  
For all RT-qPCR assays, graphs were generated and statistical analyses were 
performed using Bio-Rad CFX Manager™ software. Data are presented as a bar chart 
of mean ± SE unless otherwise noted. Individual statistical tests used are noted in 
figure legends. Statistical significance was considered to be p ≤ 0.05. Figures were 





2.13 Whole-mount immunofluorescence 
Dissection and immunocytochemical labelling. Gross preparation of cranial and 
abdominal muscles were freshly dissected, pinned and fixed in 4% paraformaldehyde 
in phosphate buffered saline, rocking, for 15 minutes. Fixed preparations were finely 
dissected under a microscope (Leica) to isolate muscles of interest. Refer to Figure 
2.6 for a schematic detailing the anatomical location of muscles isolated; the cranial 
muscles (rostral and caudal levator auris longus (LALr/LALc), abductor auris longus 
(AAL) and auricularis superior (AS)) and the transversus abdominis (TVA) were 
utilised in all whole-mount immunofluorescence experiments. Muscles were 
permeabilised for 1 hour in 2% Triton-PBS, followed by blocking in 4% bovine serum 
albumin, 1% Triton-PBS. Muscles were incubated for a minimum of 48 hours at 4°C in 
primary antibody solution at the following concentrations: synaptic vesicle protein 2 
(Developmental Studies Hybridoma Bank, Iowa) 1:100; neurofilament 2H3 
(Developmental Studies Hybridoma Bank, Iowa) 1:50, in 4% bovine serum albumin, 
1% Triton-PBS. Preparations were washed 3x10 minutes in PBS and incubated for a 
minimum of 24 hours in 488-conjugated IgG secondary antibody solution (Jackson 
ImmunoResearch) at a concentration of 1:250 in phosphate buffered saline, and 
covered to prevent photobleaching. Preparations were washed 3x 10 minutes and 
incubated for 90 minutes in tetramethylrhodamine-conjugated α-bungarotoxin (TRITC-
α-BTX) (Life Technologies) at a concentration of 1:250 in phosphate buffered saline.  
Preparations were washed 3x 10 minutes in phosphate buffered saline and mounted 
on slides (Menzel-Glasser) in Mowiol Mounting Medium® (Sigma-Aldrich) and 







Imaging and analysis. Quantification of endplate occupancy and neurofilament 
accumulation, was performed using a Leica DMi8 inverted epifluorescent microscope 
(Leica Microsystems) (10x, 20x and 40x objectives; 0.53, 0.55 and 0.9NA; Leica DMi8 
microscope; Leica DFC7000-T camera). Labelled pre-synaptic nerve terminals were 
visualised using 488nm excitation and 520nm emission optics, while TRITC-α-BTX-
labelled endplates were visualised using 543nm excitation and 590nm emission 
optics. Quantification of endplate occupancy and neurofilament accumulation was 
performed blind, and incorporated a minimum of 50 neuromuscular junctions (NMJs) 
from at least three distinct fields of view per muscle (n=number of muscles muscle, N= 
number of mice; n=2 muscles, ie. one pair per muscle type, per N). Endplate 
occupancy was quantified to the following criteria: fully occupied, ie. complete 
coverage of the post-synaptic endplate by the branches of the nerve terminal; partially 
occupied, ie. partial withdrawal of the pre-synaptic nerve terminal from the post-
synaptic endplate, or vacant, ie. complete withdrawal of the pre-synaptic nerve 
terminal from the post-synaptic endplate. Neurofilament accumulation was quantified 
to the following criteria: Stage 1: no accumulation visible; Stage 2: individual nerve 
terminal branches swollen, complexity of nerve terminal branching retained; Stage 3: 
severe accumulation, complexity of nerve terminal branching largely lost, underlying 
post-synaptic endplate largely obscured; Stage 4: complete and absolute obscurity of 
the post-synaptic endplate by the neurofilament-engorged nerve terminal. To measure 
endplate size TRITC-α-BTX-labelled endplates were imaged using 543 nm excitation 
and 590 nm emission optics, and images were exported from Leica Application Suite 
LASX software (Leica Microsystems) as a TIFF file and analysed in greyscale using 
Fiji ImageJ software.  Individual endplate measurements were determined using the 
“freehand draw” tool in Fiji ImageJ software; a minimum of from at least three distinct 
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fields of view per muscle (n=2 muscles, ie. one pair per muscle type, per N). All 
quantification was performed blinded to ensure there was no knowledge of genotype. 
Images were blinded to ensure there was no knowledge of genotype. Individual 
statistical tests and n numbers used are noted in figure legends. Statistical significance 
was considered to be p ≤ 0.05. 
Confocal microscopy was performed using a Nikon A1R+ Resonant Scanning System 
(Nikon) (10x and 40x objectives; 0.3 and 1.3 oil NA; Nikon A1R+ microscope; 
simultaneous image acquisition). 488 and 543 nm laser lines were used for excitation.  
The resultant confocal Z-series produced in NIS Elements 2D Analysis software were 
exported and merged using Fiji ImageJ software. 














Chapter TWO: Results 
 
2.14. Cellular and molecular characterisation of the motor unit in the 
early symptomatic Cre-ER; SMN2; Δ7; SmnRes  mouse  
 
The initial aim of this study was to identify and characterise what cellular and molecular 
perturbations may exist in the Cre-ER; SMN2; Δ7; SmnRes (SmnRes) mouse model, 
newly established in our breeding facilities, at a designated early symptomatic time 
point. I selected postnatal day 4 (P4), a time point near the limits of the therapeutic 
window, as the age at which I would perform this pathological investigation. Published 
findings by Lutz et al (2011) and our own phenotypic observations (unpublished) 
identified P4 as a point within the disease time course at which a neuromuscular 
phenotype was significantly distinguishable. Characterisation of pathology present in 
the early-symptomatic P4 SmnRes mouse would serve as a baseline for the ultimate 
aim of determining what pathological features are capable of recovery upon postnatal 
restoration of SMN.  
2.14.1. Pre-synaptic nerve terminal loss and abnormal accumulation of neurofilament 
in the SmnRes mouse at P4.  
In order to evaluate the pathological status of the motor neuron at P4, I examined 
morphological correlates of both pre- and post-synaptic pathology at the 
neuromuscular junction (NMJ) in a range of muscles from the abdomen and head of 
the mouse, selected for their differential exhibition of NMJ pathology in other mouse 
models of SMA. The transversus abdominis (TVA; an abdominal muscle from the 
anterior abdominal wall), the levator auris longus (LAL; a cranial muscle comprised of 
two distinct bands, rostral (LALr) and caudal (LALc)), the auricularis superior (AS; a 
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cranial muscle), and abductor auris longus (AAL; a cranial muscle) were isolated as 
whole-mount muscle preparations for the visualisation and analysis of complete pre-
synaptic nerve terminals and associated acetylcholine receptor (AChR) endplates. 
Aforementioned muscles examined have been previously characterised to be 
differentially affected in several mouse models of SMA (Mélissa Bowerman et al., 
2012; Murray et al., 2008; Thomson et al., 2012). In particular, the TVA has been 
reported to be highly vulnerable in other murine models of SMA as well as in other 
mouse models of motor neuron degeneration (Mélissa Bowerman et al., 2012; Murray 
et al., 2008; Newbery et al., 2005).  
The TVA and the cranial muscles (LALc, LALr, AS and AAL) were dissected from 
early-symptomatic P4 SmnRes mice. Dissections were performed to isolate the TVA 
from the surrounding abdominal muscles, while the superficial layer (LALc and LALr), 
and deep layer (AS and adjacent AAL) of the cranial muscles were kept attached at 
the midline (refer to Figure 2.6) and subsequently processed as a flat “quadrant,” with 
all four individual muscles remaining highly distinct. Care was taken in all dissections 
to maintain the integrity of the muscle along with the respective nerve supply. Pre-
synaptic axons and nerve terminals were labelled with antibodies directed against total 
neurofilament (NF) and synaptic vesicle protein 2 (SV2) (green; see Methods), while 
post-synaptic AChR endplates were labelled with tetramethylrhodamine-conjugated α-
bungarotoxin (BTX) (red; see Methods).  
Almost 100% of endplates examined within muscles belonging to wildtype or 
heterozygous P4 animals were fully innervated by the pre-synaptic nerve terminal. Full 
innervation was defined as complete coverage of the post-synaptic endplate by the 
branches of the nerve terminal; a representative confocal micrograph highlighting a 
cluster of fully innervated endplates within the LALc of a P4 control mouse is visible 
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as the top-left image of Figure 1A. However, a striking proportion of endplates across 
all muscles in the SmnRes animals featured either partial or complete withdrawal of the 
pre-synaptic endplate (depicted in Figure 2.7A by arrowhead and arrow, respectively). 
Statistical analysis of the percentages of fully innervated, partially innervated, or 
vacant endplates in the TVA, LALc, LALr, AS and AAL of SmnRes mice compared to 
respective muscles in littermate controls revealed a significant decrease in the 
percentage of fully occupied endplates and a significant increase in the percentage of 
partially occupied or vacant endplates across all muscles of the P4 SmnRes mouse 
(Figure 2.7B). A comparison of the mean percentage of vacant endplates within 
individual SmnRes muscles highlighted an intermuscular spectrum of vulnerability to 
denervation, with the AAL featuring the relatively smallest percentage of partially 
innervated or vacant endplates; endplates within the LALr, AS, TVA and LALc suffered 
increasingly severe losses of the pre-synaptic nerve terminal, respectively (Figure 
2.7B).  
An abnormal presence of aggregated neurofilament (NF) infiltrating the pre-synaptic 
terminal is a pathological hallmark consistently reported across a number of mouse 
models of SMA (Mélissa Bowerman et al., 2012; Cifuentes-Diaz et al., 2002; Kariya et 
al., 2008; Kong et al., 2009; Murray et al., 2008). Marked NF accumulation was 
immediately evident within the NMJs of P4 SmnRes muscles compared to those of 
littermate controls. Severity of accumulation was quantified based on an 
independently-devised scoring criteria. Individual endplates across all muscles were 
categorised as one of the following: Stage 1: no accumulation visible; Stage 2: 
individual nerve terminal branches swollen, complexity of nerve terminal branching 
retained; Stage 3: severe accumulation, complexity of nerve terminal branching largely 
lost, underlying post-synaptic endplate largely obscured; Stage 4: complete and 
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absolute obscurity of the post-synaptic endplate by the neurofilament-engorged nerve 
terminal.  Statistical analyses confirmed the significant presence of severely 
accumulated neurofilament (Stages 3 & 4) across the AAL, LALr, AS, TVA and LALc 
of P4 SmnRes mice compared to the equivalent muscles of P4 littermate controls 
(Figure 2.7C). Comparison of the mean rank of percentages of endplates within all 
SmnRes  muscles scored as being affected by Stage 4-type accumulation also 
produced an intermuscular spectrum of pathology in the same order as the spectrum 











2.14.2. Shrinkage of post-synaptic endplates in the P4 SmnRes mouse. 
In addition to assessing the extent of denervation and NF infiltration of the pre-synaptic 
nerve terminal at P4 in the SmnRes mouse, the size of post-synaptic AChR densities 
were quantified independently to determine whether any morphological alterations 
were detectable. A statistical comparison of endplate size measured in the AAL, LALr, 
AS, TVA and LALc of P4 SmnRes mice compared to equivalent muscles in P4  littermate 
controls revealed a consistent and significant shrinkage of post-synaptic endplate area 
across all muscle groups (Figure 2.8A, 2.8B). There was no significant variability in 
endplate size between muscles (data not shown). 
In contrast to the apparent intermuscular spectrum of vulnerability to pre-synaptic 
nerve terminal loss and NF accumulation, the mean endplate area within all muscles 
characterised (AAL, LALr, AS, TVA and LALc) did not vary significantly between 
muscle type, suggesting that these post-synaptic alterations may be occurring 
independently and are not influenced by the status of their associated pre-synaptic 














2.14.3. Upregulation of components of the p53 apoptotic cell death pathway at the 
transcriptional and protein level at P4 in the SmnRes mouse.  
Structural disruption of motor neuron synaptic compartments accompanies a 
multifarious body of molecular dysregulation in multiple mouse models of SMA, 
occurring either as a direct result of SMN depletion, or as part of secondary cascades 
triggered by the degenerative process.  It is of crucial interest in the SMA research 
field to elucidate which specific molecular events precede—and thereby potentially 
initiate—the degenerative process, and whether these perturbations also occur in a 
compartmentalised manner to mirror the apparent dissociation between the timing of 
synaptic and somatic structural changes. 
A recent transcriptional screen of laser-captured motor neurons from pre-symptomatic 
Smn2B/- mice by Murray et al. detected an upregulation of transcripts involved in the 
p53 signalling pathway, despite a lack of phenotype or structural alterations at the 
neuromuscular junction (Murray et al., 2015). Transcriptional analysis of spinal cords 
containing motor neuron cell bodies from pre-symptomatic severe “Taiwanese” mice 
confirmed a similar phenomenon, implicating an upregulation of the p53 apoptosis 
pathway as a potential modulator of subsequent disturbances in the rest of the motor 
neuron (Murray et al., 2015).  
It was therefore of interest to determine whether apoptotic cell death-associated 
transcripts would continue be upregulated after onset of neuromuscular phenotype 
and synaptic pathology. RT-qPCR confirmed that the transcripts of three separate 
components of the p53 pathway, Cdkn1a, Fas, and PMAIP, were all significantly 
upregulated at P4 within the spinal cord of the SmnRes mouse (Figure 2.9A).  
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Quantitative fluorescent western blotting (QFWB) to measure relative levels of Fas in 
P4 SmnRes spinal cords confirmed that this robust upregulation was also translated at 
the protein level (Figure 2.9B, 2.9C).  
The combined data suggests that a pre-symptomatic upregulation of p53 transcripts 
continues through the onset of morphological alterations at the distal compartments of 
SMA motor neurons and accompanying neuromuscular symptoms. In addition to 
serving as a future molecular criterion upon which to assess the efficacy of SMN 
restoration, these findings suggest that aberrant p53 signalling may be intrinsically 







2.14.4. Conservation of select aspects of SMA-specific early-symptomatic 
transcriptional dysregulation in the SmnRes model.  
In addition to the RNAseq screen of motor neurons from pre-symptomatic Smn2B/- mice 
performed by Murray et al., numerous transcriptional screens of SMA neural tissue 
(i.e. laser-captured motor neurons or spinal cords) at either pre- or early-symptomatic 
time points in both the Δ7 and SMN2;Smn-/- models have identified a subset of 
transcripts implicated in the SMA degenerative process. Chondrolectin (Chodl), 
reported to be downregulated in three separate studies of two different mouse models 
of SMA, promotes defects in motor axonogenesis upon knockdown in zebrafish. The 
SUMOlyation enzyme ubiquitin specific peptidase-like 1 (Uspl1) and transcription 
factor Etv1 were also both consistently downregulated across all three screens and  
have been implicated in aberrant neurodevelopment (Murray et al., 2008; Zhang et al., 
2011; Zhang et al., 2013).  
In order to assess whether aberrant expression of Chodl, Uspl1 and Etv1 transcripts 
was similarly conserved in the SmnRes model, TaqMan® probe-based gene expression 
RT-qPCR assays were performed to measure the relative level of transcriptional 
expression in SmnRes spinal cords compared to wildtype controls. Relative levels of 
Chodl (Figure 2.10A) and Uspl1 (Figure 2.10B) were significantly and robustly 
downregulated and upregulated respectively, in accordance with trends reported by 
both the Murray and Zhang screens. There was no significant difference in the relative 
levels of Etv1 between SmnRes and wildtype spinal cord replicates (Figure 2.10C). 
However, alterations in the expression of Etv1 transcripts in the SmnRes mouse may 
be of a magnitude requiring a greater sensitivity for detection, such as the 
transcriptional analysis of laser-capture motor neurons rather than the spinal cord, 
which includes additional neuronal and non-neuronal cells.   
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In providing a preliminary characterisation of the molecular dysfunction present at P4 
in the SmnRes model, these experiments demonstrate that similar transcriptional 
disturbances occurring at early symptomatic time points in more commonly used 
mouse models of SMA are also present in the SmnRes mouse. Although both Lutz et. 
al (2011) and our own observations indicate that symptomatic onset only occurs at P4, 
these findings suggest that a significant degree of both structural and molecular 






2.15  Characterisation of phenotypic rescue mediated by induction 
of SMN at P4  
The second aim of this study was to determine what cellular and molecular aspects of 
SMA-specific motor neuron damage may be reversible. Having demonstrated the 
presence of a broad range of morphological and molecular deficits at the early-
symptomatic time point P4, all litters including SmnRes pups were gavaged at P4 with 
75mg/kg tamoxifen (TM) according to methodology outlined by Lutz et al. in order to 
promote Cre-mediated recombination of the floxed, inverted Res allele (see Methods 
for details of allelic construct). SmnRes pups harbouring one copy of the Cre-ER allele 
(Cre-ER; SMN2; Δ7; SmnRes mice; hereby referred to as SmnRes + TM mice) were 
capable of Cre-mediated recombination of the inverted Res allele, and therefore 
underwent re-expression of full-length SMN.  SmnRes pups lacking the Cre-ER allele 
(SMN2; Δ7; SmnRes mice; hereby referred to still as SmnRes mice) do not harbour the 
capacity for Cre-mediated recombination, and therefore continue to follow the typical 
disease time course. Regardless of Cre-ER expression status, heterozygous or 
wildtype pups were simultaneously treated with tamoxifen to serve as littermate 
controls. To compare the phenotypic profile of recombined (SmnRes + TM) mice versus 
non-recombined SmnRes mice, all treated litters were weighed and subjected to a 
motor test to assess muscular strength at day of treatment (P4) and every two days 
thereafter. Mice were then sacrificed at P10, a normal end-stage in the disease time 
course of the SmnRes mouse, and tissues were processed as detailed previously. 
Whole-mount muscle preparations and spinal cords were utilised as the basis of 
cellular and molecular analyses to determine what aspects of motor neuron pathology 




2.15.1. Phenotypic correction of the SmnRes mouse following re-expression of full-
length SMN at P4.  
At time of treatment with tamoxifen at P4, both SmnRes and SmnRes + TM pups were 
markedly smaller and lighter than wildtype or heterozygous littermate controls (Figure 
2.11A).  Following a single administration of 75mg/kg tamoxifen (TM) via oral gavage 
at P4, SmnRes mice, which do not harbour the Cre-ER allele, followed the typical 
phenotypic time course of SMA mice, failing to thrive and remaining significantly 
smaller than littermate controls at time of sacrifice at P10. Conversely, Cre-ER mice 
(SmnRes + TM) mice gained weight over the 6 days following treatment, at a magnitude 
and rate comparable to that of treated littermates. By sacrifice at P10, the mean weight 
of    SmnRes + TM pups was nearly indistinguishable from that of littermate controls 
(Figure 2.11A).   
Prior to treatment with tamoxifen at P4, the performance of all SmnRes (non-Cre 
expressing), SmnRes + TM (Cre- expressing), and control pups in a time-to-right test 
was noted (see Methods for a detailed description of the time-to-right assay). While 
P4 control mice were able to right themselves well within the 30 second cut-off time, 
both P4 SmnRes and SmnRes + TM pups exhibited an obvious difficulty in turning 
themselves over, with the majority assessed completely unable to right themselves 
within the cut-off period (Figure 2.11B). After tamoxifen treatment, all mice were 
subjected to further time-to-right tests at P6, P8 and P10. The SmnRes mouse, which 
does not harbour the Cre-ER allele and therefore does not undergo re-expression of 
full-length SMN, continued to perform poorly in the time-to-right assay, and was still 
unable to right itself within 30 seconds at any assessed time point. In contrast, SmnRes 
+ TM animals, which re-express full-length SMN upon metabolism of tamoxifen, 
exhibited a rapid and robust improvement in motor performance at all time points 
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assessed (Figure 2.11B). By time of sacrifice at P10, the righting ability of SmnRes + 
TM animals was virtually indistinguishable from littermate controls, with all pups 
assayed able to right themselves within 10 seconds. Perhaps most strikingly, an 
improvement in righting ability was immediately evident by P6, only 48 hours after 
treatment, in three of the four SmnRes + TM mice. The fourth SmnRes mouse, which 
failed to right itself within the 30 second cut-off in one of two trials, was highly active 
during both trials despite poor righting ability. This atypical activity distinguished it from 
the age-matched SmnRes pup which exhibited a marked decrease in movement and 









2.15.2. Amelioration of pre-synaptic terminal loss and neurofilament accumulation 
across all muscle groups in the P10 SmnRes + TM mouse after tamoxifen-mediated re-
expression of full-length SMN at P4.  
Whole-mount preparations of the tamoxifen-treated P10 TVA, AAL, LALr, AS, and 
LALc muscles from SmnRes mice, SmnRes+ TM mice, and littermate controls were 
immunocytochemically labelled for imaging and analysis of their neuromuscular 
junctions. As these muscles had been characterised within the P4 SmnRes mouse to 
be differentially vulnerable to cellular correlates of pre-synaptic pathology, it was of 
interest to evaluate not only whether pathology had worsened in the P10 SmnRes 
mouse, but also to determine whether any morphological abnormalities were altered 
within muscles belonging to SmnRes+ TM mice.  
At P4, prior to dosage with tamoxifen, the AS, TVA and LALc of SmnRes mice exhibited 
the greatest extent of pre-synaptic nerve terminal loss and accumulation of 
phosphorylated neurofilament at P4 in the untreated SmnRes mouse (see Figure 2.7).  
Upon examination of the AS, TVA and LALc of P10 SmnRes mice, which lack the Cre-
ER allele, it was immediately evident that their highly pathological status at P4 was 
predictably retained at P10 (Figure 2.12A, B, C: middle column). Quantification of 
the percentage of fully occupied, partially occupied, or vacant endplates within the P10 
SmnRes  AS, TVA and LALc confirmed that a significant percentage of endplates within 
all muscles were either only partially innervated or complete vacant of any innervation 
by the pre-synaptic nerve terminal. (Figure 2.12D). Similarly, quantification of 
neurofilament infiltration of the pre-synaptic nerve terminal, using an identical staging 
criteria as applied to P4 SmnRes muscles, revealed the significant accumulation of 
phosphorylated neurofilament to a severe extent (Stages 3 and 4) at the 
neuromuscular junction of P10 SmnRes mice. (Figure 2.12E).  
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Remarkably, the structural integrity of neuromuscular junctions within the AS, TVA and 
LALc of SmnRes + TM P10 mice appeared strikingly unimpaired, even under high 
confocal resolution (Figure 2.12A, B, C: right column). Indeed, quantification of the 
percentage of vacant AChR endplates confirmed that there was no significant 
difference in the percentage of vacant endplates within the AS, TVA and LALc of P10 
SmnRes mice compared to those within equivalent muscles from P10 littermate 
controls. However, within the AS and TVA of SmnRes + TM mice, a small but significant 
percentage of endplates remained only partially innervated, suggesting that while re-
expression of full-length SMN at P10 mediates a clear improvement in pre-synaptic 
terminal loss, the stability of the synaptic interface may not be entirely restored.  
Quantification of NF accumulation within the AS, TVA and LALc  of P10 SmnRes  + TM 
mice confirmed that there was no longer a statistically relevant presence of NMJs 
exhibiting the most severe degree of infiltration (Stage 4) compared to littermate 
controls (Figure 2.12E). However, both the AS and TVA still exhibited a significant 
percentage of endplates harbouring severe Stage 3-type accumulation, again 
suggesting that while restoration of SMN at P4 rescues defects in synaptic innervation, 
it may not be sufficient to promote an absolute recovery of neuromuscular junction 









Quantification of pre-synaptic nerve terminal loss and accumulation of phosphorylated 
neurofilament within the cranial muscles relatively resistant to NMJ pathology at P4 
(AAL and LALr) between SmnRes and SmnRes + TM P10 mice compared to littermate 
controls confirmed a similar phenomenon of pathological amelioration (Figure 2.13). 
While the AAL and LALr of P10 SmnRes mice still harboured a small percentage of 
partially or entirely denervated post-synaptic endplates, the percentage of partially 
innervated or vacant endplates within the AAL and LALr of SmnRes + TM mice at P10 
was negligible and not statistically significant from that of muscles from P10 littermate 
controls. The statistical analysis of the percentage of endplates exhibiting abnormally 
accumulated neurofilament also confirmed that there was no longer a significant 
presence of severe NF infiltration (Stage 3 or 4) within the AAL or LALr of P10 SmnRes+ 
TM  mice, while the AAL and LALr of non-Cre-ER expressing P10 SmnRes mice still 
contained a significant percentage of NMJs scored as being severely affected 






2.15.3. Preservation of post-synaptic endplates and reinnervation by the previously 
withdrawn pre-synaptic nerve terminal within the cranial musculature of the P10 
SmnRes + TM mouse. 
The previous data demonstrate that tamoxifen-induced re-expression of full-length 
SMN promotes a robust improvement in the proportion of fully innervated 
neuromuscular junctions in both highly vulnerable muscles (eg. LALc) and relatively 
resistant muscles (eg. LALr). It remained unknown as to whether the high percentage 
of fully innervated endplates present in the muscles of P10 SmnRes + TM mouse were 
due to either one of two situations: 
(1) intervention with SMN at P4 merely preserves synapses still intact at point 
of treatment, while denervated endplates remain vacant and fade by P10, or 
(2) previously withdrawn pre-synaptic nerve terminals undergo reinnervation of 
the post-synaptic endplate upon restored expression of full-length SMN 
In order to elucidate whether re-expression of SMN merely preserved intact NMJs or 
promoted reinnervaton of vacant post-synaptic endplates, individual epifluorescent 
micrographs of the LAL (both caudal and rostral bands) were montaged to reconstruct 
the entire innervation pattern of the LAL. Nerve terminals and motor axons were 
labelled with antibodies against neurofilament (NF) and synaptic vesicle protein 2 
(SV2) and AChR endplates were labelled with TRITC-conjugated α-bungarotoxin. A 
representative montage of the LALc and LALr from a P10 control mouse is visible in 
Figure 2.14A. Note the distinct presence of five endplate regions within the rostral 
band (identified as R1-R5) and two endplate regions within the caudal band (C1 and 
C2), first identified by Murray et. al., 2009.  
C2 and R3-R5 were selected as regions highly unlikely to be damaged or lost from 
variability in dissection between muscles due to their proximity to the midline. The total 
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number of TRITC-BTX labelled endplates within the C2 region of the LALc and within 
the R3-R5 region of the LALr, were counted and subjected to statistical analyses. The 
C2 region in the LALc of P10 SmnRes mice suffered a marked and significant loss of 
endplates compared to littermate controls. However, analysis of the number of 
endplates remaining in the C2 region of the LALc of P10 SmnRes + TM mice revealed 
no significant variability from littermate controls, suggesting that no perceptible loss of 
endplates had occurred between treatment at P4 and analysis at P10 (Figure 2.14C).  
A comparison of the number of endplates remaining within the R3-R5 region of the 
LALr highlighted no significant difference in the number of endplates in muscles from 
SmnRes mice nor in SmnRes + TM mice compared to littermate controls (Figure 2.14D).  
Together with the remarkable improvement in neuromuscular junction integrity across 
all muscles reported in Figures 2.12 and 2.13, these data suggest that tamoxifen-
mediated re-expression of SMN at P4 promotes neuronal regeneration to enable the 
pre-synaptic terminal to reinnervate vacant AChR endplates. This phenomenon is 










Chapter TWO: Discussion 
2.16  Overview of Results 
The results presented in this chapter firstly reveal that a significant degree of 
morphological and molecular alterations are evident within the motor unit of the  
SmnRes mouse model of SMA at an early symptomatic time point  of P4. Within both 
the cranial and abdominal musculature, neuromuscular junctions (NMJs) of P4 SmnRes 
mice exhibit cytoarchitectural defects ranging from abnormally accumulated 
neurofilament at the pre-synaptic nerve terminal and shrinkage of the post-synaptic 
endplate, to perhaps most notably, a significant loss of synaptic integrity between the 
pre-synaptic nerve terminal and post-synaptic endplate.  These morphological 
abnormalities at the synapse are accompanied by transcriptional and protein changes 
within the spinal cord, in which a number of molecular factors, including those 
associated with apoptotic cell death and other degenerative cascades implicated in 
SMA, are aberrantly expressed   
Secondly, I report a robust rescue of neuromuscular phenotype, as indicated by weight 
gain and motor performance, following induction of full-length SMN at P4 in the SmnRes 
mouse. Thirdly, and perhaps most importantly, I have demonstrated that intervention 
with SMN at P4, a time point I have characterised by marked cellular and molecular 
pathology, results in a striking amelioration of aforementioned pathological correlates 
at the NMJ, including denervation and neurofilament accumulation. Moreover, I have 
determined that these improvements in NMJ integrity following restoration of SMN may 
be attributed to the reinnervation of vacant endplates by the previously withdrawn pre-
synaptic nerve terminal. Overall, these results suggest that while NMJ is indeed a 
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highly vulnerable pathological target in SMA, it is not without the capacity for profound 
structural regeneration following therapeutic intervention with SMN.  
 
2.17. Correlates of cellular and molecular pathology are present at 
P4 in the SmnRes mouse model of SMA.  
Mounting evidence from a number of SMN-based gene therapy and ASO studies 
suggests that maximal efficacy in therapeutic intervention may only be achieved when 
SMN is restored at a pre- or early-symptomatic time point, thereby highlighting the 
existence of a “therapeutic window of opportunity” (Foust et al., 2010; Hua et al., 2011; 
Passini et al., 2011; Porensky et al., 2012).   In order to evaluate the pathological 
status of the NMJ prior to and following therapeutic intervention with SMN, I selected 
a time point near the limits of this “window”, at which phenotypic rescue would still be 
possible. Lutz et. al. (2011) observed that the SmnRes mouse exhibited deficits in 
muscular strength by P4; this observation was recapitulated in our hands (Lutz et al., 
2011; Figure 2.11).  
Although both Lutz et. al (2011) and our own observations identified P4 as an early 
symptomatic time point in the SmnRes disease course, the results from these 
experiments reveal, surprisingly, the marked presence of  pre- and post-synaptic  
pathological hallmarks within all muscles analysed, particularly in the TVA and in the 
LALc and AS of the cranial muscles. These structural defects at the synapse were 
accompanied by a significant degree of molecular dysregulation at both the 
transcriptional and protein level within the spinal cord. These findings, highlighting the 
extensive disruption of NMJ cytoarchitecture in the SmnRes mouse at the start of 
symptomatic onset, support the popular idea that the synapse is an early and 
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significant pathological target in SMA. Similarly, these results highlighting a significant 
disruption of multiple molecular pathways at the time of symptomatic onset in the 
SmnRes mouse also support the theory that degenerative cascades are initiated prior 
to severe phenotypic decline (Bäumer et al., 2009).  Together, these findings suggest 
that effective therapeutic intervention in patients presenting at time of diagnosis with 
neuromuscular symptoms must take into account the potential morphological and 
molecular deficits that may already have manifested at the synapse and beyond.   
 
2.18. Postnatal restoration of SMN at P4 in the SmnRes  mouse 
promotes correction of structural defects and reinnervation of the 
NMJ 
Remarkably, intervention with full-length SMN in the P4 SmnRes mouse results in a 
robust correction of the numerous structural deficits outlined above, including the 
denervation of NMJs, across all muscles analysed. By montaging epifluorescent 
micrographs of the SmnRes LALc and LALr in order to assess the number of post-
synaptic endplates remaining within the musculature, I have revealed that this 
phenomenon may be attributed to the regeneration of the pre-synaptic nerve terminal 
input rather than a mere retention of synapses intact at time of restoration.   
 
2.18.1 Implications of neuronal regeneration: therapeutic relevance and a new 
perspective from reports of clinical trials of Nusinersen (formerly ISIS-SMNRx) 
Unlike within the CNS, synapses within the PNS have been widely reported to be 
capable of regeneration from injury-induced Wallerian degeneration (Barry & 
Ribchester, 1995; Comley et al., 2011). However, these regenerative capacities have 
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not been explored in NMJs denervated as a result of disease-induced, “die-back” 
mechanisms. A number of studies in mouse models of SMA have reported the 
absence of gross structural defects in NMJs following early therapeutic intervention 
with SMN; however, restoration of SMN was performed extremely early within the 
disease course, often at a pre-symptomatic time point, and thus appeared to merely 
prevent, rather than correct, NMJ damage (Foust et al., 2010; Hua et al., 2011; Passini 
et al., 2011). While Lutz et. al (2011) reported an improvement in NMJ integrity 
following restoration of SMN after onset of symptoms, it was unknown whether SMN-
based intervention merely halted degeneration at the time of treatment, or whether 
postnatal restoration of SMN was capable of enabling the damaged motor neuron to 
regenerate and thereby repair degeneration at the synapse (Lutz et al., 2011).  In this 
thesis, I have presented promising evidence that the SMA NMJ is indeed capable of 
regenerating itself following therapeutic intervention with SMN. This phenomenon is 
evident not only in muscles exhibiting comparably mild pathology at P4, but also in the 
highly vulnerable LALc, AS, and TVA. To date, these results represent the first 
indication of neuronal regeneration present within a mouse model of SMA following 
postnatal restoration of SMN.  
In a clinical context, these findings suggest that the NMJs of SMA patients harbour a 
similar regenerative capacity following treatment with the number of SMN-based 
therapies currently under clinical trial. As there is no current prenatal screening for 
SMA, patients are typically diagnosed because they are exhibiting neuromuscular 
abnormalities or failing to meet developmental milestones. As my results from P4 
SmnRes mice have suggested, a marked degree of structural damage to the synapse 
may have already occurred by the time neuromuscular symptoms have manifested. 
By demonstrating that damaged synapses from early symptomatic mice are capable 
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of structural repair following SMN-based intervention, these findings indicate that 
SMN-based therapeutics may be a realistic and efficacious option for the vast majority 
of patients diagnosed after neuromuscular symptoms have begun.   
Although the functional implications of these findings are currently outwith the scope 
of this study, an interesting body of unpublished electromyographical results from 
recent Nusinersen (formerly ISIS-SMNRx) trials have reported a marked improvement 
in compound muscle action potential-motor unit estimation (CMAP-MUNE) scores in 
Type 1 patients treated at an early symptomatic time point (unpublished results 
presented by Stephen Kolb, 2016). In conjunction with the findings presented in this 
thesis, these clinical results from Type 1 cohorts suggest that synaptic function, as 
well as structure, harbours the capacity for repair following postnatal restoration of 
SMN. 
 
2.18.2 Systemic involvement in therapeutic outcome 
The results presented in this thesis reveal that tissue-wide restoration of SMN in the 
SmnRes mouse at P4 promoted a robust improvement in neuromuscular phenotype, 
as evidenced by improvement in motor performance.  However, a remarkable aspect 
of this phenotypic improvement lay in the fact that several treated mice, exhibiting a 
marked difficulty in righting at P4, were subsequently able to completely and rapidly 
right themselves within 48 hours of tamoxifen administration. While the findings 
presented in this chapter indicate a profound degree of regeneration and repair 
occurring within damaged NMJs in the abdominal musculature following SMN 
restoration, the increasing implication of systemic defects in SMA must be considered. 
In other words, is this improvement in motor performance purely the result of 
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reinnervation of denervated muscles by the pre-synaptic nerve terminal, or does 
restoration of SMN also correct systemic defects present in the P4 SmnRes mouse? It 
would therefore be of interest to not only investigate the timing of this reinnervation 
phenomenon following induction of SMN at P4, but also to perform a histopathological 
analysis of the SmnRes mouse, pre- and post-rescue, to determine whether any 
systemic defects present at P4 also recover.  
 
2.19. On a future perspective 
2.19.1 Further characterisation of the rescue phenomenon 
From the results presented in this chapter, it may be suggested that cytoarchitectural 
defects present at the NMJ in the P4 SmnRes mouse harbour undergo an exceptional 
degree of repair following re-expression of SMN. Naturally, future work is needed to 
determine whether the molecular dysregulation identified in the P4 SmnRes mouse is 
similarly ameliorated. Lutz et. al (2011) reported an improvement in snRNP assembly 
following induction of SMN at P4; it would be of interest to determine whether other 
molecular correlates of SMA similarly improve following SMN-based intervention (Lutz 
et al., 2011). As discussed in the introduction to this thesis, effective therapeutic 
intervention must consider the widespread histological and molecular implications of 
SMN depletion. It would therefore be of interest to determine whether molecular 
cascades downstream of SMN, such as components of the ubiquitin proteasome 
system, are altered following re-expression of SMN at P4, within the motor unit and 
beyond.  
Finally, this study provide a basis for the further characterisation of the SMN-based 
therapeutic window. The results presented in this chapter demonstrate that phenotypic 
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recovery following restoration of SMN at a point “within” the therapeutic window is 
accompanied by a striking amelioration of pathological correlates at the NMJ; the 
pathological status of NMJs in a model of late intervention outwith this window, in 
which we do not expect phenotypic improvement, remain unknown. By analysing NMJ 
pathology from SmnRes mice in which SMN has been restored at different time points, 
both within and outwith the therapeutic window, it may be possible to determine which 
aspects of NMJ pathology fail versus successfully recover upon re-expression of SMN. 
Ultimately, deciphering which cellular aspects of synaptic pathology must be corrected 
in order to mediate successful phenotypic improvement will provide a mechanistic 
insight into the temporal limitations of SMN-based therapeutic intervention.  
 
2.19.2 Manipulation of the therapeutic window with combinational therapeutics 
By understanding the cellular and molecular events that occur following restoration of 
SMN at either pre- or post-symptomatic phases of the disease, it will then be possible 
to develop targeted methods, such as administration of previously identified non-SMN 
based candidate drugs, to pharmacologically manipulate and extend this therapeutic 
time window. This work will not only significantly enhance our understanding of what 
cellular and molecular factors constitute successful clinical outcome, but also 
maximise the benefit of SMN-based therapies for all SMA patients, regardless of time 






Chapter THREE: Introduction 
3.1. Overview 
The distal compartments of the lower motor neuron are vulnerable to degenerate in 
response to a broad range of disease, injury and toxin-induced insults.  A number of 
genetic factors have been identified to influence the response of the axon and synapse 
to degeneration, most prominently from studies of the protective properties conferred 
by the spontaneous mouse mutation, WldS  (Ferri, Sanes, Coleman, Cunningham, & 
Kato, 2003; Thomas H Gillingwater et al., 2006; Mack et al., 2001; Wang et al., 2001; 
Wang, Davis, Culver, & Glass, 2002) A growing body of evidence suggests that 
developmental maturity may also significantly regulate the vulnerability of synaptic 
compartments of the motor neuron in response to traumatic injury. A study profiling 
the synaptic response to injury over the postnatal developmental period in mice 
determined that neuromuscular junctions (NMJs) of very young mice appear to exhibit 
a reduced rate of degeneration, which is steadily lost through subsequent 
developmental maturation (Murray, Comley, Gillingwater, & Parson, 2011). 
 
3.2. Age-dependent vulnerability in the motor neuron soma 
Since Waller’s experiments in the mid-19th century describing a systematic process of 
anterograde degeneration in severed frog cranial nerves, the mechanisms regulating 
neurodegeneration following the application of a traumatic stimulus have been 
extensively studied (Waller, 1850). From a number of these studies, it appears that 
the degenerative response of the motor neuron cell body, or soma, is markedly 
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influenced by age-dependant mechanisms. For example, following the crush or 
transection of the motor neuron axon, neonatal soma have been reported to undergo 
rapid death, whereas adult soma appear comparably more resilient (Kapoukranidou 
et al., 2005; L. Li et al., 1998; Pollin, McHanwell, & Slater, 1991). In modern 
neuroscience, the neuron is considered a highly subdivided structure, with soma, axon 
and synapses harbouring highly distinct and independent metabolic processes. This 
theory resulted from observations that degeneration following disease or injury-
mediated trauma also occurs in a compartmentalized manner (Gillingwater & 
Ribchester, 2001). In consideration of this apparent compartmentalized response to 
degeneration, and the observation that response to injury is developmentally regulated 
at the cell body, a number of studies have sought to elucidate whether the distal 
synapses of motor neurons from very young versus older mice may also harbour 
distinct responses to nefarious stimuli.  
 
3.3. Age-dependant vulnerability at the neuromuscular junction 
3.3.1 Age-dependent synaptic response to injury in the Wld(s) mouse 
As described in the general introduction to this thesis, the WldS mutation confers 
axonal protection from a number of injury, toxic, and disease-induced insults (Ferri et 
al., 2003; Gillingwater et al., 2006; Mi et al., 2005; M S Wang et al., 2001; Wang, Wu, 
Culver, & Glass, 2001; Wang et al., 2002). Although early reports by Perry (1992) and 
Ribchester (1995) initially suggested that the protective axonal phenotype faded after 
six months of age, subsequent morphological and biochemical comparisons of young 
adult versus mice older than 7 months revealed that neither the expression of Wld at 
the protein level nor the degenerative response to axotomy appears to differ between 
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young and mature adult WldS mice (Perry, Brown, & Tsao, 1992; Ribchester et al., 
1995 Gillingwater et al., 2002). However, the study by Gillingwater et al. (2002) 
identified a notable discrepancy in the rate of degeneration at the neuromuscular 
junction between young and older adult Wlds mice. In contrast to the robust axonal 
protection exhibited in Wlds mice of all ages, axotomy in nerves from 7 month old Wlds 
mice initiated a rapid and near-immediate dissolution of nerve terminal integrity at the 
neuromuscular junction, although minimally slowly than wildtype age-matched 
controls. Interestingly, similar traumatic procedures in the nerves of 2 month old Wlds 
mice promoted a marked delay in the degeneration of the neuromuscular junction; 
indeed, at approximately 120 hours post-axotomy, up to up to 90% of post-synaptic 
densities were still innervated by the pre-synaptic nerve terminal (Gillingwater et al., 
2002). These data were supplemented by electrophysiological recordings revealing a 
rapid decline in endplate potential (EPP) recordings from neuromuscular junctions in 
the 7 month old mice compared to the relatively resilient recordings from 2 month old 
mice, suggesting that loss of synaptic function as well as a breakdown of synaptic 
cytoarchitecture was a comparably accelerated event in older Wlds mice compared to 
younger Wlds mice (Gillingwater et al., 2002)  In addition to providing further evidence 
supporting a significant degree of compartmentalization in the neurodegenerative 
process, these findings served as an early indication that age-dependant factors may 
influence the vulnerability of the distal synapse in the murine motor neuron.   
3.3.2 Age-dependent synaptic response to injury in the wildtype mouse 
The major quandary resulting from experiments performed exclusively in Wlds mice 
concerned whether this phenomenon of age-dependant vulnerability was relevant to 
normal processes of motor neuron degeneration, or whether it was merely an 
extension of Wld interacting with additional, possibly developmentally regulated, 
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endogenous factors within the neuron. In a surprising discovery, similar nerve injury 
experiments performed in wildtype mice revealed an astonishing degree of age-
dependant protection at the neuromuscular junction (Murray et al., 2011). 
Fascinatingly, these results were recapitulated in two distinct models of motor neuron 
damage, suggesting that age-dependent regulation of synaptic vulnerability may be a 
ubiquitous phenomenon in the wildtype mouse motor neuron (Murray et al., 2011). 
 
3.3.3. The wildtype neuromuscular junction in hypoxia-reperfusion injury 
In addition to the wide range of disease and injury-induced stimuli mentioned 
previously, nerve cells within both the CNS and PNS, including motor neurons, have 
been shown to be highly vulnerable to damage from hypoxia-reperfusion injury (Baxter 
et al., 2008; Watzlawik et al., 2015). A study by Baxter et al (2008) elegantly 
characterised this hypoxia-reperfusion damage on a morphological level through 
devising a novel ex vivo murine muscle preparation, containing both pre-synaptic 
nerve terminals and post-synaptic densities, that was capable of being maintained in 
oxygenated physiological solution (Baxter et al., 2008). By depleting the O2 
concentration of the solution to hypoxic levels, Baxter et al. (2008) were then able to 
generate significant damage to neuromuscular junction connectivity by initiating 
reperfusion with normal O2 concentrations (Baxter et al., 2008). By demonstrating the 
marked vulnerability of NMJs to hypoxia-reperfusion damage, this ex vivo model is 
clinically relevant to surgical situations, in which extended tourniquet application has 
been suspected of promoting chronic damage to peripheral nerves (Saunders, Louis, 
Weingarden, & Waylonis, 1979). These findings are also of particular interest in 
conjunction with the growing implication for defective vasculature and accompanying 
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hypoxia of the PNS and skeletal muscle in a number of neurodegenerative diseases, 
including ALS and SMA (Moreau et al., 2006; Somers et al., 2016). 
Murray et al. (2011) applied this ex-vivo hypoxia-reperfusion technique in a variety of 
cranial and abdominal muscles isolated from P2-P28 wildtype C57BL/6 mice in order 
to generate a time course analysis of the NMJ response to hypoxic stress. Strikingly, 
it was immediately evident that preservation of synaptic integrity post-injury diminished 
in a systematic manner in line with the age of the mice (Murray et al., 2011). Indeed, 
it was possible to visualise a nearly linear drop-off in NMJ integrity as measured 6 
hours post-reperfusion. From P2 to P10, NMJs appeared robustly resistant to hypoxia-
reperfusion-induced degeneration, with minimal denervation of the pre-synaptic 
terminal detectable in injured muscles of P2 to P10 mice 24 hours after the procedure. 
After P10, NMJ integrity, as measured by the number of fully occupied endplates 
present 24 hours after reperfusion, dropped steadily in line with the age of the mouse 
until P21 and older, by which virtually no endplates remained fully innervated 6 hours 
after injury (Murray et al., 2011). Muscles previously characterised to be differentially 
vulnerable to degeneration in mouse models of the motor neuron disease spinal 
muscular atrophy (SMA) (Mélissa Bowerman et al., 2012; Murray et al., 2008; 
Thomson et al., 2012) exhibited very little variability in their response to hypoxia-
reperfusion injury; neuromuscular junctions within the TVA, LAL, AS, and AAL all 
adhered to this phenomenon of an age-dependant drop-off in resistance to 
degeneration, with only subtle differences reported between muscle types (Murray et 
al., 2011). These findings suggest that this apparent developmentally-regulated 
vulnerability is ubiquitous to all synapses within in the murine skeletal musculature.  
Functional assessment of NMJs identified as robustly resistant to hypoxia-reperfusion 
injury, ie. those from neonatal mice P10 and younger, revealed that these synapses 
111 
 
appear to be functionally as well as structurally preserved 24 hours after injury (Murray 
et al., 2011). Application of the styryl dye FM1-43FX, which is only taken up by 
synapses actively undergoing vesicular uptake, robustly labelled all visible endplates 
within P10 muscles to an extent comparable with non-hypoxic controls, suggesting 
that synaptic functionality is also retained in the muscles of very young mice (Murray 
et al., 2011).  
3.3.4. The wildtype neuromuscular junction in axotomy 
In an attempt to determine whether this phenomenon of an age-dependant increase 
in neuromuscular junction vulnerability was reproducible in a separate model of 
peripheral nerve injury, Murray et al. (2011) performed similar time course analyses of 
neuromuscular junctions in the deep lumbrical muscles 24 hours after axotomy of their 
nerve supply, the tibial nerve. Remarkably, these experiments revealed a striking 
conservation of the age-dependant increase in vulnerability identified by the hypoxia-
perfusion experiments; NMJs appeared robustly protected from nerve cut-induced 
Wallerian degeneration up until P21, after which virtually all synaptic integrity 
appeared to be lost (Murray et al., 2011). 
This age-dependant increase in neuromuscular junction vulnerability to injury is 
illustrated in Figure 3.1., which depicts the steady decline in neuromuscular junction 
integrity in conjunction with chronological age of the mouse. This phenomenon was 
demonstrated to be conserved in the levator auris longus (LAL), auricularis superior 
(AS) and abductor auris longus (AAL) as well as in the abdominal transversus 
abdominis (TVA) subjected to hypoxia-reperfusion damage, and in the deep lumbrical 
muscles following tibial nerve crush (Murray et al., 2011). From these experiments, it 
is therefore evident that a robust protection of neuromuscular junctions following 
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traumatic injury occurs until approximately 10-12 days of age, after which the extent 
of the protective phenomenon decreases steadily until it is virtually non-existent by 
P21.  
 
Figure 3.1.  Schematic diagram illustrating the progressive, age-dependant decline 
in neuromuscular junction resistance to both axotomy and hypoxia-reperfusion 
induced injury produced by both physical trauma and hypoxia-reperfusion. This 
phenomenon was evident in multiple cranial and abdominal muscles subjected to 
hypoxia-reperfusion injury, as well as in the deep lumbrical muscles following tibial 
nerve crush, suggesting the existence of a conserved and ubiquitous response 
mechanism regulating the degenerative response that is applicable to different types 




3.3.5. Differential responses to neuromuscular junction degeneration: an intrinsic 
synaptic factor or ubiquitous developmental regulation? 
The data reported by Murray et al. (2011) strongly suggested that a number of 
mechanisms intrinsic to the developing mouse may regulate NMJ integrity in response 
to multiple degenerative insults. However, Murray et al. (2011) additionally sought to 
determine whether this endogenous preservation of NMJ integrity in neonatal mice 
was determined by the age of the animal, rather than the developmental “age” of the 
synapse. Regeneration of the neuromuscular junction following either physical or 
toxin-induced motor neuron injury has been consistently reported to produce 
developmentally immature, polyinnervated synapses (Barry & Ribchester, 1995; 
Brown & Ironton, 1978; Fawcett & Keynes, 1990; Werle & Herrera, 1991).  Murray et 
al. (2011) generated “neonatal” synapses in adult mice via the introduction of a 
preconditioning lesion in the tibial nerve (Murray et al., 2011). Surprisingly, the 
regenerated NMJs analysed within the lumbrical muscles of older mice appeared to 
degenerate as rapidly as non-conditioned synapses after a tibial nerve cut was 
performed. Indeed, the significant degree of denervation reported within these 
“immature” synapses 24 hours post-procedure was indistinguishable from the 
percentage of degeneration suffered by their “mature” counterparts (Murray et al., 
2011). These findings suggested that the surrounding neonatal environment, or 
indeed, the age of the entire motor neuron, rather than the synapse itself, dictates the 






3.4.  Aims of this chapter 
3.4.1 Summary 
To summarise, the neuromuscular junction has been demonstrated to be an early and 
critical pathological target in not only a range of heritable and spontaneous motor 
neuron diseases, but also in following injury. For this reason, determining the 
mechanisms that influence synaptic vulnerability may provide relevant insight on the 
neurodegenerative process. Studies of the spontaneous WldS  mutation, which confers 
a significant delay in axonal degeneration following injury in mice of all ages, revealed  
that NMJs within the muscles of older adult mice were not protected from synaptic 
fragmentation after axotomy, compared to the relative resilience exhibited in NMJs 
from young adult WldS mice undergoing identical injury (Gillingwater et al., 2002). 
Similar studies investigating the synaptic response to both nerve crush and hypoxia-
reperfusion injury revealed, surprisingly, that this age-dependent phenomenon was 
also present in wildtype mice (Murray et al., 2011). NMJs of neonatal mice until 
approximately P10 appeared robustly resistant degeneration, with a large majority 
remaining structurally and functionally intact 24 hours after either hypoxia-reperfusion 
or transection injury (Murray et al., 2011). Conversely, identical procedures in mice of 
increasing chronological age produced a progressive decline in NMJ protection until 
approximately P21, by which the vast majority of NMJs underwent rapid and near-
complete denervation (Murray et al., 2011). Experiments utilising a preconditioning 
lesion to generate immature neuromuscular junctions in adult mice failed to mitigate 
this rapid degeneration of NMJs post axotomy, suggesting that the molecular factors 
responsible for this period of protection do not originate from the neuromuscular 
junction itself, but rather are a product of the neonatal environment (Murray et al., 
2011). It is therefore possible to hypothesise that a series of dynamic molecular 
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changes are occurring in the wildtype mouse over this postnatal period that account 
for this dramatic decrease in NMJ protection.  
I have performed an extensive time-course proteomic analysis of the molecular 
changes occurring over this critical period of increasing synaptic vulnerability, in 
tissues comprising the immediate environment of the neuromuscular junction: namely, 
the nerve and post-synaptic muscle. I have then utilised both functional enrichment 
analysis and predictive pathway analysis to gain further insight into the cellular 
processes evolving over this period in the wildtype mouse that may account for an 
increase in rate of axonal and synaptic degeneration.  
 
3.4.2 Aims 
AIM 3: Profile molecular alterations occurring in both the pre-synaptic nerve and 
post-synaptic muscle over the period of increasing NMJ vulnerability in the 
wildtype C57BL/6 mouse. 
3a. Evaluate the efficacy of the TMT10plex™ mass tagging technique, which 
to date has not been definitively evaluated in whole-tissue studies, as a 
quantitative proteomics method.  
3b. Perform functional annotation enrichment analysis on applicably filtered 
proteomic results to understand what biological processes may be evolving 
over this critical postnatal period. 
3c. Utilise pathway analysis software to generate cellular and molecular 
predictive networks from the data set to further understand what mechanisms 
may account for an age-dependant synaptic vulnerability to degeneration.   
116 
 
Chapter THREE:  Methods 
3.5 Postnatal nerve and muscle time course proteomics study 
3.5.1 Extraction and sample preparation.   
Murine nerves (distal portion of the sciatic nerve) and lumbrical muscles (n=5 mice per 
timepoint; each n consists of left and right set of nerves/muscle respectively) from 
wildtype C57BL/6J mice were freshly dissected, snap frozen on dry ice and stored at 
-80°C (Figure 3.2). Tissue was thawed at room temperature, and dissociated in 150µl 
(muscle) or 250µl (nerve) of label-free buffer containing 1% Halt protease inhibitor 
cocktail (Sigma-Aldrich); 1.21g Tris hydroxyl methylamine in 80ml ultra-pure dH2O, 
pH to 7.6 using HCl, made up to 100ml using dH2O, 0.4g SDS added for every 10ml. 
Dissociation was performed using 2x cycles of the following: (1) 1 minute of a  pre-
programmed “M-tube protein” dissocation in a gentleMacs tissue dissociator (Millentyl 
Biotech), followed by (2) centrifugation at 300g for 2 minutes at room temperature. 
Homogenate was cooled on ice for 20 minutes to allow foam to dissipate. Homogenate 
was then centrifuged at 20000rpm for 20 minutes at 4°C, and protein concentration of 
isolated supernatant was determined by microBCA Assay kit (Pierce). Extracted 
protein samples were stored at -80°C until processing for TMT labelling.  
Total protein concentration was determined by loading 7.5µg of protein per timepoint 
on a NuPAGE™ Novex™ 4-12% Bis-Tris protein gel (Invitrogen, UK) alongside 3µl of 
SeeBlue® Plus2 Protein Standard (Thermo Fisher). Gel was run at 80V for 5 minutes 
to ensure equal running, then 150V for 50 minutes. Gel was excised and incubated for 
2 hours at room temperature in InstaBlue Coomassie Brilliant Blue pre-mixed solution 
(Expedeon). Gel was washed 3x 5 minutes in ddH2O. The intensity of total protein 
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bands was determined by scanning in the 700nm channel with the Li-COR Odyssey® 
infrared imaging system (Li-COR Biosciences) at a resolution of 169µm and analysing 
the intensity of identical sections of total protein banding in the 700nm with the 
Odyssey® ImageStudio Lite software (Version 5.2).  
 
3.5.2 Tandem mass tag (TMT) labelling and fractionation of extracted samples.  
Tandem mass tagging and fractionation of extracted samples was performed by the 
FingerPrints Proteomics facilities at the University of Dundee, to the following protocol: 
Protein samples were thawed, trypsinised and desalted at room temperature. 100µg 
of desalted tryptic peptides per sample were dissolved in 100µl of 100mM   
tetraethylammonium bromide (TEAB). The 10 different tandem mass tag (TMT) labels 
comprising the TMT10plex™ kit (Thermo Fisher Scientific) were dissolved in 41µL 
anhydrous acetonitrile. Each dissolved label was added to a different sample; see 
Figure 3.2 for the specificities of which label corresponded to which sample. The 
sample-label mixture was incubated for 1 hour at room temperature. Labelling reaction 
was stopped by adding 8µl of 5% hydroxylamine per sample.  
Following labelling with TMT, samples were mixed, desalted, and dried in a speed-vac 
at 30°C. Samples were re-dissolved in 200µl ammonium formate (NH₄HCO₂) (10mM, 
pH 10) and peptides were fractionated using an Ultimate 3000 RP-High pH High 
Performance Liquid Chromatography column (Thermo-Scientific) containing an 
XBridge C18 column (XBridge peptide BEH, 130Å, 3.5 µm, 2.1 X 150 mm) (Waters, 
Ireland) with an XBridge guard column (XBridge, C18, 3.5 µm, 2.1X10mm) (Waters, 
Ireland). Buffers A and B used for fractionation consist, respectively, of (A) 10mM 
ammonium formate in milliQ water and (B) 10mM ammonium formate with 90% 
118 
 
acetonitrile. Before use, both buffers were adjusted to pH10 with ammonia. Fractions 
were collected using a WPS-3000FC auto-sampler (Thermo-Scientific) at 1 minute 
intervals. Column and guard column were equilibrated with 2% Buffer B for twenty 
minutes at a constant flow rate of 0.2ml/min. 175µl per sample was loaded onto the 
column at a rate of 0.2ml/min, and the separation gradient was started 1 minute after 
sample was loaded onto the column. Peptides were eluted from the column with a 
gradient of 2% Buffer B to 5% Buffer B in 6 minutes, and then from 5% Buffer B to 
60% Buffer B in 50 minutes. Column was washed for 16 minutes in 100% Buffer B and 
equilibrated at 2% Buffer B for 20 minutes as mentioned previously. The fraction 
collection started 1 minute after injection and stopped after 80 minutes (total 80 
fractions, 200µl each). The total number of fractions concatenated was set to 15 and 
the content of the fractions was dried and suspended in 50µl of 1% fomic acid prior to 
analysis with LC-MS.  
 
3.5.3 LC-MS/MS Analysis   
Liquid chromatography- tandem mass spectrometry was performed by FingerPrints 
Proteomics Facilities at the University of Dundee, to the following protocol:  
Analysis of peptide readout was performed on a Q Exactive™ HF Hybrid Quadrupole-
Orbitrap™ Mass Spectrometer (Thermo Scientific) coupled with a Dionex Ultimate 
3000 RS (Thermo Scientific). LC buffers were made up to the following: Buffer A (2% 
acetonitrile and 0.1% formic acid in Milli-Q water (v/v)) and Buffer B (80% acetonitrile 
and 0.08% formic acid in Milli-Q water (v/v). Aliquots of 15µl per sample were loaded 
at a rate of 5µL/minute onto a trap column (100 μm × 2 cm, PepMap nanoViper C18 
column, 5 μm, 100 Å, Thermo Scientific) which was equilibrated with 98% Buffer A. 
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The trap column was washed for 6 minutes at the same flow rate and then the trap 
column was switched in-line with a resolving C18 column (Thermo Scientific) (75 μm 
× 50 cm, PepMap RSLC C18 column, 2 μm, 100 Å). Peptides were eluted from the 
column at a constant flow rate of 300 nl/min with a linear gradient from 95% Buffer A 
to 40% Buffer B in 122 min, and then to 98% Buffer B by 132 min. The resolving 
column was then washed with 95% Buffer B for 15 min and re-equilibrated in 98% 
Buffer A for 32 min. Q Exactive™ HF was used in data dependent mode. A scan cycle 
was comprised of a MS1 scan (m/z range from 335-1800, with a maximum ion injection 
time of 50 ms, a resolution of 120 000 and automatic gain control (AGC) value of 
3x106) followed by 15 sequential-dependant MS2 scans (with an isolation window set 
to 0.4 Da, resolution at 60000, maximum ion injection time at 200 ms and AGC 1x105. 
To ensure mass accuracy, the mass spectrometer was calibrated on the first day that 
the runs were performed. 
 
3.5.4 Database search and protein identifications  
Raw MS data from the 15 fractions were searched against mouse (Mus musculus) 
protein sequences from UniProtKB/Swiss-Prot using the MASCOT search engine 
(Matrix Science, Version 2.2) through Proteome Discoverer™ software (Version 1.4, 
Thermo Fisher). Parameters for database search were as follows: MS1 Tolerance: 
10ppm; MS2 Tolerance: 0.06da; fixed modification: Carbamidomethyl (C) Variable 
Modification: Oxidation (M), Dioxidation (M), Acetyl (N-term), Gln->pyro-Glu (N-term 
Q), TMT 10(N-term and K); maximum missed cleavage: 2; and target FDR 0.01.  
All identifications were quantified as relative ratios of expression compared to the first 
time point (P12) through Proteome Discoverer™ software (Thermo Fisher, Version 
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1.4). Relative ratios along with UnitProtKB/Swiss-Prot identifications were exported 
into Microsoft Excel as a raw data file containing ID, ratio of change in expression at 
each time point (P15, P18, P21, P24) compared to P12=1.  
 
3.5.5 Filtering of raw data.  
Raw proteomic identifications (5628 proteins identified in nerve time course; 4414 
proteins identified in muscle time course), were further filtered to exclude any proteins 
with altered expression less than 20% in either direction at P24 compared to P12. The 
20% cut-off has been demonstrated successfully in previous label-free and isobaric 
mass-tagged experiments in neural tissue and skeletal muscle as an ideal threshold 
to obtain a stringent data set (Comley et al., 2011; Fuller, Hurtado, Wishart, & Gates, 
2014; Mutsaers et al., 2011; Mutsaers, Lamont, Hunter, Wishart, & Gillingwater, 2013; 
Wishart et al., 2012, 2014).  
 
3.5.6 Selection of relevant expression clusters from filtered data in  BioLayout 
Express3D 
 
Filtering raw proteomic data by an expression change of  >20% at P24 than at P12 in 
produced a separate filtered list of proteins in nerve and muscle. These lists were 
imported separately into BioLayout Express3D and clustered based on relative 
expression profile from P12 to P24. Algorithms in BioLayout Express3D generate a 
visual network to represent each data set, utilising special proximity to represent the 
similarity in expression profile of individual proteins over time. The resultant visual 
networks were utilised to distinguish expression clusters that followed either a general 
upward or downward trend in expression from P12 to P24. These “upregulated” and 
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“downregulated” clusters in nerve and muscle respectively were analysed on an 
individual basis to exclude clusters that did not follow an experimentally relevant 
expression profile from P12 to P24. For example, clusters containing proteins that 
exhibited a consistent increase or decrease in expression over were selected, while 
clusters consisting of proteins that exhibited an overall upregulation or downregulation 
but oscillated in expression during middle time points were excluded. Manual selection 
of experimentally desirable clusters yielded 1734 proteins in the nerve and 1874 
proteins the muscle, respectively, that were suitable for functional clustering and 
pathway analysis.  
 
3.5.7  DAVID Analysis.  
In two separate analyses, first with raw protein identifications, and later with filtered 
data sets, relative expression ratios compared to the first time point (P12) were sorted 
by consistency in change in expression over all five time points in Microsoft Excel. 
Proteins exhibiting a consistent upregulation or downregulation in nerve or muscle 
from P12 through all four subsequent time points to P24, regardless of magnitude of 
change, were submitted as a gene list and converted into DAVID IDs against the 
DAVID 6.7 Mus musculus database. Four separate analyses were performed from the 
following lists of proteins, grouped as: (1) Consistent upregulated expression in nerve, 
(2) Consistent downregulated expression in nerve, (3) Consistent upregulated 
expression in muscle, and (4) Consistent downregulated expression in muscle. These 
lists were analysed using the Functional Annotation Clustering tool in DAVID 
Bioinformatics Resources (Version 6.7) to produce a list of functional annotations. 
Functional annotations are ranked by a DAVID enrichment score. An enrichment score 
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greater than 1.3 in DAVID is equivalent to p<0.05, and considered to be statistically 
significant. As with many gene ontological methods, these functional annotations 
provide an indication of which biological functions may be upregulated within the data 
set over time, but are often subject to a number of sampling- and database-based 
biases, and are therefore are imperfect indicators of biological validity. For this reason, 
I performed a more precise functional analysis utilising Ingenuity Pathway Analysis 
(IPA) software, which utilises an “expert-curated” database.  
3.6 In Silico Protein Pathway Analysis  
The Ingenuity Pathway Analysis (IPA) application (Ingenuity Systems, Silicon Valley, 
CA) was used to visualise and explore the cellular and molecular pathways that may 
have been altered as a result of expression changes over time, IPA generates 
networks of gene and protein interactions and disease associations, amongst other 
results, based on in silico predicted or experimentally reported interactions stored 
within the “hand-curated” Ingenuity Knowledge database. The majority (90%) of data 
comprising the Ingenuity Knowledge database are derived from peer-reviewed 
publications; the remaining 10% of stored interactions have been identified by other in 
silico techniques.  Networks generated by IPA were set to a maximum of 35 member 
molecules, and were ranked according to a score calculated by a right-tailed Fisher’s 
exact test, which takes into account total protein input and size of the produced 
network.  Network scores represent the relevance of the particular network to the 
overall analysis (ie. proteomic alterations in nerve or muscle between P12 and P24). 
In this study, networks generated by IPA were limited to those producing the top 25 
scores.  For more information on the computational methodology underpinning IPA, 
please refer to http://www.ingenuity.com/.  
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Separate pathway analyses were performed on the filtered nerve and muscle data 
sets, which produced 25 predictive molecular networks each. A third, combined 
analysis, which consolidated nerve and muscle results, enabled the identification of 
molecular overlap within networks generated from nerve and muscle data. 
Extrapolation of this overlap through the Pathway Designer function generated a 
combined network in which molecular interactions conserved between both nerve and 
muscle data sets were explored.   
3.7     Image Processing  
















3.8 Quantitative fluorescent western blotting (QFWB) 
 
3.8.1 Extraction and sample preparation.  
Anatomically consistent segments of nerve (sciatic nerve, intercostal nerve, brachial 
plexus) were freshly dissected, snap-frozen on dry ice and stored at -80°C. Tissue 
was homogenized using a handheld motorized pestle (VWR International) in 100µl 
RIPA buffer (Fisher Scientific) with 1% Halt protease inhibitor cocktail (Sigma Aldrich). 
Homogenate was cooled on ice for 10 minutes, then centrifuged at 4°C at 14000rpm 
for 10 minutes. Centrifuged samples were immediately re-transferred to ice and 
supernatant was removed by pipetting, while pellet was discarded. Concentration of 
extracted protein was determined by micro-BCA kit (Pierce Biosystems). 
3.8.2 Quantitative fluorescent western blotting.  
Samples were prepared to load between 10 and 25µg of protein in 10 µl deionised 
water and 5µl of NuPage® LDS Sample buffer 4X (Invitrogen, UK). Samples were 
denatured at 98°C for 2 minutes and were loaded in a NuPAGE™ Novex™ 4-12% 
Bis-Tris protein gel (Invitrogen, UK) alongside 5µl of Novex® Sharp Pre-stained 
Protein Standard (Thermo Fisher). Gels were run at 80mV for 5 minutes to ensure 
equal stacking, then 150mV for 50 minutes. Gels were excised, removed to a pre-
prepared i-Blot2® transfer stack (Invitrogen, UK) and transferred using an 8.5 minute 
transfer cycle in the i-Blot2® transfer system (Invitrogen, UK).  
After transfer, membranes were excised and transferred to 20ml Falcon tubes 
containing 5ml of Ponceau S solution; 0.1% Ponceau S (Sigma-Aldrich), 0.5% acetic 
acid (Sigma-Aldrich) in ddH2O. Membranes were stained for 20 minutes, rolling, at 
room temperature then washed in ddH2O until bands were visible. Membranes were 
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scanned in greyscale using a CanoScan LiDE220 digital scanner (Canon) and saved 
as a TIFF image for total protein analysis. Membranes were washed in ddH2O and 
blocked in 5ml Odyssey® Blocking Buffer (Li-COR Biosciences) at room temperature 
for 30 minutes.  
Membranes were incubated in primary antibody solution containing primary antibodies 
at the following concentrations (ROCK2 1:200, Abcam; SIRT2 1: 500, Abcam; 
calretinin 1:1000, Swant) in a solution of 1% tween-20 (Sigma) in 5ml Odyssey® 
Blocking Buffer (Li-COR Biosystems) at 4°C overnight. Antibodies to SIRT2 and 
calretinin were generously provided by members of the Gillingwater laboratory.  
The following day, membranes were washed 6x 5 minutes in PBS, rolling, at room 
temperature. Membranes were incubated in secondary antibody solution containing 
either IRDye® 680RD donkey anti-mouse IgG (H+L) or IRDye® 680RD  donkey anti-
rabbit IgG (H+L) antibodies (Li-COR Biosciences) at a concentration of 1:5000 
(0.02%) in a solution of 1% tween-20 (Sigma) in 5ml Odyssey® Blocking Buffer (Li-
COR Biosciences). Membranes were incubated for 90 minutes at room temperature 
and covered to prevent photobleaching.  
After secondary antibody incubation, membranes were washed 2x 5 minutes, then 3x 
10 minutes in PBS, rolling, at room temperature. Membranes were dried and stored at 
4°C prior to imaging and analysis. 
3.8.3 Measurement and analysis. 
 TIFF images of Ponceau-stained blots were imported into Odyssey® ImageStudio 
Lite software (Version 5.2). ImageStudio Lite (Version 5.2) was used to analyse the 
intensity of identical sections of total protein banding against background. Readouts 
of the intensity of total protein banding relative to background were imported into 
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Microsoft Excel (Windows 2013) to calculate loading consistency and normalisation 
factors. Western blots were imaged on the 700nm channel using the Odyssey® 
Infrared Imaging System at a resolution of 169µm. All quantification was performed on 
the 700nm channel, with the intensity of bands normalised using the factors generated 
from total protein analysis. All statistical analysis and generation of graphs was 
performed in GraphPad Prism7 (Windows). All data are presented as a scatter plot of 
individual n  with mean ± SE unless otherwise noted. Individual statistical tests used 
are noted in figure legends. Statistical significance was considered to be p ≤ 0.05. 














Chapter THREE: Results 
3.9  TMT10plex™ isobaric mass tag labelling yields powerful mass 
spectrometry throughput and comprehensive identification of the 
nerve and muscle proteome. 
The preliminary aim of this study was to evaluate the efficacy of the novel 
TMT10plex™ reporter ion kit as a labelling technique for quantitative mass 
spectrometry. Previous work has demonstrated how iTRAQ isobaric labelling and 
label-free methods can be used for proteomic analysis of  murine peripheral nerves 
and skeletal muscles (Comley et al., 2011; Mutsaers et al., 2011; Mutsaers et al., 
2013). Recent advances in the structural design of isobaric tagging reagents have 
enabled the development of “multiplex” tandem mass-tag reporter ion kits, which 
enable the concurrent quantitative analysis of multiple samples, in contrast to the 
limitations of earlier duplex methods. I designed a time-course study to analyse five 
distinct time points spanning the decline in NMJ protection by Murray et. al (2011), 
within both the sciatic nerve and lumbrical muscles, with the aim of determining the 
coverage potential of the 10plex™ reporter ion kit. 
Consolidation of raw peptide outputs across all five time points within sciatic nerve and 
muscle samples respectively were translated into protein identifications by searching 
against human protein sequences using the MASCOT protein database (Matrix 
Science, Version 2.2)    and quantified as relative ratios of expression compared to the 
first time point (P12) through Proteome Discovery software (Thermo Fisher, Version 
1.4). This produced a list of raw muscle and nerve output respectively; within these 
lists, only proteins identified by a >95% total ion score confidence interval and 2 or 
more unique peptides were deemed reliable for analysis. Within the sciatic nerve 
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samples, 7440 total proteins were identified by a >95% total ion score confidence 
interval, of which 5628 were identifiable by 2 or more unique peptides 
(Supplementary Table 1). Within the lumbrical muscle samples, 6079 total proteins 
were identified by a >95% total ion score confidence interval, of which 4414 were 
identifiable by more than 2 unique peptides (Supplementary Table 2). These results, 
which provided a comparably greater coverage of both the nerve and muscle 
proteome than previous isobaric or label-free studies, implicate TMT10plex™ as a 
robust and powerful labelling technique.  
 
3.10 Validation of expression profiles reported in TMT10plex™ 
proteomics study by quantitative fluorescent western blotting 
(QFWB) of select candidate proteins in peripheral nerves.  
In order to confirm the veracity of expression trends identified by the proteomics study, 
I selected individual protein candidates for validation by quantitative fluorescent 
western blotting. Candidates were selected from the unfiltered nerve data set based 
on their magnitude of change over the experimental period, implicated modulation of 
injury-induced neuronal degeneration based on the published literature, and 
availability of quality antibodies suitable for fluorescence-based western blotting. Of 
particular interest was calretinin (CALB2), identified in a comparative proteomics study 
to be consistently up-regulated across two mouse models of neurodegenerative 
disease and a model of injury-induced stroke. Translationally, CALB2 knockdown has 
been demonstrated to potently delay degeneration of the olfactory receptor neuron in 
Drosophila (Wishart et al., 2012). The raw proteomic output of this study reported a 
change in expression of CALB2 of nearly 750% from P12 to P24 (7.488 P24/P12 ratio). 
NAD-dependent deacetylase sirtuin-2 (SIRT2) exhibited more modest increases in 
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expression in the raw proteomic data (1.330 P24/P12 ratio) but has been similarly up-
regulated across a number of neurodegenerative disease and injury models (Amorim 
et al., 2015; Wishart et al., 2012). Finally, the raw data reported that rho-associated 
kinase 2 (ROCK2) underwent negligible changes in expression at P24 compared to 
P12.  It was therefore selected as another validation candidate as an internal control.  
All signals from western blots were quantified against total protein load (Ponceau S 
stain) in order to reliably determine expression changes (Figure 3.3A). SIRT2 
exhibited a significant increase in expression (1.423 ± 0.06; P24/P12 ratio of mean ± 
SEM) (Figure 3.3C), thus confirming the direction and magnitude of expression 
change reported in the TMT data.  Similarly, expression of CALB2 by QFWB reported 
an increase in expression significant at P21 (3.107 ± 0.09; P21/P12 ratio of mean ± 
SEM), which profiled expression changes reported by the proteomic data, albeit to a 
lesser magnitude (Figure 3.3D). Despite a slight trend towards an increase in relative 
expression over time, overall, there was no significant difference in expression levels 
of ROCK2 between P12-P24, in concurrence with the TMT data (Figure 3.3B). The 
QFWB data therefore indicate that TMT10plex™ proteomic analysis is likely to 
accurately profile molecular alterations occurring over the P12-P24 postnatal period, 
albeit not to a precise magnitude. While several quantitative labelling strategies such 
as iTRAQ appear to modestly compress expression ratios, thus resulting in an 
underreporting of protein expression changes, very little is known about such 
phenomena in the relatively novel TMT10plex™ technology (Karp et al., 2010). For 
this reason, future work is required to gauge the precision of TMT output versus more 
traditional quantitation methods.  







3.11 Filtering and expression cluster selection of raw proteomic 
output produces a comprehensive yet concentrated list of proteins 
suitable for additional functional clustering and pathway analysis 
 
3.11.1 Filtering of raw proteomic output.  
Raw proteomic output (5628 proteins identified in nerve time course; 4414 proteins 
identified in muscle time course), was further filtered to exclude any proteins with 
altered expression less than 20% in either direction at P24 compared to P12. Previous 
studies have demonstrated that the 20% cut-off threshold produces a reliable and 
stringently consolidated data set (Wishart et al., 2010; Comley et al., 2011; Mutsaers 
et al., 2011; Wishart et al., 2012; Wishart et al., 2014; Fuller et al., 2014).   
Selection of relevant expression clusters generated in BioLayout Express3D 
A list of proteins with altered expression >20% at P24 compared to P12 in sciatic 
nerve, and a list of proteins with altered expression >20% at P24 than at P12 in 
lumbrical muscles, were imported separately into BioLayout Express3D and clustered 
based on relative expression profile from P12 to P24. A separate visual network for 
each data set was generated, utilising special proximity to represent the similarity in 
expression profile of individual proteins over time (Figure 3.4A; Figure 3.5A). Utilising 
these visual networks, it was possible, in both nerve and muscle datasets, to 
distinguish a large body of proteins, comprising numerous specific expression profiles, 
that followed either a general upward or downward trend in expression from P12 to 
P24 (Figure 3.4B&F; Figure 3.5B&F). Consolidating these generally “upregulated” or 
“downregulated” set of proteins into their respective expression clusters provided an 
elegant graphical representation of the specific expression pattern of each cluster of 
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proteins generated by the software. This made it possible to select groups of proteins 
comprising a cluster that followed an the predicted relevant expression profile from 
P12 to P24. Clusters containing proteins that exhibited a consistent increase or 
decrease in expression over time (Figure 3.4C&G; Figure 3.5C&G) were selected, 
while clusters consisting of proteins that exhibited an overall up-regulation or down-
regulation but oscillated in expression during middle time points were excluded 
(Figure 3.4D&H; Figure 3.5D&H).  
Individual selection of experimentally desirable clusters further narrowed the pool of 
nerve and muscle protein identifications to a total of 1734 proteins in nerve samples 















Graphical representation of the filtering process, first by magnitude (ie. >20% change 
threshold) then by direction of change (ie. selection of relevant BioLayout profiles) 
reveals the extent of data refinement performed to transform raw LC-MS/MS protein 
identifications to a reliable data set suitable for pathway analysis and further functional 









3.12 Functional annotation analysis of filtered proteomics output 
enhances enrichment in both nerve and muscle for mitochondrial 
and oxidative phosphorylation pathway components in upregulated 
proteins, and RNA binding and processing pathways in 
downregulated proteins. 
The refined nerve and muscle datasets were sorted into four lists: (1) Consistent 
upregulated expression in nerve, (2) Consistent downregulated expression in nerve, 
(3) Consistent upregulated expression in muscle, and (4) Consistent downregulated 
expression in muscle. These lists were analysed using the Functional Annotation 
Clustering tool in DAVID Bioinformatics Resources (Version 6.7) to produce a list of 
functional annotations of filtered proteins. Table 3.1 lists the 10 most significantly 
enriched biological clusters generated from functional annotations either consistently 
upregulated or consistently downregulated between P12 and P24 in nerve. Table 3.2 
lists the 10 most significantly enriched biological groups generated from functional 
annotations either consistently upregulated or consistently downregulated between 
P12 and P24 in muscle. An enrichment score greater than 1.3 in DAVID is considered 













Table 3.1: Statistically altered functional clusters of sciatic nerve dataset filtered by 
magnitude and direction of expression from P12 to P24.  
Filtered: Up from P12-P24 in Nerve Filtered: Down from P12-P24 in Nerve 
Cluster Name Enrichment 
Score 





8.44 mRNA processing/ 
Spliceosome 
25.24 






















Nucleotide binding 3.7 Protein transport 
(Golgi) 
6.54 
Endocytosis 3.3 Endoplasmic 
reticulum membrane 
5.41 





Functional annotation analysis of proteins consistently upregulated within the sciatic 
nerve between P12 and P24 from the final refined dataset revealed a marked 
enrichment for biological groups implicated in oxidative phosphorylation and 
mitochondrial respiration. The most significant cluster was comprised of proteins 
involved in NAD-dependent “redox” processes. The majority of the remaining top-10 
biological groups produced by this analysis included clusters comprised of proteins 
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involved in magnesium binding, nucleotide binding, endocytosis, and cytoskeletal 
actin binding.  
Functional annotation analysis of proteins consistently down-regulated within the 
sciatic nerve between P12 and P24 from the final refined dataset yielded the dominant 
presence of biological groups comprised of proteins involved in mRNA processing and 
binding, as well as RNA-editing machinery such as the RNP complex and 
spliceosome. Other top groups contained proteins pertaining to endoplasmic reticulum 























Table 3.4: Statistically altered functional clusters of lumbrical muscle dataset filtered 
by magnitude and direction of expression from P12 to P24.  
Filtered: Up from P12-P24 in Muscle Filtered: Down from P12-P24 in 
Muscle 
Cluster Name Enrichment 
Score 
Cluster Name Enrichment 
Score 
Mitochondria 134.15 Endoplasmic 
reticulum 
12.26 
Mitochondrial membrane 82.63 Protein transport 10.38 
Oxidation reduction/electron 












22.5 Actin cytoskeleton 
organisation 
8.52 
Mitochondrial lumen 21.82 Non-membrane 
bound organelle 
7.83 












Respiratory ETC/ Oxidative 
phosphorylation/mitochondrial 





Functional annotation analysis of proteins consistently up-regulated within the 
lumbrical muscles between P12 and P24 from the final refined dataset similarly 
suggested an overwhelming dominance of clusters implicated in mitochondrial—
specifically, electron transport chain—activity. Indeed, 9 of the 10 most significantly 
enriched functional clusters identified pertained to mitochondrial metabolic activity. 
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The top cluster identified comprised of mitochondrial proteins, with an enrichment 
score of 134.15.  
Functional annotation analysis of proteins consistently down-regulated in within the 
musculature between P12 and P24 from the final refined dataset produced several 
biological groups enriched for proteins implicated in endoplasmic reticulum activity, 
RNA processing and RNA splicing. Of additional interest were groups comprised of 
proteins involved in actin binding and cytoskeletal dynamics.  
While by no means an in-depth representation of the biological events occurring over 
this developmental period, the functional annotation analysis of the filtered data 
suggests an interesting parallel between nerve and muscle datasets. It is evident that 
clusters pertaining to mitochondrial and redox functions from up-regulated proteins, 
and to RNA binding and splicing machinery from down-regulated proteins, dominate 
both the muscle and nerve data sets. These data invite the considerations of parallel 
mechanistic changes occurring within both the nerve and muscle from P12 to P24, 










3.13  In silico pathway analysis of refined muscle and nerve data 
sets identifies comprehensive networks implicated in oxidative 
phosphorylation, redox sensitivity, and RNA and protein binding.  
In order to explore any potential cellular or molecular pathways that may be modified 
as a result of the expression alterations present in the refined proteomic data, I 
performed a systems level analysis using Ingenuity Pathway Analysis software. 
Through performing a separate analysis on nerve and muscle data sets independently, 
it was possible to generate a visual representation of molecular networks comprised 
of interactions between proteins in each respective data set, on the basis of 
experimentally observed interactions reported in the literature. Combining IPA-
generated nerve and muscle output to produce a parallel analysis then enabled the 
identification of any molecular overlaps between the functional networks proposed to 
be altered in both nerve and muscle between P12 and P24.  
For the nerve analysis, the filtered list of 1734 proteins was imported into Ingenuity 
Pathway Analysis (IPA); of these, 1713 were mappable by the software and therefore 
suitable for data mining of the published literature to generate interaction networks. All 
networks were scored by a unique value, based on total protein input and network 
size, that represents the relevance of the particular network to the overall analysis (i.e. 
proteomic alterations in nerve between P12 and P24). Networks generated by IPA 
were limited to 25 networks comprising a maximum of 35 members per network.  
For the muscle analysis, the filtered list of 1874 proteins imported produced 1862 
mappable proteins suitable for network generation. The combined analysis of nerve 
and muscle included all mappable proteins from both nerve and muscle data sets 
(1713 and 1862, respectively) analysed in parallel, before utilisation of a “combined 
pathways” function to pinpoint potential conserved molecular pathways.  Expression 
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of all proteins comprising imported nerve and muscle lists had been reported as a ratio 
in relation to expression at P12; IPA converted all ratios into fold-change in relation to 
P12. Pathway analysis of nerve, muscle, and combined data sets only included 
proteins exhibiting a >1.2 fold change at P24 from P12.  
3.13.1 The top molecular network generated by IPA-based pathway analysis of sciatic 
nerve proteins with altered expression over the experimental period implicates RNA 
metabolism as a key process evolving between P12 and P24.    
The top network generated by pathway-based analysis of nerve proteomic data 
comprised functions involved in RNA post-transcriptional modification. The 34 
molecules comprising this top network were not only all present within our data set, 
but were also almost entirely down-regulated over the experimental time period. 
Additionally, the interactions between proteins constituting this network were almost 
entirely direct interactions and therefore had been reported in the published literature 
as experimentally observed. Upon visualisation of the network, it is evident that the 
majority of these molecular interactions from a core, or “hub”; molecules comprising 
this centre “hub” include MCM2, a component of the minichromosome-maintenance 
protein complex, Synaptotagmin-binding cytoplasmic RNA-interacting protein 
(SYNCRIP), and various other ribonucleoproteins (RNPs). The implications of 
decreasing RNA-binding and post-transcriptional modification activity over time 
elegantly parallel the functional annotation analysis of the filtered nerve data, which 
demonstrated an overwhelming enrichment for processes of RNA metabolism, 
particularly the post-transcriptional functions of spliceosome assembly and 









3.13.2 Additional pathway analysis of sciatic nerve proteins with altered expression 
over the experimental period highlights a network involved in sodium channel 
localisation and redox sensitivity.  
Another network generated by pathway-based analysis of nerve proteomic data 
included functions broadly divided into sodium channel localisation and, perhaps more 
interestingly, sensitivity to redox activity (Figure 3.9.A).  Hierarchical reordering of this 
network by number of interactions (Figure 3.9.B) revealed the dominance of 
Parkinsonism-Associated Declygase 7(PARK7) as a senior molecular hub of this 
network, including three direct interactions with proteins such as the NADH-dependent 
redox enzyme malate dehydrogenase 1 (MDH1), the mitochondrial enzyme Pyrroline-
5-carboxylate reductase 1 (PYCR1), and glutathione peroxidase, a major enzyme 
involved in response to oxidative damage. Additionally, PARK7 was shown to 
indirectly interact with the oxidative-stress protein superoxide dismutase (Sod), linked 
to ALS.  The redox sensitivity functions of this molecular network serve as an 
interesting potential correlate to the apparent up-regulation in mitochondrial and redox 






3.13.3 The top molecular network generated by IPA-based pathway analysis of 
lumbrical muscle proteins with altered expression over the experimental period 
implicates RNA binding and ribonucleoprotein activity as a key process evolving 
between P12 and P24.    
In a remarkable parallel to the results produced by pathway analysis of the nerve data, 
the top network generated by pathway-based analysis of lumbrical muscle proteomic 
data also comprised functions involved in RNA binding and ribonucleoprotein activity. 
This network consisted of 35 molecules, which were all present within our data set. 
Additionally, the interactions between proteins constituting this network were all direct 
and therefore experimentally observed according to reports in the published literature. 
Although this network appears to lack a single molecular hub, central molecules 
comprising this radiating network are overwhelmingly components of 
ribonucleoprotein complexes, responsible for binding RNA for post-transcriptional 
modification; all of these RNP components appear to exhibit a consistent decrease in 
expression between P12 and P24. These results, again suggesting a marked 
decrease in RNA-binding, spliceosomal assembly and post-transcriptional 
modification activity over the experimental period, not only recapitulate results 
produced by the functional clustering analysis of filtered muscle data, but also parallel 
both network-based and functional clustering-generated suggestions of a similar 












3.13.4 Multiple networks generated by IPA-based pathway analysis of lumbrical 
muscle proteins with altered expression over the experimental time period implicate 
a marked increase in mitochondrial membrane and oxidative phosphorylation activity 
between P12 and P24.  
Perhaps unsurprisingly with consideration to the results produced by functional 
clustering analysis of the filtered muscle dataset, a large majority of the remaining top 
25 networks produced by pathway analysis of the muscle data comprise  mitochondrial 
respiratory components; specifically, components of the electron transport chain. Two 
such networks are presented as Figure 3.11A and Figure 3.11B. In the Figure 3.11A, 
note the presence of a dominant subnetwork comprised entirely of direct interactions 
between proteins identified to be consistently up-regulated within the dataset; 
investigation into the functional characterisation of these proteins using information 
stored within the Ingenuity Knowledge Base reveals that they are all components of 
complexes I and IV of the electron transport chain, located within the inner 
mitochondrial membrane. Within this subnetwork, the ubiquitous enzymatic complex 
NADH dehydrogenase, or complex I, serves as the clear hub; direct interactions with 
NADH dehydrogenase are highlighted in blue.  
A separate network visible in Figure 3.11B also reveals the robust direct 
interconnectivity of subunits of complexes I and III of the electron transport chain. A 
clear subsection of the generated network is based entirely on direct interactions 
between proteins identified to be consistently up-regulated within the dataset.  
These findings, which recapitulate molecular trends identified to be significantly 
enriched through functional clustering analysis via an easily discernible visual network, 
invite the consideration of an escalating involvement of oxidative phosphorylation 






3.14  Convergence of pathway analysis-generated networks from 
nerve and muscle data sets highlights multiple conserved direct 
interactions between components of the oxidative phosphorylation 
pathway. 
 
Using the Path Designer function in Ingenuity Pathway Analysis, it was possible to 
identify a molecular overlap between a predictive network generated from the previous 
independent nerve analysis, and a network generated from the previous muscle 
analysis.  Extrapolation of this convergence into a visual network, organised by cellular 
location, revealed the conservation of multiple direct interactions between components 
of the electron transport chain in both nerve and muscle data sets (Figure 3.12). In 
adherence with the previous functional clustering analyses of nerve and muscle data 
sets, these results demonstrated an increased expression in proteins involved in the 
mitochondrial electron transport chain over the P12-P24 period. This predicted 
mechanistic overlap in functional pathways occurring in both the sciatic nerve and the 
innervated lumbrical muscles implicated mitochondrial electron transport chain activity 
as a candidate pathway potentially modulating the vulnerability status of the 







Chapter THREE: Discussion 
3.15   Overview of Results 
In this chapter, I utilise TMT10plex™ tandem mass-tagging proteomics in order to 
profile the molecular changes occurring in the sciatic nerve and lumbrical muscles 
over a time course corresponding to a reported escalation in neuromuscular junction 
vulnerability to injury. Firstly, these results demonstrate a robust and comprehensive 
coverage of the nerve and muscle proteome with TMT10plex™ technology, yielding a 
protein abundance profoundly exceeding those produced by label-free studies of 
peripheral nerves or skeletal muscle. To date, this study is one of the first applications 
of TMT10plex™ in the quantitative proteomic study of whole tissues. Secondly, 
functional enrichment analyses of filtered proteomic output, refined by both magnitude 
of change and expression pattern over time, reveals a significant and conserved 
enrichment for an increase in the processes of oxidative phosphorylation (OXPHOS) 
and mitochondrial respiration over time in both the nerve and muscle. Similarly, 
functional enrichment analyses of filtered nerve and muscle data sets protein suggests 
a significant decrease in the processes of RNA binding and post-transcriptional 
modification over time in both tissues. These findings are supplemented by multiple 
pathway analysis-generated molecular networks strongly implicating an escalation in 
OXPHOS activity and cellular responses to oxidative stress over this period of 
increasing neuronal vulnerability. Finally, comparative pathway analyses combining 
nerve and muscle time course data sets identifies an overlap in interactive networks 
suggesting a conserved increase in mitochondrial bioenergetics, particularly in 
expression of components comprising complex I of the electron transport chain. 
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3.16 TMT10plex™ mass tagging is a powerful tool enabling a 
comprehensive exploration of the murine nerve and muscle 
proteome. 
Previous studies utilising quantitative proteomics in the molecular characterisation of 
murine nerves and skeletal muscles have successfully obtained a modest proteome 
coverage through both iTRAQ isobaric labelling and label-free techniques (Comley et 
al., 2011; Mutsaers et al. 2011; Mutsaers et al., 2013). In particular, a label-free 
proteomic approach to elucidating the molecular perturbations present in mouse 
models of spinal muscular atrophy (SMA)  have resulted in the successful identification 
of peripheral biomarkers and therapeutically targetable candidates (Mutsaers et al. 
2011; Mutsaers et al., 2013; Wishart et al., 2014; Powis et al., 2016). Several studies 
have sought to assess the efficacy of label-free versus chemical labelling (including 
iTRAQ and tandem mass tagging)  techniques; in studies utilising whole tissues, label-
free methods have traditionally been favoured as a more powerful and reliable 
quantification method (Latosinska et al., 2015; Trinh et al., 2013; X. Wang, Anderson, 
Smith, & Dabney, 2012). However, recent modifications to the labelling reagents used 
in multiplexed quantitation have been anticipated to produce a greater coverage 
capacity compared to previously available chemical labelling methods(Braun et al., 
2015; Edwards & Haas, 2016). In this study, I have demonstrated that the recently 
developed TMT10plex™ tandem mass tagging system is not only a robustly viable 
technique in the time course molecular analysis of both nerve and muscle, but that it 
also produces a prolific coverage of the mouse proteome, exemplified by the markedly 
greater abundance attained than previously reported label-free studies of the murine 
musculature utilising the same identification criteria (Mutsaers et al., 2011; Mutsaers, 
et al., 2013).  
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It should also be noted that this proteomic analysis was performed under consideration 
of recent evidence suggesting that the proteomic composition of different segments of 
the same tissue varies significantly. Eaton et al. (2013) demonstrated a marked 
discrepancy in the expression levels of β-actin and neurofilament-light between 
proximal and distal regions of the sciatic nerve, inviting speculation that a similar 
inconsistency may also exist throughout the proteome (Eaton et al., 2013). 
Consequentially, care was taken to ensure that all tissue samples used in this study 
were anatomically consistent. These conditions, in conjunction with the validation of 
select candidates within the data set by quantitative fluorescent western blotting 
(Figure 3.2), suggest that the robust coverage generated in this TMT10plex™ study 
is truly representative of global changes in the nerve and muscle proteome over the 
postnatal developmental period.  
3.17  Conserved molecular changes occur in both nerve and muscle 
over the time course.  
After establishing that “immature,” regenerated NMJs in adult mice failed to exhibit the 
marked resistance to Wallerian degeneration observed in the NMJs of neonatal 
“immature” mice, Murray et al. (2011) reasoned that the molecular factors potentially 
regulating this age-based vulnerability to degeneration were not intrinsic to the NMJ 
itself, but rather originated from either the rest of the motor neuron, or else in the 
surrounding synaptic environment (Murray et al., 2011). Consequentially, this study 
therefore sought to profile molecular changes occurring in both the sciatic nerve and 
in the deep lumbrical muscles over the period corresponding to a steady drop in 
neuroprotection. Functional annotation analysis of proteins exhibiting a steady 
upregulation over this P12-P24 period revealed a striking enrichment for the processes 
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of OXPHOS and associated mitochondrial functions, in both the nerve and the muscle 
(Table 3.1, Table 3.2). Indeed, the most enriched biological group identified from the 
nerve data, comprised of proteins involved in mitochondrial redox reactions, earned 
an enrichment score of 8.44, while the top biological group in muscle, comprised of 
proteins involved in mitochondrial activity, earned an enrichment score of 134.15; for 
context, a DAVID enrichment score of >1.3 is considered to be loosely equivalent to 
p<0.05 (Huang, Sherman, & Lempicki, 2009). While the biological relevance of these 
findings will be discussed subsequently, this apparent synchronicity in heightened 
mitochondrial activity between the motor neuron and muscle are particularly 
compelling in consideration of the hypothesis that the developmental age of the motor 
neuron and surrounding environment may regulate synaptic vulnerability to injury-
induced degeneration. 
3.17.1. Elevated mitochondrial biodynamics are conserved between both nerve and 
muscle.  
Pathway analysis of proteomic alterations occurring in both the nerve and the muscle 
further suggested a conserved escalation in mitochondrial OXPHOS activity. For 
example, a number of molecular networks generated from analysis of the filtered 
muscle data set feature proteins involved in mitochondrial activity, particularly 
involving electron I of transport chain (Figure 3.11A; Figure 3.11B).  It should noted 
that these networks were predominantly comprised of direct interactions between 
proteins present within the data set, rather than predicted or indirect interactions.  
Interestingly, a top nerve network, comprising proteins involved in the cellular 
response to oxidative stress, highlighted a hierarchal role for PARK7, a major neuronal 
oxidative stress sensor in which mutations cause autosomal recessive early-onset 
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Parkinson’s disease (H. M. Li, Niki, Taira, Iguchi-Ariga, & Ariga, 2005; Niki, Takahashi-
Niki, Taira, Iguchi-Ariga, & Ariga, 2003; Shendelman, Jonason, Martinat, Leete, & 
Abeliovich, 2004; Takahashi et al., 2001; Yokota et al., 2003). PARK7 has also been 
identified to be markedly upregulated in both iPSC motor neurons from Type 1 SMA 
patients as well as in hippocampal synaptosomes from severe Taiwanese SMA mice; 
accordingly, SMA has been recently added to the list of neurodegenerative conditions 
in which oxidative stress may impart a major pathological influence (Fuller et al., 2015; 
Miller, Shi, Zelikovich, & Ma, 2016; Wishart et al., 2014).  
Taken together, these findings invite consideration of a concurrent increase in 
OXPHOS activity and oxidative stress response mechanisms, in both the nerve and 
muscle. A possible explanation linking these findings is that the apparent rise in 
oxidative stress response capacity within the nerve homeostatically accompanies a 
developmental escalation in electron transport chain activity, which is a major source 
of reactive oxygen species (Hamanaka & Chandel, 2010). 
3.18  Mitochondrial bioenergetics and neurodegeneration.  
3.18.1.     Mitochondria in heritable and spontaneous neurodegenerative disease 
Due to the high metabolic demand of neuronal tissues, it is perhaps unsurprising that 
defective mitochondrial activity appears to be a major pathological candidate –and 
subsequently, an attractive therapeutic target—in a number of neurodegenerative 
disorders (Fernández-Vizarra, Enríquez, Pérez-Martos, Montoya, & Fernández-Silva, 
2011). Within the central nervous system (CNS), the most definitive association 
between aberrant mitochondrial dysfunction and neurodegeneration originates from 
studies of Parkinson’s disease patients and animal models alike; indeed, rotenone-
induced inhibition of complex I of the electron transport chain in rodents is considered 
162 
 
a robust replication of the Parkinsonian disease course ( Schapira et al., 1989; Cannon 
et al., 2009; Park et al., 2006). Defects in mitochondrial motility, trafficking and basal 
respiration capacity, coupled with morphological abnormalities, have been widely 
reported in both patient tissues and in animal models of Alzheimer’s disease, 
Huntington’s disease, Batten Disease, and other heritable and spontaneous CNS 
conditions, as well as in the non-demented aging brain (Blass, Sheu & Gibson, 2000; 
Bobba et al., 2013; Goebel, Heipertz, Scholz, Iqbal, & Tellez-Nagel, 1978; Hamilton, 
Pellman, Brustovetsky, Harris, & Brustovetsky, 2016; Hauptmann et al., 2009; 
Kondziella, Hammer, Sletvold, & Sonnewald, 2003; Yao et al., 2009; Luiro et al., 2006; 
Yin, Manczak, & Reddy, 2016). 
Altered mitochondrial dynamics, including alterations in OXPHOS activity and 
accompanying production of reactive oxygen species are similarly implicated in 
heritable and spontaneous diseases of the peripheral nervous system, including ALS. 
Specifically, the production of reactive oxygen species via defects in the mitochondrial 
electron transport chain appear to be major pathological candidates in degenerative 
diseases of the motor neuron. For example, it has recently been suggested that the 
mechanism by which TAR DNA-binding protein 43 (TDP-43), the quintessential ALS 
mutation, exerts its toxic gain-of-function is by binding to mRNAs encoding subunits 
of complex I of the electron transport chain; the subsequent disassembly of complex I 
appears to promote a rise in oxidative stress in vitro  (Wang et al., 2016). Aberrant 
mitochondrial dynamics have also been implicated in SMA, with significant levels of 
oxidative stress within the motor neuron cell body and axon, accompanying structural 
mitochondrial abnormalities and OXPHOS defects, reported in the Δ7 mouse model 




3.18.2  Mitochondria in WldS-senstitive and archetypal Wallerian Degeneration 
Although recent evidence has suggested that mitochondria are not crucial in the 
execution of injury-induced Wallerian degeneration, mitochondrial biodynamics have 
been widely reported to be capable of modestly influencing the rate and extent of 
Wallerian degeneration  (Barrientos et al., 2011; Kitay, McCormack, Wang, Tsoulfas, 
& Zhai, 2013; Loreto, Di Stefano, Gering, & Conforti, 2015; Villegas et al., 2014). 
The mechanistic contribution of mitochondria to the injury-induced degenerative 
process have been investigated in both the protective WldS model (Kitay et al., 2013), 
and in wildtype mice alike (Barrientos et al., 2011; Villegas et al., 2014). From these 
studies, it has become evident that neuronal mitochondria regulate a number of 
molecular processes within the distal compartments of the neuron that harbour a 
marked influence upon degenerative outcome following injury, such as the regulation 
of axoplasmic Ca2+ levels, production of reactive oxygen species, and maintenance of 
electron transport chain integrity (Avery et al., 2012; Barrientos et al., 2011). For 
example, the capacity for mitochondria to open a mitochondrial permeability transition 
pore (mPTP) within their inner membrane in response to cellular stresses enables 
them to dictate the activation of cell death signalling pathways. In the context of 
injurious axotomy, the rise in intracellular Ca2+  levels following injury-induced loss of 
neuronal membrane integrity promotes the opening of mPTPs which in turn appear to 







3.18.3 Elevated mitochondrial bioenergetics as a preconditioning contributor to 
neuronal vulnerability 
However, the findings presented in this chapter are the result of proteomic 
experiments performed on tissues in which no disease- nor injury-induced 
degenerative perturbations have occurred. Rather, I present evidence for the dynamic 
molecular changes occurring throughout this postnatal developmental period, such as 
an escalation in mitochondrial bioenergetics, to “pre-condition” the distal 
compartments of the motor neuron to degenerate following injury. In other words, while 
increased OXPHOS activity itself is not inherently pro-degenerative, do increased 
mitochondrial bioenergetics in the motor axon and musculature of the mature wildtype 
mouse pre-condition the distal synapse to degenerate more rapidly upon traumatic 
insult?  
While the majority of studies correlating OXPHOS activity to neurodegeneration 
disease or injury models report the consequences of dysregulated mitochondrial 
respiration as mentioned previously, a small but growing body of evidence has 
presented a correlation of elevated basal levels of healthy bioenergetic activity to 
neuronal vulnerability. A study of differential vulnerability to Parkinsonian degeneration 
between populations of dopaminergic neurons in the brain proposed that the leading 
discrepancy between otherwise functionally similar neuronal populations lay in the 
elevated basal OXPHOS levels of the vulnerable group (Pacelli et al., 2015).  
While the mechanisms by which endogenously elevated OXPHOS activity may pre-
condition the neuron to increased vulnerability remain unknown, a potential 
explanation may be that increased basal mitochondrial bioenergetics produce overall 
higher levels of reactive oxygen species, which may promote more aggressive 
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degeneration upon loss of axonal integrity following traumatic insult. Indeed, the 
results from this chapter indicating an upregulation of molecular networks responsible 
for oxidative stress response over the P12-P24 period provide compelling support for 
this theory. Based on the current understanding that mitochondria dynamically 
regulate the axoplasmic Ca2+ levels required for the initiation of the degenerative 
cascade, it is also possible that alterations in mitochondrial demand over this 
developmental maturation period also invoke differential, age-dependant capacities 
for this homeostatic regulation (Avery et al., 2012).  
 
3.19. On a future perspective 
In order to support my hypothesis, it would firstly be of utmost interest to assess basal 
OXPHOS activity within both the nerve and musculature over this P12-P24 period in 
order to identify any age-dependant differences. Subsequently, it would also be of 
interest to investigate whether manipulation of basal OXPHOS activity within the motor 
neuron and surrounding musculature, with a number of readily available 
pharmacological compounds, is capable of attenuating the phenomenon of an age-
dependant synaptic response to injury. The ex-vivo whole-mount culture model 
provides an attractive platform upon which to test these compounds, as it circumvents 
potential difficulties in mechanism of delivery and pharmacodynamics that often 







Chapter FOUR:  General Discussion 
4.1 Overview of Results  
In this study, I have examined two distinct situations of neuromuscular junction 
vulnerability: firstly, in a mouse model of spinal muscular atrophy, in muscles exhibiting 
a marked presence of structural pathology; remarkably, therapeutic intervention with 
SMN promoted a robust improvement in these cytoarchitectural defects, suggesting 
that the PNS may be able to regenerate from die-back neuropathies as well as it can 
from injury-induced Wallerian degeneration.  Secondly, I have profiled a number of 
molecular changes occurring in the nerve and muscle of wildtype mice over a time 
period in which NMJ resistance to injury-induced degeneration drops dramatically. My 
findings implicate an escalation in OXPHOS activity and similar mitochondrial 
bioenergetics over this period of increasing vulnerability, inviting the consideration of 
elevated mitochondrial bioenergetics as a determinant of accelerated injury-induced 
degeneration at the NMJ.   
4.2 The changing molecular profile of the neonatal mouse: 
implications for mouse models of disease and beyond 
Although the results presented in this thesis highlight several cellular and molecular 
events potentially impacting upon NMJ vulnerability to degeneration, it is difficult to 
draw an extensive conclusion between two highly distinct situations. Indeed, it remains 
unknown whether any commonality exists between the degenerative process in SMA, 
and WldS-sensitive pathways (Kariya et al., 2009). However, my results highlighting a 
broad range of molecular changes evolving over postnatal development in the wildtype 
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mouse inevitably invite a reconsideration of molecular experiments performed in 
mouse models across a diverse age spectrum. If the murine proteome indeed evolves 
dramatically over developmental maturation as suggested by my results, this suggests 
that a broad array of molecular pathways, including those potentially impacting upon 
pathogenic cascades, may be markedly influenced by the age of the mouse. For 
example, it is tempting to consider what implications these findings may have in the 
comparison of traditional, shorter-lived mouse models of SMA, which exhibit a lifespan 
typically less than 20 days, to newer, therapeutically-manipulated mouse models 
which often live for up to a year. Future investigations evaluating whether age-
dependant changes within the wildtype proteome alter pathogenic pathways therefore 
be of great interest.   
4.3 Conclusions 
The work described in this thesis details several cellular and molecular factors that 
may determine motor neuron vulnerability to both degenerative disease and injury. In 
summary, I have shown that: 
1. A significant degree of cellular and molecular pathology is present within the 
motor unit at time of symptomatic onset in a mouse model of SMA. 
2. Therapeutic intervention with full-length SMN at this symptomatic time point not 
only promotes a robust rescue of neuromuscular phenotype and extension of 
lifespan, but also results in the marked repair of several pathological correlates 
at the NMJ, including regeneration of the pre-synaptic nerve terminal.  
3.  Proteomic analysis of the wildtype mouse nerve and muscle over P12-P24, a 
time period previously characterised by a marked rise in NMJ vulnerability to 
axotomy- and hypoxia-reperfusion-induced degeneration, highlights a number 
of altered molecular pathways occurring over postnatal development, including 
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Supplementary Table 1a: Top 50 proteins exhibiting increased 










P07759 Serine protease inhibitor A3K OS=Mus musculus 
GN=Serpina3k PE=1 SV=2 - [SPA3K_MOUSE] 
9.230 
Q08331 Calretinin OS=Mus musculus GN=Calb2 PE=1 SV=3 - 
[CALB2_MOUSE] 
7.448 
Q8VCT4 Carboxylesterase 1D OS=Mus musculus GN=Ces1d 
PE=1 SV=1 - [CES1D_MOUSE] 
5.279 
P28665 Murinoglobulin-1 OS=Mus musculus GN=Mug1 PE=1 
SV=3 - [MUG1_MOUSE] 
5.244 
P31428 Dipeptidase 1 OS=Mus musculus GN=Dpep1 PE=1 
SV=2 - [DPEP1_MOUSE] 
4.385 
O54786-2 Isoform ICAD-S of DNA fragmentation factor subunit 
alpha OS=Mus musculus GN=Dffa - [DFFA_MOUSE] 
3.647 
Q9WU63 Heme-binding protein 2 OS=Mus musculus GN=Hebp2 
PE=1 SV=1 - [HEBP2_MOUSE] 
3.632 
P00329 Alcohol dehydrogenase 1 OS=Mus musculus GN=Adh1 
PE=2 SV=2 - [ADH1_MOUSE] 
3.073 
P47880 Insulin-like growth factor-binding protein 6 OS=Mus 
musculus GN=Igfbp6 PE=2 SV=2 - [IBP6_MOUSE] 
2.986 
P24549 Retinal dehydrogenase 1 OS=Mus musculus 
GN=Aldh1a1 PE=1 SV=5 - [AL1A1_MOUSE] 
2.835 
Q91V77 Protein S100-A1 OS=Mus musculus GN=S100a1 PE=4 
SV=1 - [Q91V77_MOUSE] 
2.566 
P50114 Protein S100-B OS=Mus musculus GN=S100b PE=2 
SV=2 - [S100B_MOUSE] 
2.557 
P09470 Angiotensin-converting enzyme OS=Mus musculus 
GN=Ace PE=1 SV=3 - [ACE_MOUSE] 
2.525 
A2AG50 MAP7 domain-containing protein 2 OS=Mus musculus 
GN=Map7d2 PE=1 SV=1 - [MA7D2_MOUSE] 
2.507 
P23953 Carboxylesterase 1C OS=Mus musculus GN=Ces1c 
PE=1 SV=4 - [EST1C_MOUSE] 
2.452 
P0C7M9 C-type lectin domain family 2 member L OS=Mus 
musculus GN=Clec2l PE=2 SV=1 - [CLC2L_MOUSE] 
2.412 
Q05AA6 Dystrophin-related protein 2 OS=Mus musculus 




P21447 Multidrug resistance protein 1A OS=Mus musculus 
GN=Abcb1a PE=1 SV=3 - [MDR1A_MOUSE] 
2.378 
D3YXJ9 MCG51871 OS=Mus musculus GN=Cldn24 PE=4 SV=1 - 
[D3YXJ9_MOUSE] 
2.313 
P19246 Neurofilament heavy polypeptide OS=Mus musculus 
GN=Nefh PE=1 SV=3 - [NFH_MOUSE] 
2.310 
P51910 Apolipoprotein D OS=Mus musculus GN=Apod PE=2 
SV=1 - [APOD_MOUSE] 
2.300 
Q00519 Xanthine dehydrogenase/oxidase OS=Mus musculus 
GN=Xdh PE=1 SV=5 - [XDH_MOUSE] 
2.299 
D3Z2P8 Sulfotransferase 1A1 (Fragment) OS=Mus musculus 
GN=Sult1a1 PE=2 SV=1 - [D3Z2P8_MOUSE] 
2.298 
Q9WU79 Proline dehydrogenase 1, mitochondrial OS=Mus 
musculus GN=Prodh PE=2 SV=2 - [PROD_MOUSE] 
2.288 
Q5SVE1 Disintegrin and metalloproteinase domain-containing 
protein 23 OS=Mus musculus GN=Adam23 PE=2 SV=1 - 
[Q5SVE1_MOUSE] 
2.264 
B1AYL1 Protein Scn7a OS=Mus musculus GN=Scn7a PE=2 
SV=1 - [B1AYL1_MOUSE] 
2.260 
Q8R0Y6 Cytosolic 10-formyltetrahydrofolate dehydrogenase 
OS=Mus musculus GN=Aldh1l1 PE=2 SV=1 - 
[AL1L1_MOUSE] 
2.241 
Q8K406 Leucine-rich repeat LGI family member 3 OS=Mus 
musculus GN=Lgi3 PE=1 SV=1 - [LGI3_MOUSE] 
2.235 
P14602 Heat shock protein beta-1 OS=Mus musculus GN=Hspb1 
PE=1 SV=3 - [HSPB1_MOUSE] 
2.204 
P24288 Branched-chain-amino-acid aminotransferase, cytosolic 
OS=Mus musculus GN=Bcat1 PE=2 SV=2 - 
[BCAT1_MOUSE] 
2.148 
F6X0U1 Acyl-coenzyme A thioesterase THEM5 (Fragment) 
OS=Mus musculus GN=Them5 PE=2 SV=1 - 
[F6X0U1_MOUSE] 
2.128 
Q9R1Q8 Transgelin-3 OS=Mus musculus GN=Tagln3 PE=1 SV=1 
- [TAGL3_MOUSE] 
2.114 
P06801 NADP-dependent malic enzyme OS=Mus musculus 
GN=Me1 PE=1 SV=2 - [MAOX_MOUSE] 
2.091 
Q9R0P9 Ubiquitin carboxyl-terminal hydrolase isozyme L1 
OS=Mus musculus GN=Uchl1 PE=1 SV=1 - 
[UCHL1_MOUSE] 
2.024 
E0CXZ9 Voltage-gated potassium channel subunit beta-2 
OS=Mus musculus GN=Kcnab2 PE=2 SV=1 - 
[E0CXZ9_MOUSE] 
1.987 
P15105 Glutamine synthetase OS=Mus musculus GN=Glul PE=1 
SV=6 - [GLNA_MOUSE] 
1.975 
P17809 Solute carrier family 2, facilitated glucose transporter 
member 1 OS=Mus musculus GN=Slc2a1 PE=1 SV=4 - 
[GTR1_MOUSE] 
1.965 
Q8BQV2 Choline O-acetyltransferase OS=Mus musculus 




P16388 Potassium voltage-gated channel subfamily A member 1 
OS=Mus musculus GN=Kcna1 PE=2 SV=1 - 
[KCNA1_MOUSE] 
1.955 
Q64669 NAD(P)H dehydrogenase [quinone] 1 OS=Mus musculus 
GN=Nqo1 PE=1 SV=3 - [NQO1_MOUSE] 
1.932 
Q9JHW9 Aldehyde dehydrogenase family 1 member A3 OS=Mus 
musculus GN=Aldh1a3 PE=2 SV=1 - [AL1A3_MOUSE] 
1.898 
Q2VLH6 Scavenger receptor cysteine-rich type 1 protein M130 
OS=Mus musculus GN=Cd163 PE=1 SV=2 - 
[C163A_MOUSE] 
1.895 
Q3UPR9 Somatomedin-B and thrombospondin type-1 domain-
containing protein OS=Mus musculus GN=Sbspon PE=2 
SV=1 - [SBSPO_MOUSE] 
1.890 
P47867 Secretogranin-3 OS=Mus musculus GN=Scg3 PE=1 
SV=1 - [SCG3_MOUSE] 
1.889 
Q61644 Protein kinase C and casein kinase substrate in neurons 
protein 1 OS=Mus musculus GN=Pacsin1 PE=1 SV=1 - 
[PACN1_MOUSE] 
1.887 
P68368 Tubulin alpha-4A chain OS=Mus musculus GN=Tuba4a 
PE=1 SV=1 - [TBA4A_MOUSE] 
1.879 
F6TMY4 Protein Sptbn5 (Fragment) OS=Mus musculus 
GN=Sptbn5 PE=4 SV=1 - [F6TMY4_MOUSE] 
1.866 
Q8R1G2 Carboxymethylenebutenolidase homolog OS=Mus 
musculus GN=Cmbl PE=2 SV=1 - [CMBL_MOUSE] 
1.857 
P10649 Glutathione S-transferase Mu 1 OS=Mus musculus 
GN=Gstm1 PE=1 SV=2 - [GSTM1_MOUSE] 
1.852 
Q8CGA4 UPF0452 protein C7orf41 homolog OS=Mus musculus 
















Supplementary Table 1b: Top 50 proteins exhibiting decreased 
expression between P12-P24 in the sciatic nerve 
Accession Description P24/P12 
Ratio 
P02772 Alpha-fetoprotein OS=Mus musculus GN=Afp PE=2 SV=1 
- [FETA_MOUSE] 
0.128 
P70180 Atrial natriuretic peptide receptor 3 OS=Mus musculus 
GN=Npr3 PE=1 SV=3 - [ANPRC_MOUSE] 
0.331 
P09535 Insulin-like growth factor II OS=Mus musculus GN=Igf2 
PE=1 SV=1 - [IGF2_MOUSE] 
0.359 
G5E832 Adenomatosis polyposis coli 2 OS=Mus musculus 
GN=Apc2 PE=4 SV=1 - [G5E832_MOUSE] 
0.396 
P49718 DNA replication licensing factor MCM5 OS=Mus 
musculus GN=Mcm5 PE=2 SV=1 - [MCM5_MOUSE] 
0.397 
Q61881 DNA replication licensing factor MCM7 OS=Mus 
musculus GN=Mcm7 PE=2 SV=1 - [MCM7_MOUSE] 
0.398 
P03987-2 Isoform 2 of Ig gamma-3 chain C region OS=Mus 
musculus - [IGHG3_MOUSE] 
0.421 
Q61576 Peptidyl-prolyl cis-trans isomerase FKBP10 OS=Mus 
musculus GN=Fkbp10 PE=1 SV=2 - [FKB10_MOUSE] 
0.431 
Q3V1T4 Prolyl 3-hydroxylase 1 OS=Mus musculus GN=Lepre1 
PE=2 SV=2 - [P3H1_MOUSE] 
0.443 
P08121 Collagen alpha-1(III) chain OS=Mus musculus 
GN=Col3a1 PE=2 SV=4 - [CO3A1_MOUSE] 
0.443 
Q8BKG3 Inactive tyrosine-protein kinase 7 OS=Mus musculus 
GN=Ptk7 PE=1 SV=1 - [PTK7_MOUSE] 
0.443 
Q61500 Integral membrane protein 2A OS=Mus musculus 
GN=Itm2a PE=2 SV=2 - [ITM2A_MOUSE] 
0.472 
P11276 Fibronectin OS=Mus musculus GN=Fn1 PE=1 SV=4 - 
[FINC_MOUSE] 
0.490 
Q8CG70 Prolyl 3-hydroxylase 3 OS=Mus musculus GN=Leprel2 
PE=2 SV=1 - [P3H3_MOUSE] 
0.512 
Q91VK1 Basic leucine zipper and W2 domain-containing protein 2 
OS=Mus musculus GN=Bzw2 PE=1 SV=1 - 
[BZW2_MOUSE] 
0.513 
Q9CY57-5 Isoform 5 of Chromatin target of PRMT1 protein OS=Mus 
musculus GN=Chtop - [CHTOP_MOUSE] 
0.514 
Q922W5 Pyrroline-5-carboxylate reductase 1, mitochondrial 
OS=Mus musculus GN=Pycr1 PE=1 SV=1 - 
[P5CR1_MOUSE] 
0.516 
Q921X9 Protein disulfide-isomerase A5 OS=Mus musculus 
GN=Pdia5 PE=2 SV=1 - [PDIA5_MOUSE] 
0.518 
Q9DCC1 RNA guanylyltransferase and 5'-phosphatase, isoform 
CRA_a OS=Mus musculus GN=Rngtt PE=2 SV=1 - 
[Q9DCC1_MOUSE] 
0.520 
Q8BMK4 Cytoskeleton-associated protein 4 OS=Mus musculus 




Q8C4J7 Transducin beta-like protein 3 OS=Mus musculus 
GN=Tbl3 PE=2 SV=1 - [TBL3_MOUSE] 
0.527 
P30412 Peptidyl-prolyl cis-trans isomerase C OS=Mus musculus 
GN=Ppic PE=1 SV=1 - [PPIC_MOUSE] 
0.532 
Q61555 Fibrillin-2 OS=Mus musculus GN=Fbn2 PE=1 SV=2 - 
[FBN2_MOUSE] 
0.535 
Q99LJ6 Glutathione peroxidase 7 OS=Mus musculus GN=Gpx7 
PE=2 SV=1 - [GPX7_MOUSE] 
0.539 
E9QMH7 Inhibitor of nuclear factor kappa-B kinase-interacting 
protein OS=Mus musculus GN=Ikbip PE=2 SV=1 - 
[E9QMH7_MOUSE] 
0.545 
Q07113 Cation-independent mannose-6-phosphate receptor 
OS=Mus musculus GN=Igf2r PE=1 SV=1 - 
[MPRI_MOUSE] 
0.550 
D3YVW2 Golgi integral membrane protein 4 OS=Mus musculus 
GN=Golim4 PE=2 SV=1 - [D3YVW2_MOUSE] 
0.561 
O89086 Putative RNA-binding protein 3 OS=Mus musculus 
GN=Rbm3 PE=1 SV=1 - [RBM3_MOUSE] 
0.561 
P28667 MARCKS-related protein OS=Mus musculus 
GN=Marcksl1 PE=1 SV=2 - [MRP_MOUSE] 
0.562 
Q922Q8 Leucine-rich repeat-containing protein 59 OS=Mus 
musculus GN=Lrrc59 PE=2 SV=1 - [LRC59_MOUSE] 
0.565 
Q62148 Retinal dehydrogenase 2 OS=Mus musculus 
GN=Aldh1a2 PE=1 SV=2 - [AL1A2_MOUSE] 
0.569 
Q62009 Periostin OS=Mus musculus GN=Postn PE=1 SV=2 - 
[POSTN_MOUSE] 
0.570 
E9PWF0 Thrombospondin-3 OS=Mus musculus GN=Thbs3 PE=2 
SV=1 - [E9PWF0_MOUSE] 
0.571 
Q3V1M1 Immunoglobulin superfamily member 10 OS=Mus 
musculus GN=Igsf10 PE=2 SV=2 - [IGS10_MOUSE] 
0.572 
Q9CQS8 Protein transport protein Sec61 subunit beta OS=Mus 
musculus GN=Sec61b PE=1 SV=3 - [SC61B_MOUSE] 
0.573 
Q9CY50 Translocon-associated protein subunit alpha OS=Mus 
musculus GN=Ssr1 PE=1 SV=1 - [SSRA_MOUSE] 
0.575 
Q9D1M7 Peptidyl-prolyl cis-trans isomerase FKBP11 OS=Mus 
musculus GN=Fkbp11 PE=2 SV=1 - [FKB11_MOUSE] 
0.577 
O35405 Phospholipase D3 OS=Mus musculus GN=Pld3 PE=2 
SV=1 - [PLD3_MOUSE] 
0.580 
Q8C850 Scavenger receptor class A member 3 OS=Mus 
musculus GN=Scara3 PE=2 SV=1 - [SCAR3_MOUSE] 
0.580 
A2AAY5 SH3 and PX domain-containing protein 2B OS=Mus 
musculus GN=Sh3pxd2b PE=1 SV=1 - [SPD2B_MOUSE] 
0.585 
P27659 60S ribosomal protein L3 OS=Mus musculus GN=Rpl3 
PE=2 SV=3 - [RL3_MOUSE] 
0.588 
Q9Z247 Peptidyl-prolyl cis-trans isomerase FKBP9 OS=Mus 
musculus GN=Fkbp9 PE=1 SV=1 - [FKBP9_MOUSE] 
0.589 
P61514 60S ribosomal protein L37a OS=Mus musculus 




E9QKE9 Homeobox protein cut-like 1 OS=Mus musculus 
GN=Cux1 PE=2 SV=1 - [E9QKE9_MOUSE] 
0.590 
E9Q0X4 Collagen alpha-1(XVI) chain OS=Mus musculus 
GN=Col16a1 PE=2 SV=1 - [E9Q0X4_MOUSE] 
0.593 
Q8VE73-3 Isoform 2 of Cullin-7 OS=Mus musculus GN=Cul7 - 
[CUL7_MOUSE] 
0.594 
Q60716-2 Isoform IIa of Prolyl 4-hydroxylase subunit alpha-2 
OS=Mus musculus GN=P4ha2 - [P4HA2_MOUSE] 
0.598 
Q8CEC6 Peptidylprolyl isomerase domain and WD repeat-
containing protein 1 OS=Mus musculus GN=Ppwd1 PE=2 
SV=2 - [PPWD1_MOUSE] 
0.604 
P62855 40S ribosomal protein S26 OS=Mus musculus 
GN=Rps26 PE=2 SV=3 - [RS26_MOUSE] 
0.611 
Q9D0F3 Protein ERGIC-53 OS=Mus musculus GN=Lman1 PE=2 


















Supplementary Table 2a: Top 50 proteins exhibiting increased 
expression between P12-P24 in the lumbrical muscles 
Accession Description P24/P12 
Ratio 
P07759 Serine protease inhibitor A3K OS=Mus musculus GN=Serpina3k PE=1 
SV=2 - [SPA3K_MOUSE] 
7.162 
Q5XKE0 Myosin-binding protein C, fast-type OS=Mus musculus GN=Mybpc2 
PE=1 SV=1 - [MYPC2_MOUSE] 
5.143 
P04247 Myoglobin OS=Mus musculus GN=Mb PE=1 SV=3 - [MYG_MOUSE] 4.596 
P00329 Alcohol dehydrogenase 1 OS=Mus musculus GN=Adh1 PE=2 SV=2 - 
[ADH1_MOUSE] 
4.484 
Q9DBG1 Sterol 26-hydroxylase, mitochondrial OS=Mus musculus GN=Cyp27a1 
PE=1 SV=1 - [CP27A_MOUSE] 
4.229 
Q5SX39 Myosin-4 OS=Mus musculus GN=Myh4 PE=1 SV=1 - [MYH4_MOUSE] 4.087 
Q9CQC9 GTP-binding protein SAR1b OS=Mus musculus GN=Sar1b PE=1 SV=1 - 
[SAR1B_MOUSE] 
3.820 
G5E8K5-5 Isoform 5 of Ankyrin-3 OS=Mus musculus GN=Ank3 - [ANK3_MOUSE] 3.814 
A2AI91 Phosphorylase b kinase regulatory subunit alpha, skeletal muscle 
isoform OS=Mus musculus GN=Phka1 PE=2 SV=1 - [A2AI91_MOUSE] 
3.755 
B2RS77 Ankyrin repeat domain 2 (Stretch responsive muscle) OS=Mus 
musculus GN=Ankrd2 PE=2 SV=1 - [B2RS77_MOUSE] 
3.607 
Q7TSH2 Phosphorylase b kinase regulatory subunit beta OS=Mus musculus 
GN=Phkb PE=1 SV=1 - [KPBB_MOUSE] 
3.602 
Q62234 Myomesin-1 OS=Mus musculus GN=Myom1 PE=1 SV=2 - 
[MYOM1_MOUSE] 
3.573 
J3QNP9 Protein Gm590 OS=Mus musculus GN=Gm590 PE=4 SV=1 - 
[J3QNP9_MOUSE] 
3.468 
Q8BZ71 SH3 and cysteine-rich domain-containing protein 3 OS=Mus musculus 
GN=Stac3 PE=2 SV=1 - [STAC3_MOUSE] 
3.436 
Q8R429 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 OS=Mus 
musculus GN=Atp2a1 PE=2 SV=1 - [AT2A1_MOUSE] 
3.412 
P0C5K1 Serine/threonine-protein kinase SBK2 OS=Mus musculus GN=Sbk2 
PE=2 SV=2 - [SBK2_MOUSE] 
3.329 
Q9R059 Four and a half LIM domains protein 3 OS=Mus musculus GN=Fhl3 
PE=2 SV=2 - [FHL3_MOUSE] 
3.272 
P70402 Myosin-binding protein H OS=Mus musculus GN=Mybph PE=1 SV=2 - 
[MYBPH_MOUSE] 
3.263 
O08528 Hexokinase-2 OS=Mus musculus GN=Hk2 PE=1 SV=1 - [HXK2_MOUSE] 3.237 
E9QJU4 Myozenin-3 OS=Mus musculus GN=Myoz3 PE=4 SV=1 - 
[E9QJU4_MOUSE] 
3.230 
F6QI82 Chloride channel protein 1 (Fragment) OS=Mus musculus GN=Clcn1 
PE=4 SV=1 - [F6QI82_MOUSE] 
3.182 
O09165 Calsequestrin-1 OS=Mus musculus GN=Casq1 PE=2 SV=3 - 
[CASQ1_MOUSE] 
3.170 





Q8CC36 Cerebral dopamine neurotrophic factor OS=Mus musculus GN=Cdnf 
PE=1 SV=1 - [CDNF_MOUSE] 
3.134 
Q8BGT5 Alanine aminotransferase 2 OS=Mus musculus GN=Gpt2 PE=2 SV=1 - 
[ALAT2_MOUSE] 
3.116 
O88492 Perilipin-4 OS=Mus musculus GN=Plin4 PE=1 SV=2 - [PLIN4_MOUSE] 3.087 
P57787 Monocarboxylate transporter 4 OS=Mus musculus GN=Slc16a3 PE=1 
SV=1 - [MOT4_MOUSE] 
3.056 
O70548 Telethonin OS=Mus musculus GN=Tcap PE=2 SV=1 - [TELT_MOUSE] 3.035 
Q9QYG0-2 Isoform 2 of Protein NDRG2 OS=Mus musculus GN=Ndrg2 - 
[NDRG2_MOUSE] 
3.017 
Q6P8J7 Creatine kinase S-type, mitochondrial OS=Mus musculus GN=Ckmt2 
PE=1 SV=1 - [KCRS_MOUSE] 
3.004 
Q9JKS4-6 Isoform 6 of LIM domain-binding protein 3 OS=Mus musculus 
GN=Ldb3 - [LDB3_MOUSE] 
2.964 
Q91V77 Protein S100-A1 OS=Mus musculus GN=S100a1 PE=4 SV=1 - 
[Q91V77_MOUSE] 
2.943 
P07934 Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart 
isoform OS=Mus musculus GN=Phkg1 PE=2 SV=3 - [PHKG1_MOUSE] 
2.930 
Q9CRA2 PDZ and LIM domain protein 5 OS=Mus musculus GN=Pdlim5 PE=2 
SV=1 - [Q9CRA2_MOUSE] 
2.922 
Q8VCR8 Myosin light chain kinase 2, skeletal/cardiac muscle OS=Mus musculus 
GN=Mylk2 PE=2 SV=2 - [MYLK2_MOUSE] 
2.900 
P14094 Sodium/potassium-transporting ATPase subunit beta-1 OS=Mus 
musculus GN=Atp1b1 PE=1 SV=1 - [AT1B1_MOUSE] 
2.890 
P13707 Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic OS=Mus 
musculus GN=Gpd1 PE=1 SV=3 - [GPDA_MOUSE] 
2.872 
P14142 Solute carrier family 2, facilitated glucose transporter member 4 
OS=Mus musculus GN=Slc2a4 PE=1 SV=3 - [GTR4_MOUSE] 
2.736 
Q7TNG8 Probable D-lactate dehydrogenase, mitochondrial OS=Mus musculus 
GN=Ldhd PE=1 SV=1 - [LDHD_MOUSE] 
2.715 
Q02566 Myosin-6 OS=Mus musculus GN=Myh6 PE=1 SV=2 - [MYH6_MOUSE] 2.712 
Q6PIE5 Sodium/potassium-transporting ATPase subunit alpha-2 OS=Mus 
musculus GN=Atp1a2 PE=1 SV=1 - [AT1A2_MOUSE] 
2.710 
Q91WC3 Long-chain-fatty-acid--CoA ligase 6 OS=Mus musculus GN=Acsl6 PE=2 
SV=1 - [ACSL6_MOUSE] 
2.708 
Q8BH86-2 Isoform 2 of UPF0317 protein C14orf159 homolog, mitochondrial 
OS=Mus musculus - [CN159_MOUSE] 
2.702 
A2A542 Voltage-dependent L-type calcium channel subunit beta-1 OS=Mus 
musculus GN=Cacnb1 PE=2 SV=1 - [A2A542_MOUSE] 
2.678 
Q9ET80 Junctophilin-1 OS=Mus musculus GN=Jph1 PE=1 SV=1 - [JPH1_MOUSE] 2.660 
Q9DCM2 Glutathione S-transferase kappa 1 OS=Mus musculus GN=Gstk1 PE=1 
SV=3 - [GSTK1_MOUSE] 
2.640 
P28650 Adenylosuccinate synthetase isozyme 1 OS=Mus musculus GN=Adssl1 
PE=1 SV=2 - [PURA1_MOUSE] 
2.638 
Q5SX40 Myosin-1 OS=Mus musculus GN=Myh1 PE=1 SV=1 - [MYH1_MOUSE] 2.634 
P05064 Fructose-bisphosphate aldolase A OS=Mus musculus GN=Aldoa PE=1 
SV=2 - [ALDOA_MOUSE] 
2.623 





Supplementary Table 2b: Top 50 proteins exhibiting decreased 
expression between P12-P24 in the lumbrical muscles 
Accession Description P24/P12 
Ratio 
P28667 MARCKS-related protein OS=Mus musculus GN=Marcksl1 
PE=1 SV=2 - [MRP_MOUSE] 
0.206 
Q9D1D6 Collagen triple helix repeat-containing protein 1 OS=Mus 
musculus GN=Cthrc1 PE=2 SV=2 - [CTHR1_MOUSE] 
0.225 
P06837 Neuromodulin OS=Mus musculus GN=Gap43 PE=1 SV=1 - 
[NEUM_MOUSE] 
0.229 
Q01320 DNA topoisomerase 2-alpha OS=Mus musculus GN=Top2a 
PE=1 SV=2 - [TOP2A_MOUSE] 
0.245 
P97311 DNA replication licensing factor MCM6 OS=Mus musculus 
GN=Mcm6 PE=1 SV=1 - [MCM6_MOUSE] 
0.249 
P13541 Myosin-3 OS=Mus musculus GN=Myh3 PE=2 SV=2 - 
[MYH3_MOUSE] 
0.256 
P26645 Myristoylated alanine-rich C-kinase substrate OS=Mus musculus 
GN=Marcks PE=1 SV=2 - [MARCS_MOUSE] 
0.258 
Q07646-2 Isoform 2 of Mesoderm-specific transcript protein OS=Mus 
musculus GN=Mest - [MEST_MOUSE] 
0.272 
P25206 DNA replication licensing factor MCM3 OS=Mus musculus 
GN=Mcm3 PE=1 SV=2 - [MCM3_MOUSE] 
0.283 
Q91XV3 Brain acid soluble protein 1 OS=Mus musculus GN=Basp1 
PE=1 SV=3 - [BASP1_MOUSE] 
0.299 
D3Z1Z8 Stathmin (Fragment) OS=Mus musculus GN=Stmn1 PE=2 SV=1 
- [D3Z1Z8_MOUSE] 
0.300 
E9PWG6 Protein Ncapg OS=Mus musculus GN=Ncapg PE=4 SV=1 - 
[E9PWG6_MOUSE] 
0.306 
P49718 DNA replication licensing factor MCM5 OS=Mus musculus 
GN=Mcm5 PE=2 SV=1 - [MCM5_MOUSE] 
0.311 
P01837 Ig kappa chain C region OS=Mus musculus PE=1 SV=1 - 
[IGKC_MOUSE] 
0.312 
P70677 Caspase-3 OS=Mus musculus GN=Casp3 PE=1 SV=1 - 
[CASP3_MOUSE] 
0.319 
Q9ET66 Peptidase inhibitor 16 OS=Mus musculus GN=Pi16 PE=2 SV=1 
- [PI16_MOUSE] 
0.322 
P13542 Myosin-8 OS=Mus musculus GN=Myh8 PE=1 SV=2 - 
[MYH8_MOUSE] 
0.322 
P97321-3 Isoform 3 of Seprase OS=Mus musculus GN=Fap - 
[SEPR_MOUSE] 
0.325 
P62965 Cellular retinoic acid-binding protein 1 OS=Mus musculus 
GN=Crabp1 PE=1 SV=2 - [RABP1_MOUSE] 
0.326 
O35646 Calpain-6 OS=Mus musculus GN=Capn6 PE=1 SV=2 - 
[CAN6_MOUSE] 
0.332 
Q05186 Reticulocalbin-1 OS=Mus musculus GN=Rcn1 PE=1 SV=1 - 
[RCN1_MOUSE] 
0.341 
Q8BH97 Reticulocalbin-3 OS=Mus musculus GN=Rcn3 PE=2 SV=1 - 
[RCN3_MOUSE] 
0.350 
Q6WVG3 BTB/POZ domain-containing protein KCTD12 OS=Mus 
musculus GN=Kctd12 PE=1 SV=1 - [KCD12_MOUSE] 
0.355 
Q61881 DNA replication licensing factor MCM7 OS=Mus musculus 




Q3V1T4 Prolyl 3-hydroxylase 1 OS=Mus musculus GN=Lepre1 PE=2 
SV=2 - [P3H1_MOUSE] 
0.358 
P61750 ADP-ribosylation factor 4 OS=Mus musculus GN=Arf4 PE=2 
SV=2 - [ARF4_MOUSE] 
0.371 
P26350 Prothymosin alpha OS=Mus musculus GN=Ptma PE=1 SV=2 - 
[PTMA_MOUSE] 
0.376 
Q8C167-2 Isoform 2 of Prolyl endopeptidase-like OS=Mus musculus 
GN=Prepl - [PPCEL_MOUSE] 
0.379 
Q8CG48 Structural maintenance of chromosomes protein 2 OS=Mus 
musculus GN=Smc2 PE=1 SV=2 - [SMC2_MOUSE] 
0.380 
Q9Z247 Peptidyl-prolyl cis-trans isomerase FKBP9 OS=Mus musculus 
GN=Fkbp9 PE=1 SV=1 - [FKBP9_MOUSE] 
0.381 
P01864 Ig gamma-2A chain C region secreted form OS=Mus musculus 
PE=1 SV=1 - [GCAB_MOUSE] 
0.386 
Q8K297 Procollagen galactosyltransferase 1 OS=Mus musculus 
GN=Colgalt1 PE=1 SV=2 - [GT251_MOUSE] 
0.388 
Q60715-2 Isoform 2 of Prolyl 4-hydroxylase subunit alpha-1 OS=Mus 
musculus GN=P4ha1 - [P4HA1_MOUSE] 
0.392 
Q5I012-4 Isoform 4 of Putative sodium-coupled neutral amino acid 
transporter 10 OS=Mus musculus GN=Slc38a10 - 
[S38AA_MOUSE] 
0.397 
Q922W5 Pyrroline-5-carboxylate reductase 1, mitochondrial OS=Mus 
musculus GN=Pycr1 PE=1 SV=1 - [P5CR1_MOUSE] 
0.403 
P09535 Insulin-like growth factor II OS=Mus musculus GN=Igf2 PE=1 
SV=1 - [IGF2_MOUSE] 
0.410 
Q3UQ28 Peroxidasin homolog OS=Mus musculus GN=Pxdn PE=2 SV=2 
- [PXDN_MOUSE] 
0.415 
P41731 CD63 antigen OS=Mus musculus GN=Cd63 PE=1 SV=2 - 
[CD63_MOUSE] 
0.417 
P19324 Serpin H1 OS=Mus musculus GN=Serpinh1 PE=1 SV=3 - 
[SERPH_MOUSE] 
0.423 
P50543 Protein S100-A11 OS=Mus musculus GN=S100a11 PE=2 SV=1 
- [S10AB_MOUSE] 
0.424 
Q9QXS6-3 Isoform E2 of Drebrin OS=Mus musculus GN=Dbn1 - 
[DREB_MOUSE] 
0.426 
Q62356 Follistatin-related protein 1 OS=Mus musculus GN=Fstl1 PE=1 
SV=2 - [FSTL1_MOUSE] 
0.428 
Q8BZQ7 Anaphase-promoting complex subunit 2 OS=Mus musculus 
GN=Anapc2 PE=1 SV=2 - [ANC2_MOUSE] 
0.431 
Q9D1M7 Peptidyl-prolyl cis-trans isomerase FKBP11 OS=Mus musculus 
GN=Fkbp11 PE=2 SV=1 - [FKB11_MOUSE] 
0.431 
P27046 Alpha-mannosidase 2 OS=Mus musculus GN=Man2a1 PE=1 
SV=2 - [MA2A1_MOUSE] 
0.433 
Q9JIG8 PRA1 family protein 2 OS=Mus musculus GN=Praf2 PE=2 SV=1 
- [PRAF2_MOUSE] 
0.435 
P29351-3 Isoform 3 of Tyrosine-protein phosphatase non-receptor type 6 
OS=Mus musculus GN=Ptpn6 - [PTN6_MOUSE] 
0.436 
Q9JI44 DNA methyltransferase 1-associated protein 1 OS=Mus 
musculus GN=Dmap1 PE=1 SV=1 - [DMAP1_MOUSE] 
0.436 
Q8BV57 Soluble scavenger receptor cysteine-rich domain-containing 
protein SSC5D OS=Mus musculus GN=Ssc5d PE=1 SV=1 - 
[SRCRL_MOUSE] 
0.436 
Q9Z110-2 Isoform Short of Delta-1-pyrroline-5-carboxylate synthase 







Supplementary Table 3: Statistically altered functional clusters of unfiltered 
proteins exhibiting consistent alterations in expression in sciatic nerve from P12 to 
P24.  
 
Up from P12-P24 in Nerve Down from P12-P24 in Nerve 
Cluster Name Enrichment Score Cluster Name Enrichment Score 






3.86 RNA processing/RNA 
binding 
11.92 






3.14 Endoplasmic reticulum 8.98 
Actin cytoskeleton 3.11 Ribosomal activity 8.12 
Calcium binding 3.04 Endoplasmic reticulum 
membrane 
5.59 
Nucleotide binding 3.01 WD40-repeat motif 3.95 
Vesicular endocytosis 2.73 Translation initiation 
factors 
3.65 
Calcium binding 2.61 Ribonucleoprotein 
complex biogenesis 
3.38 








Supplementary Table 4: Statistically altered functional clusters of unfiltered 
proteins exhibiting consistent alterations in expression in lumbrical muscles from 
P12 to P24.  
Up from P12-P24 in Muscle Down from P12-P24 in Muscle 
Cluster Name Enrichment Score Cluster Name Enrichment Score 





47.34 Protein transport 7.07 
Myofibril contraction 19.74 Cytoskeletal protein 
binding 
5.86 






14.32 Lysosomes 5.63 
Redox cofactor 11.44 Vesicular transport 4.73 
Glucose metabolism 11.41 Lipid binding 4.55 
Cellular respiration 10.79 Golgi-associated  
vesicular transport 
4.21 
Nucleotide binding 8.23 Endoplasmic reticulum 3.5 
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